var title_f33_54_34656="Fibrous pleural tumor III CT";
var content_f33_54_34656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Fibrous tumor of pleura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral decubitus views show the extreme mobility and pliability of this tumor. These features are nearly diagnostic of a fibrous tumor of the pleura.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34656=[""].join("\n");
var outline_f33_54_34656=null;
var title_f33_54_34657="Gram stain sputum 7B answer";
var content_f33_54_34657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Test for oxidase activity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On chocolate agar, Neisseria meningitidis forms moderate-sized, translucent colonies which turn black (positive) when a drop of oxidase reagent is added.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34657=[""].join("\n");
var outline_f33_54_34657=null;
var title_f33_54_34658="Endometrioma sonogram Doppler";
var content_f33_54_34658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endometrioma with color doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal ultrasound with color Doppler image of the left adnexa showing a benign endometrioma of the left ovary viewed with color Doppler imaging. No flow within the cyst can be demonstrated; however, blood flow is demonstrated within the wall of the cyst in the ovarian tissue itself (long arrow). Also identified within the left ovary is a small follicle (short arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thomas D Shipp, MD. Copyright &copy; Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34658=[""].join("\n");
var outline_f33_54_34658=null;
var title_f33_54_34659="Uchida tubal ligation C";
var content_f33_54_34659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uchida tubal ligation C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 357px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFlAZsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK8/1z4n6d4X19tN8ZWd1o0Mh/wBF1Fl820nHpvXlG9QwH16UAegUVQ0bWdN1u0W60e/tb63YAiS3lVxj8Kv0AFFFFABRRRQAUUVyOm+M4rnVvF6XNuLbSfDzJG96z5Ej+V5kox2CgqOvJJoA66iqGg6rb65otlqlkJRa3kSzxeahRtrDIyD04q/QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUV3bQXlu9vdwRTwOMPHKgZWHoQeDUtFAHler/AzwlcTNdaCL7w5fltwuNKuWi5zn7ucfpWLqHg/4vaHFnwz46tdYjU/LBqlsqvt/38HJ+uK9puoTPbvEJZISwwJIyAy+4zkfnWJPZeI7eM/2fq9ndHPAv7T5iPdo2Uf+O0AeIX3xB+OGhZTUvA1pfANgS2sbSK30COT+Yqkn7RHjKzO3WPh1dxsGwdqTR8Dr95TzXsvibX/Fnh7w9f6pNo+h3qWcTTMsepSQllUZON0JGfQZ/GvPNT+JPjXwRp2lQeKdJ0ZtW1y7YwS3GreXFbKxBCOnl5VUXCk5IzznnFAGGn7VunJs+2eE9RhJOGIuFOPplRmtTT/2qPCE0sq3umavaxggIyokm4Y5JG4Y5+tdbqXijxcYb0S+HfBsP2II1w9zru5IQ3Ks48kbQR0zjPbNc3c6l4q1ZZwmifCzV0Rtrxpe+Ydw6qdy4yPegDpfDXx8+H2vSiJNYNhMTgJfxGLP/AuV/WvNdJu5/E/xR1r4fRzw3fh281eXX728tZhItxblEKwMV4ClgoPr0pmq6b4h1mzutMi+BXh21ndCDd+fCqISMbwyhT3yPmrhvhZ8KfiDYanqt3otwkLWFydOvbe11VrWSVgqvgSKpG0blPXrQB9soqoioihUUYAAwAKWvm2LU7zRnkXxjpPxV0xk+U3Fpqsl/b/XeuPr0NVv+FleCFZvJ+JnjyzmjAUCeJZVU/7StCc/iaAPpuob1pUs53tlDzrGxjU9C2OB+deSm81uOxS70v4u6HeRMoaMajZW2189MtEyEflWX4g+LXifwRp6XvifT/DOtWG4I9zoeqbXBPQ+VICTzjoe9AGta/Eq/wDEnhPw5YaGLaPxjr0bh0X5005UJWaZ16/KRhVPViB616zbRvFbRRyytNIiBWkYYLkDkke/Wvkr9n/4i+EdD1XxFqd7bag2va3evILWysmnMEG4sACOTyxzgdhxX0Dp3xY8FXsyQtrsFlct0gv0a1f8pAKAO5oqG0u7e8hEtnPFPEejxOGU/iKy/G9zdWXg3XbrTy63kFjNJCUGWDhCRj3zQBtUVw/hjxppMGheD7LVNXWbWtVsbdo4uZJpmMQLOwUEgZzljgV3FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUN7dQ2VnPdXLFIIUMkjBS21QMk4HPSgCaiorS5hvLWG5tZUmt5kEkciHKupGQQfTFS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHG/EU/b5/Dvh8AMNT1FHnU9DBAPOcH2JRE/wCB1neFLOHxV4t8Q+IdTt4rm1t5W0nTkljDKI4yPNcAjq0mR9Eqp411VrHxdrWrqpY+HfDztCDyDPcyHaAPX/R1H/Aq7PwRox8P+EtK0t3MktvAomkPV5T8zt+LFj+NAGnNY2kyTJNawSJOAJQ0YIkA6bvXHvWFfeAvCN/cvcXvhjRZrh/vyPZRlm+pxzXS0UAZltoGlW2nS2NvYW8dpLCLeSNVwGjAICn2AJA9M1wHwf0q31DwJ4hNtd3EEOraxqMgntJtrovnNGpjbt8sa4Ndx4o8NWPia1S11V7w2YzvggupIEmBxw+wgsOOhOK4rwn8HtN8MaWINI1fV9PvBNNJ9psblo1ZXclVaFi0bbVKrkrzjNAGp46udX8L6DqF7pGpyXmpXQtrLTLK7jV1NwSF6jDEsMlsnAwT0Fc78M7GSwuL3w9478OQPr17JLfz6n5aTWuoszZwrEfKyqVXYR0XIrm9S13WfEvxGg0vQb0XFzpsUlnbXtwi7YCCEutQZRhSw5ijXoW3HoTXpHgzSLDUIdPvrd9P1LQbFVbQrlGkknBKlZpJHY4ZmYnoPXuaAMtdF8LXllY3Fz8MEjkurw2zwtpdvvgGSPOfB/1ffPJwelea/GPRfhxF4K1D7B4dtNL1uW+Gn2f+j+W87CRN0kW04ZNpOGr6Xrz/AMR+F/DNlcXLaPoPh6bxbdwyTWMF4qjzHQglgOSAGKk7cf1oA5Wb4OaHpesi/wDhrrjeG/EVvH5LRxSCeKToSskbEnnAJ/lVqW88d2zxWPjvwZpXinSW4kutMCu4HqYJev4Guv0zwTpM+u23ivUbO1PiprMW9xeWbusZYrhioz16gE5IFa3g63ksdGFg1nd2sNlI1tbm7uRPJPEpwspYEn5uTg8464oA8d1G0+GlvMbi0n1r4f6kBu8+GKaxUn/aUgxN/WuQ8VfHm98Nafq/hu7vdM8WPPZlbLWLBhGPnDL++UcbgOfl9vXj6he4sbq4msZJbaWZADJbsQzAHoSvvXlXg3wj4b8Ya5451e80ixe0nun0OCNIVULDAAsjjA4ZpC/zdcItAHnv7PnxJ+GHhfwza2lzI+m688YW8vLuAsZW9BIucIOMKcAfrX0doXiDR9fg87RNUsr+MDJNvMr7fqAePxrw0fCLxH4JgubXwva6B4t8NyyGQ6RrNuiXCg9Qk2ME+7YHtXH6z4a8Fx6iGMHiD4UeJmYGG4mZjZO2Oiyq23GR13KPr0oA+tqK+aNA+OGteCNSl0X4ixJren25VItf0kCRJFIGCx4VuvOMHjoetddrvxa0rWNasj4d1zb4e0yJNS1S6tk3SXLM22GyjUjO925YYzgAZGTQB7TRXI+C18XXl1Lqniie0srW4T/R9GgiDPbDqDJNn5nx1AG0HoTXXUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSEBgQwBB4IPelooA87S6f4e+II7S648HalNttZieNNuGP8AqmPaJyflPRTx0Ir0Sq2p2Fpqun3FjqNvFc2dwhjlhlXcrqeoIrg9H1O+8Daza+HfEU0t1oV0wi0jV5OSjdrW4b+9/cc/fHB+YcgHotFFFABRVDUtZ07TJoo9QvIrZpQSplO1Tj3PA61E3iLRVxu1jThnpm5T/GgDUorEn8WeHoELy67pir/19If61mXXxH8J2x/e6xHj+8kUjr+aqRQB11FYNh4x8N38cb2mu6Y+/wC6puUVj/wEnP6VuRyJIuUdWHXKnNADqKKKAEZgqlmICgZJPAAplvPFcwJNbSxzQuMrJGwZWHqCOtLNGk0LxTIrxOpVlYZDA8EEVX0rTrLSdPhsdLtYbSyhG2KCFAqIM5wAOnJNAGN4u8WW/hWSyk1Kyv306dmWW9t4TKlsRjHmBcsAc9QCOOa1rbVrC51CSxgu4nvY4kneAH51jbO1iPQ4NXiMjB6U0RoJTIEXzCNpbHJHpmgDznxpokQ1mBEmeeXxJrNks0ZHCQ2qGVlBHb9y2fd8V6RXkPjD4caJe/Ejw/JY/b9KuLkX17PcabdvC5lxGNw5IBO85IAzW7J4F8RWit/YXxE16AkYC6jBb3yj/vpFb/x6gD0Gisbw/aazp3hyO31fU49Z1iNG3XRgFssrZJUFVyFHQZH1qS21C+W9sLO90yYSTWxlmuoGV7eGQYzHkkNzk4O3BAoA1a434veKv+EN+H+q6tGcXQTybYAE/vX+VePbr+Fb1h4g0q/tbW5tr+AxXTMsBdthkKnDBQ2CSD7V4h+0k/8Awk/jbwF4FiZTHfXf2q6w2MRj5Rn2I8z8hQBrfAjw5Po3w5bWWu7e213X9htri8XOyP8A5Yx4yCScs5AOSznrXtcUaRRrHEipGowqqMAD6Vx3jOXTbKTwhaPfW1lANWhhggNoJxKwjfZGv/PM8Ah+2Md67OgArifE+qah4X0TUNc1LT7bWL+K6aOwW2QRGGCRlCiSRs7QMZduntxUfja7mv8Axr4S8OWkroGnbVr0xkgiC3xsU+zStH9dhrmPin8QZLPxLa+Exo9lfaTezRQajdPIbgQxOcSJJAnzKcEYJ4+agCn+z3Z2esR6p4yicxPJPPbW2k21yZIbFN+XAGcM7sN27gYIxxXqfg61S18PW2y0vLNpy1w9veTGWWN5GLsrNk9yeAcDpXGeMNI0fwT4OutJ8Gabb6ZqviB10y0W0TaxldSvmHHP7tN7k/7Pqa9Gsbf7JZW9uHeQQxrHvc5ZsDGT78UAZfiXwroniVEGs2Edw8f+rlDNHKn+66kMPwNc/wCGfhrpvhHUEn8J3t/plq8pkurIymeG4z6h8lW/2gc+ua7uigCCyFyIm+2tC0m9tpiBA25O3Oe+MZp1zbw3UDwXUUc0DjDxyKGVh6EHg1LWD4k03WLqWC70HWmsbiBWH2aaFZba5zggSDG8dMbkYEZPBoA5PxL8EvA+uW9xENMfTPPOZP7Nma3Rj6mMfIf++a8K0D4IatF4n1TXPhxq0DW+iX/lWP8AaKbvtM8QxJ0G3CuWUEjkg9Ote1+NvirB4Y8Nahb69bzaV4q+xSPbWio80U8gXAaKVV2su4jOdpHcCuj+EM+ky/DrQU0G6gubaO0jDNEwJ8wjLbh1DbiSc85oA808B+LvireRXLXcXh/VdRtZWjvNFkJs7u3weGDY2MpGCDyDkc9a7/QfifpV1qEWleIrS98M61JwtpqieWsh/wCmcv3H9sHJ9K3/ABN4U0vxE0M12ksGoW+fs1/ayGK4gJ/uuP5HIPcGuK8UHWdH0t7Lxto8fjTwtINkl1a2oN3Fzw0tuBtYD+/HgjGdo60Aep0V4P4f8Sy+EdMGr+ENTfxb8PEx51nvL3+kr/s7vmZF/uPhgPbJr2jQNZ0/xBpNtqejXcV3Y3C745YzkEf0PqDyKANCiuZ8KeIbjXNe8VWzQRJYaVepZQTLnMrCFHk3duGfHFdNQAUUUUAFFFISFGSQB6mgBaKKKACiiigAooooAK5/WtYm0TVreXUDEuhXOIWuDwbaYn5d5/uNnGexxng8dBVTV/sX9lXZ1URHTxExn877mwD5s+2KALdUNd0ix17R7vS9Wt1ubG6QxyxN0YfXsQcEEcgjNeceDfH9rp/jG98GagZ2tIBC+mam53xTRSoGjjdxwG6hc/eA9evq1AHmeia7feBdZsvC/jC5e5026bytH1uVsmTHS3uD2lx0bo+PXNd1q0urRzQf2Xa2k8Rz5pmmKMvpgBTn9KTxJoWneJNFutK1m2S5srhdro3UejKezA8gjkGuC0PWtT+HuoWvh7xtePe6LcOIdL1+Xjk/dt7k9nx91+jfUGgDrbq78VIF+z6VpchPXN4wA/8AHKzJLzxkzMX8L6M5A+U/b/8AFPpXbUUAYHh8668v/E607SrVACQbWZnOc8DlRUfit/FcNzaS+F4dIubZc/aYL13jkfpjYyggd+oro6KAPP8AU4/FWpMwn8IeG5kI+b7Zd+YW9v8AVn9a5x9HsrC4kuZvh5qej3Yxm88P3CkqfVVRlyPYqR7V7HRQB5Va+KoYnFvZePLeObhRBr9mI5AfQt+7yfwrqLLUvFEM0b3dnpeqafJgCfTZirrk9Sr8MPo2a6S90+zvo2jvbS3uEYYKyxhgfzrmbv4eaC7eZpsd1o1z1E2l3L2xz7hTtb8QaAOj1DVLHTWt11C8gtTcP5UXnOEDvjO0E9+OlSwm4M8/m+T9nyvklCdxGOd3br0x2ridS0XxQtvLZ3f9jeLNIOCINRj+z3HHbeoaNj77VqXSfFmk6HaQaZq2l33heGACGEXyKbcgD+CZGZMf7xB9qAO1iljl3eVIj7GKNtIOGHUH3p9eD/Arw/4m/wCEJuNZ0fxYrf2pqN1diO9s1nim/eFPMJDK6l9mThsc9K9LfxTqGkkL4l0C8hiA+a+07/S7fpySqgSr+KED1oAXXmRPiN4T3lgXtr5Ex0JxCcH8FJ/CusriPEWq6fczeEvEOnzwXtnHqQtvOiYMAJ0aEc9iHaPIPvXb0AFFFFAGX4g8P6R4itFtdd0201CBW3KlxEH2N6rnofcV8+6L8NfD2qftGeIbKbSGj0fS9PhkihaWVQZGC4dW3Zx97occV9LVx/h9Un+JPiy5wxeGCytQx6DCyOQP++xQBBB8M/D+l6fPb+GYW0SeaeG4e6tz5kpaNsjmTd1GQfYmtu+8RQaPBqd54jEWlaZazJHHdzzLslVguG4+78zFefTNblRXNvDdQPDcxRzQuMNHIoZWHuD1oA4LRvs83xu8QTPdxTXA0azWCJckpEZJSxz05Yjp7V0t9p+gaJd6j4quLGztrxLZvtV+sQEjRKMncQMnhR+QrmfEXwvtb3xcnivQdWvtF8RjYjXEZ86J4VABiaJuNpAHTGDg112paP8Ab9X069a/vIorQSB7ONwILkOoH71cfNtxkfWgDmfC+nf8JL4ki8b3V2tzYta7NEt1jZBBC4BeRw3PmOQB7KAO5ru6QAKAFAAHAA7UtABRWPHDrh8VSzS3dkPD4tgkVssZM7TZ5dmPAUDgAVd0u6F7bPOpyhlkRT7K5X/2WgC3RRXMfEPVrnTdBFtpZX+2NTkFhYg9FkcHMh/2UUM59loA4W/1m6v/ABjJf6NcFrq/u10PTcjciQwv5l5PgjBGRsz6rXdan4M02TU5Na0iCLTfEG1tt7CpUSNtIHnIpAlHP8WT6EVzPwl0aCWeTXLcsdLt4P7K0hWx80EbHzJz/tSyAtnuAD3r0xmCqWYgKBkk8ACgCjpz6kbi5j1GK2EKCMQzQucynb85KkfLhunJ4q/WfoOrW2uaVDqNhvNpPkxO648xQSA4/wBk4yD3BBp+oQ3bOlxZTnfDHJi2bCxzuR8u9sFlAI6j16GgDlPFnwz0HXp5b60SXRNccEf2nphEMzZ6iTHEgPcMDmvntX8Vfs1a3Ks0kWu+HNVSZoY1bZiVcYcr1UjK5xwQevAr6Ek+JmhaZDJH4rmHh3U4k3vZ37gF8d4WHyyj0KnPqAeKZ4L0F9WF74k8U2yy6hq8XlpaTgOtnac7YQDxkg7nPcn0AoA8J/Z4+I/iHxFfx+G7fUNG0uYzS31xPcwNLPqMkkpeTb8wUNg/kB6V9Y18v6j8KbKG78UaH4dtZbXxLoGzV9Bv4DtkeGQlhCx/iKyLIoJ5xj3r2v4R+OLbx34OtdQRgmowgQahbnhoZwPmBBx16j60AdrRRXNeMvGuj+EvscWpSyS317KIraytgHnmJOMqmR8o7scAUAdLXzH4g1N/jV8a5/Bo1G6t/CGkxySS/Y22m4kTCklsEfeOBkY+U1618TPE15HotjoegLJD4o8Q/wCj2kTld9qhH7ydwCQAi5PGecCuH0SHT/CPxM8EjSLcw+HpdPn0JL4kYvLhWEmSPdlb5j1JOOByAVpx8QvgwRctdT+MvBSEq8TD/SrOMdGyeSAM9yOP4a9o8G+KNK8Y6Bb6xoNyJ7OYd+GRh1Vh2I9K8Xl+N154U+IEvhvxnol/bafd3zvBd3m0PFbyD5RhNyuokyMhvu8dRVrxLan4L+Pk8T6VA48Fa5KItWt0b5LOYn5ZlXoB1z+I9KAPeaKjtp4rq3intpUlglUOkiMGVlIyCCOoqSgAooooAKjuIY7m3lgnRZIZVKOjDhlIwQakooA+abX4e32oeNfF3hW81mayuotJt49IlRvkmtFd9glT+IocLuBBGARXR/CD4ia1psk/hX4mqINS0+ZbQai78Ozf6tZD6sOVk6N069dbxxoN/q/xVbUNBuPs+v6Po8U9jlysc5M0m+GUd0cDbnsSD2pPGKWvibwxbeOtH077Rd2kL2+p6XKo3XNsGIuLSUY+/GQxX0ZeODQB69VPWNLsda0y507VbWK7sbhCksMq5Vgf89e1ebaXq934G0+0vftUut/D24jWS3vRmW40yNgCvmYyZIQD977yDrkcj1C1uIbu2iuLWWOaCVQ8ckbBlZT0II6igDyb+0Na+Ekyw6u9zrPgHpFfbTJdaWM8JN3kiHQNjI79q9W0+9ttSsYLywniubSdBJFNEwZXU9CCKmkRZEZJFDIwIZWGQQexryXVvCWufDy7m1n4Zw/bNKkZpb7wzI+I2zyXtjj5H/2eh/IUAeuUVyvgHx5ofjnTmuNFuSLmL5bmymGye2foVdDyOeM9PeuqoAKKKKACiiigApsiLIjJIoZGBDKwyCD2NU7nVLW31ey02Rm+13aSSRKFyCse3cSe33l/OrqsrZ2sDg4OD0PpQBmaL4f0nQ3uDo1jDYrOQ0kduNkZPPIQfKDzyQBmrCS3Fpp0s19ieSIO5FvGcsoyQAuSS2MD3NZfhLW5dVn120u1RLvTNRktWC8ZjIEkTY943X6kGugoA8+8deDtG8W+F7u8sLYxapc25ubKaF2gdpwN8bsoIDMGAPzA9K27vUfEcGjaVeWejxXszQI97avOIZ1YqCQmRsJBzkEj2qXxzpelahoFxNrVlcXcNirXSC13CdWQE5iKkHd2GDz0o8OC7ttE0n7OL69hucSyPqcoW4t42XcAw2/MynCkHn34oAn0LxHaavuQRXVndJ9+2vIjFIvHoeCPcEip/Dmvab4k0pNS0W5W6snd0WRQQCysVYc+4NVtQ8TaNY6/b6RqNx9nvZ03wmeF0ikzkbVlI2FuD8oOfasnw5q+gWWqax4R8KWkSXukxC5ktox5cW+Us2Nwzgk8njjIoA7KuQ8EYl8Q+NbhWyDqqw4zkZS2hz/P9Kk0rxvp8+pw6Tq8Nxoutyg7LS9XaJSOvky/clH+6c47CrXgzR7rSY9Ze+MRmv8AU7i8AjPARiFTPvtVT+NAHQ0UUUAFFFFABXN/EnW38OeAte1eFlWe1s5HhywGZMYQDPfcRgV0lecWyp8RPFstxMPM8KaBdeXbofuX98n3pD/ejiPyr2L7j/CKAN3w3PqOm/DfTJ9YmluNXFjGZWuRtd7hlGFbHQ72C10dhALWyggAA8tApx645NZuquLrWdO04HO0m8mH+ynCg/VyD/wGtmgArxfxONX8U+J2twktnLfmXTNNUjEltYAr9rviOzP8kadCNy/3jXsN/dwWFlcXl5KsNtbxtLLI3RFUZJP4CuX8CWct9NeeK9SiaO+1VVW3jcYa2s1yYoyOzHcZG/2nx/CKAOn0+zt9OsLaysYVgtLaNYYok6IijAA+gFcr8QLp9RksfCNi7rdaxu+1SRnDW9kuPOfPYtkRr7vkfdNdJrmqWmiaPeanqMvlWdpE00rYzhQM8DuewHc157DqN3oGjya7d2Qm8a+JpVistPZuV4Pkwkj7qRoS7t67ieSKANvW7qa98Rab4V8PyPaRWgjutRmt/l+zwKf3cII6FyOn91T612tYXg/w+nh/TGjkm+1ajcubi+vCuGuZj1YjsOAAOwAFbtAHJfFDwgPG3hObSknitrkSRzwTyRCQJIjBhx2Bxgkc4JqXwb4tg1wzadeqtj4jsgFvtOdvnjP99f78Z6hhxgjvXUVlaxppkMmo6Za2B16K3eG1ubqMkLnnaxX5thIGQKAOc8dA+H9YsPGSb/stnG1rqiIM7rViD5mByfLb5v8AdLeteLfE++u/hH8TbLx54YjFx4W8QIv26GFsxSv1JHYEjDKfXd2zX01GVmiMFx5UkuwCZF5XkcjB7Hnr2rw34h6LZ+CIY9KvrR9X+HmuT/Z20hAXuNNmIZ/NtgBuMYAJKj7uMj0IB2Pir4padD4V0q78JvDq+r66yw6TaK2C7t1Ljqqpn5s9Olec+MPhTbWFpofifxreS6nqcl6ItdvGmYJHDOrRDyxnCLG7pjj1Nc7+yX4TsJ/HfiTxDpc0lxounFrPT3uUAlfec7/9k7F/8fr6k1nTbXWdJvNN1GIS2d3C0EqH+JWGD/OgD5M+GXhnVvC/xX1rwPetJc3lzbwxpqnnlfJ0wMXl2Z5BcFVGPunNeu/EHSZfGXg5ptFnWyttOljbw8sOAbi6jOEb/dyCoHHGWPFcX8QNI1Kx8OaR4tC3p13wZMdM1BWZVe+sAxXzDjJwyHOfRn+tet2F7p+oR6JdeG2t7iKazB0m3VCI7ePADyvjpgYUDrnIHUkAGD8V/Blj8SvhkraleaZa6zYRiY6hHJvitZVA85Sw52cMCO2AcZFZ/wAFvFOk+O/CV94I1ww6jcabbLaXDmbzo76HGBKjYB9PcHFX9eVvhbcf2lZWkF14TunaXX4kT98k0rgfa9oBynBDLwABkZxUPxHtr7w7r2h/EPw3JA+gWNsINTtbaMZls3bcZUwMNtyGx6DI70AVfghc3Pg/xXr3wx1WVpUsB9v0iZzkyWjtypPqpI/Nuwr2qvD/AIi39o/x1+F95oN7bzapP50M8SsDm0ZN25u44Llc9TXuFABRRRQAUUUUAcTY/N8ZNWI5CaLbKc9iZpTUF4g8I/ECK8QbdD8SyLbXKAfLDf4xHJjt5qjYT/eVPWuUg1V0/anubZmYW02ii1Uj7rSqRIV9yFbNeoeL9Di8SeGtQ0mZjH9piKpIOsUg5Rx7qwU/hQByXgAf8I14n1nwRcKTYgNqWlF+QbeRz5kI/wBxzwPRh6VXv9E1b4eTzal4Hsm1Dw9IxlvPD6NhoSeWks88A9SYuh/hwaf4iXVn8HaH4rms2HiLQQZ7mADBmQDZcovswBdfoteg6bfW+p6fbX1jKs1rcxrNFIpyGVhkH8jQBQ8K+JdK8VaUmoaJdpcQHh16PE3dHU8qw7g1sVwHi7wHK+qSeJPBF1HovinH7xyuba/Uc7LhB972cfMPen+CPiJBrOqzeHvENo2heLbYDzdPncFZhj/WQP0kQ89ORg59aAKfxE+GEGu3w8QeGLttA8YwDMWo24wJv9mZejg9MkZ+o4rN8B/FG5TWIvCfxItBoviocRyHi2vh0DRt0yfT8vSvWq5f4geBtE8eaI2na9bB8fNDcJ8ssD9mRu306HvQB1FFfPugePNe+E/iG38J/FCd73RZvl03X8fw9ll78d88j3HNe/W08VzBHPbSxzQSKGSSNgysD0II4IoAkooooA43WWWL4seGW2/PLpt/Fn0Ae3b+lc78Jdfhhjt7K6SX7R4gvdT1C2kHKFY59pXk5zjB+lb3j1fsXibwXrPASDUWspT/ALNxGyD/AMiCOvN7Zho/hbSNa2sD4R8S3VveDGCLeWRkkb6ASo/0WgD0NW/sj4zyIdsdtr+khxx9+4tZCD+JjmH4R+1d3Xnfxj36dp2heLLc8+HtQju5ioyTauDFOB/wBy3/AAGvQ1YMoZSCpGQRyCKAFrm/AWu3viLRri91GwawkW9uII4WVg3lxyFVY57kDPHHNdJRQBleKl08+G9SfWbSC80+G3eaaCaMOrKiljkHg9K8c+FHwx1Dw/4cs/FHhnVpbTXNVgju7qwugslrKrfOsJO3zEwrAbgScjp2r0L41yyx/CvxGkGfNubb7IuPWZhF/wCz12VvClvbxQxDbHGoRR6ADAoA47XL+S68P3zeK/Bkl1awRGYWyiO981lBOFQd/Q4/KobC9u/FGiWF74Q1VtFNpEFl067scorbVIjkDBWXb0yp/Our8QaxZeH9EvtW1SXyrGziaaZwCSFAzwB1PtU9jcR6lplvcrG6w3MKyBJVwwVlzhh2ODyKAORsfHUtuUg8SaLfWcpB/wBLtIzdWcmO6yJkgH0YA1taZ4u8P6nKYrLV7OSYNtMRkCOD6bWwf0rIsfA39hXk8nhLVZtHspiXfThEstt5h6uqtyme4UgHrWxcaDZ3+n/8T/TtP1C72nzHW2A3kdMbiSD070AbgORkdKK8kuJPAixxpexax4Vuxykkq3Fo8fbiQZTHsCRWzYaToRsL3V08X6nqIhiMrXkeqb/JjUZ4C/L065BzQBc+I+p30v2Hwv4fnEOs6yWVp1PzWdouPOnH+0AQq/7TD0NdRoumWWhaNaabp0S29jZwrFEg4Cqoxz/U15n8NdG8WXE8njC91Sznn1hIwkN9ZkSwWaklEBRgAxB3EbcZNdv4rv45Lqw8PRysl5q28ErnKQIMytkdOCFHuwoAm8Ns1/JdavIpC3LbLcMORCpIB/4Ect+IrdqlaXmn/aX020ubU3Fqih7aORS8SkfLlQcgY6ZrG8b6rqlrbQ6b4athca5fkxwu4/dWq/xTyn+6ueAOWOAO+ADI8RP/AMJl4nHhm32vounsk+suCcSN1jthjrk4Zx6ADviu9AwMDpWP4T0C28N6JDp9qzysCZJriTmS4lY5eRz3Ynn8h0Aqn461+bRdNhg0yNZ9c1KT7Jp0B6NKQSXb0RACzH0HqRQBzPjXVLPVNZmXUZNnhbw0Re6lJ1We5AzFAB/FtyGI/vFBWr4H0m9vdQm8XeJIGh1i9j8q1tGbI0+1zlYx/ttwzn1wOiiua8D+Hodcks0WWS48M6LcO6yygZ1fUNx8y5f1RWLBR3YZ6KK9aoAKKKKACiiigBskiRRvJK6pGgLMzHAUDqSa8z8Haja+MvGw8SXLhbaKGWDQLaQ4aWEMqz3YX0YlVU/3R70ni/Vk8X3GoaTbXqWvhDTN39v6mGwJCvLWkbfT/WN2B2jknGb4V1XS9MTVfiL4nki0qwltkt9JtJBta309D8mI+oaRvmwB02jtQBQ/ZRgFp4c8X2pRVkg8RXMbYHOAkYH9a9jsNUtL+7vra0lEk1lIIpwAfkYqGx+RFfMH7P3jL/hFvFupnxRDLpOi+MZ3v9KnuiFQt5jcE54BDqMnjgdjmvc/hXPb3X/CVz28sczNr10rurA5xtCj8ulAHWNpWntLfSGzt/MvkEd0+wZnUAqA57gAkc+tfM/h7U7n4F+PtV8LakYotB1l/N0rU5wWS356NjkqM4I9QD0Jr6lrxz4laPaXq3Wh/EVftHhq/mL6ZrYUB9MnbgRyn+EZ+6/3T91u1AElp4hW6kvtqymMO6TTXSBba5XGzzZpMfvcg/LFHxjA+mfpkfiH4a+Gbm/tDFqXgeFGl+warIILu2j7+USNuw87Ym5GQM9q8Ka78Y/ALxXcR32nW2rWRAjsrq9jeSAqOVaFs/I3qOv869Fk1fxZ4v8AGvwvk8YLpk+i6yz3a6PbRuI1CqSskoYneRkEZ4FAHTfDTw3qnjH4pj4mazoqaDYRWnkaZaEATTqVKiWQdvkYgcDPy9hz7zQBgYHSigAooooAKKKxvGWpS6R4W1S+tra4urmKBjFDBGZHdyMKAo56kUAeU6p5kOkXvjOI5Fh4qN4XHe0GLaT8Nu4/8Br25WDKGU5BGQa5bw/4Ujg+Gtt4Y1P5w+nm1uyDnczqfMIP+8zGq3wm1Ga58IxaZqMm7V9EkbSr3PBLxfKr/R02OP8AeoA7IgMCGAIPBB71wXw4U+HNY1jwXK58iyIvtL3Hk2cpPyf9s5N6fTZXfVxHjINp/jrwVq8YwJZ59JnIPWOaIyKD64kgT6ZNAHb1yvxA8C6P440xbbVEkiuoDvtL63bZPav2ZGH8uh/KuqooA8Qs/iJrfwz1CDQviuGu7CQ7LLxJbRHy5QB92ZRyH9cZ/Hk17Pp97bajYwXlhPHcWk6CSKWNtyup6EGoNd0fTtf0ufTdZs4byxnXbJDKuQf8D7jkV4Ef+Ek+AGpsIo5tb+Gc8+7jLz6buPP4fofYnkA938UeHtK8U6NPpWv2Ud5YTfejfsR0YEcgj1HNeOR/CDxb4Ilkn+FvjGaK0zvGkaovmQn1APQZ9doPv3r2rQ9WsNd0m21PSLmO6sblBJFNGchh/Q9iOoNXqAPm63/aUm8PX8+j/ELwvc2mr2shinaxdWQkY5CsenfhjxjFdhof7Rfw+1S6SCTULmwZ+j3duVQexYZA/GvU77SNN1Bw9/p9ndOOjTQq5H5iszUfBHhbUohFfeHdJmQEHDWidQc+lAHH+MPHngPxJ4X1LT4PF+irO0Rkhc3SjZKmHRuvZgK5TwL4z8M+INa1bTr/AFGxOneLNNW7mhaYKIrgJ5NxEcngsAGHtzXqV18OvBt0CJ/C2ivkYP8AocY/pWLefBX4d3auH8K2CbhjMW6Mj6bSMUAUfhVrOn+M/A2q+GLu/j1GbS3m0a5mVgftEQyscwx/eTGf9oNWv8GNUnvfBUenai+/U9DmfSbsnqzQnarH/eTYfxrzbxh+zdpcWnXF18PtQ1DSdYQb4o2um8uQj+Et95fY5Nc94T8E/Gf4b+fquly2GtLdsLm/09597yv0PLAZbHcH86APqWivn2w/aZ0y2vDYeLPC+taRqKttaFUEhznHRtrD8jXeaF8a/h/rMkcMPiK3trh+PKvFa3Kn0JcBc/jQBb+NsqxfDu6L9DeWI6Z/5fIa7uvHfiPcXniLWNa8NaZfxXNpq/htrzTwsqsq3dvMCNpHZt8eT/sfWvS/COtR+IvDGl6vCuxby3SVkIIKMR8ynPcNkfhQBqyxpNG0cqK8bjaysMgj0Ip1FFABRRRQAV5P8S/B2h+KvE2i+HF0mzR7hmv9SuoYhHKLVDjZvXB/eOwXr0DHtXU/FDxBd6H4bEWihX1/U5VsNNQ8jznB+c/7KKGcnp8vvWb8IUn1O01LxVqEvn3OrSiOCXGP9FhykeB2DN5knHXzBQBYT4YaHDaww2d74htfIx5Lxa3dZix0ABkK47YIIrK0XQ9Ws7LUddtPF1+wlLLAdTijul8hCQpG0KfmOW4PRl9K7XxfcyW3h65WAkXFwUtIiOoeVhGGH03Z/CoJUj/tbTNDtowLO0gFxIuOAqkLEv5gn/gFAHEaVo/iew8QW+peIvC+j67fwq0i6xYyJBcJuHMex+oA4HzkY9KvXNr4a8XeJGSfUPEOk680IL2K39xZvtXodisFP1Xg9ea9JpjxRyMjOisyHKkjJU+ooA4PW4Nd8HaLNfWniR9QtLVci21S18+aYnhY1kj2tknAGVY885rzO4l8Za14vuI9a06Nbu9s4ftzadO0kmh6c7Ze3C4H7+XHLAk4GQMAV7l4v1yLw5oNxqMsZmkTCQQL96aZjtRB7liB7DJ7V574Rvte8CWNzJ410AOt3PJeahremzm5BkY/eki2h1RVAUbdwUKOgoA9J8OSaY+iWY0EwnTI4xHAsPCooGAuOxHTB59a0qoaXDpzh9R0vyXS9CymaBspNxw3HB69e9WvtMH2s2omi+0hPMMW4b9mcbsdcZBGaAJaKKKACsfxXp82p6NLbRarJpULc3FzEAJBCPvhXJwhI/j5xzjnkbFcR4i8Lat4s1eS11+9t4/CUbBhp1puEl9jBxO56ID/AAL17nHFAHHWlppvirTYWgiGnfCrQ1MqR8j+1mjyd5z8xhUgnnmRuTkdfKPBHhmT4/8AxO1fxN4hWWPwtZOIYYEbYWUfciBHTj5mIweePba/aO+KltqUX/CufBGyeSaVLW7mg/1a8gCBMdecA44GMeuPf/h14Vs/BHgvTdEs1VVtogZn/vyHl3J9zmgDgv2l/DOm33wfe285LL+zniawjVNxkcDYsCDqSwOAB3x2rwv4N634i+DN9FqPiHTLg+EdYwlzLEN/2eRc4JA+645yhwSOnSvo/wAGQf8ACc62vjXUwzaZBJJFoFq33FjBKm7Yf89JMHbn7qYxyxra8UeEpL65kv8ARLqO0u5VKXNtPEJbS/XGNs8ff2YYI9xxQBseHPEej+JbMXWg6lbX0BVWJhkDFQ2cbh1B4PB9Kv30NtcWU8N/HFJaSIVlSYAoykchgeMfWvjb4n+FtU+HN1Nq3g+01zwxFdW8qagsTNPZryNixzLkgMckbwpX2rkfCvji2urmNvitH4k1jS7gbYpo7+VFwDz8mQHH0I/GgD3nxF45t/CGpx+GfBQi8c2c6ui6GC1xJYkDjE2GDR9tjcr2OOB0/gPwf4n1rxbYeNPiEbWyubGB4dM0ayXCWiuMEu3OWxxjP5YxWd4B+JvwY8P6e8Phu9stHVxvkR7WVJG4/iYqdx9smvQfAPjqx8c/2hcaLaXv9lW7qkN/PEY47okHd5YbBIGAM470AddRRRQAUUUUAFVtRN4tnIdNS3ku+Ni3DsideckAnpntVmorqBbm1mgkLBJUKMUYqQCMHBHQ+9AEteZ+NGfwR44tfGMRYaJqQi03W41XiMgkQXR7/KT5bf7LD0r0ayto7OzgtYd3lQRrGm9ixwowMk8k8dafPDFcQvFPGksTjDI6hlYehBoAfXLeOrY3E/hjriLWYZCQpOMJJ+XJAyfWupooAKK5bwXper6VqPiZNSmEun3Ootdaf+8Lskbou5TnoA4bA966mgAqK6t4bu2lt7qJJoJUKSRuMqykYII7jFS0UAfOsltc/ADxobq3W5uPhtrEgWVNxf8As2cng49PfuODyBn6GtZ4rq2iuLaRZYJVDo6nIZSMgiqfiDR7LX9FvdK1SFZrO7iaKRCOxHUe46ivJfgf4kHh3Ubv4YeIrpjrOkzNHpzOp/0q12l0I4wMLnr2xQB7VRSEhQSxAA5JPaqOh6l/a2nJeLbywRyM3liXG5lBIDYHTOM496AL9FFFABRRRQBw/wATfh9Z+M7a1uoJBp/iLTnE+namiAvDIpyA395M9VP1rKudJ8Pah4QTVPi54e8O6fqK7o7qabyyrMDjekn3huxkDORmtPVta1jxD4gutB8JSx2lpZ/JqWssok8mQjIhhU8NIOCxPC5A5PFbLeEtMvbTSo9fiXW7jTSWhuL9Fdtx4LEY25xjt2oA+bvEXg/4SzvJdeCtc13RdSGRBcadBc3EIJ99pOPowqXw3Jrvg+0CaJ8UbiRY3wtnrOiXIgYnkgswLKMnqK+rEVUUKihVHAAGAKZcmUW8ptlRpwp2BzhS3bJHagDwK0+OOvWBc6vomjatbxcST6JqQ3/UQyYauw8H/HbwH4okigh1b7BdyYxBfp5Jye277p/OjVvhXL4kka68T640t0+R5dnaQxxRqT90blLHGB8xOa4zxH+y54Zvo3k0rVNQsrsjPz7ZI2b1K4BGfY0AfQMMsc8SywSJJGwyroQQR7EU+vlfT/BHjr4bSLH4d8StpyggJbakQ9hdOeySdEJ9HCn0Nem+FPi/svk0b4jaRceF9ZDeX506n7HKx6bZegz7nHHWgDJ+K+o3E/inxDNahmn0TSItPsAHxi91CQRbwPVUKfgTXseh6ZBoui2Gl2a7baygjt4xj+FFCj+VeA6pex3nx8PhyZv3914gtNUIAPzQW9iWQk9MbwPxFen/AAy8QQX9k095qJkvNbv767s7eRyxFvFL5S7B2QKiH0y/vQB0uu2ct7faKEB8mC7+0SnPBCxvtH/fRU/hTNHtbhfEPiC8uEZVklhhgJP3okiVsj23ySD8DW3VfT7pb2zjuY1KxyZKZ/iXJw30IwfxoAsUUVFdXEdrazXE7BYokMjseygZJoA4m9U+I/ijbWp+bTvDkIupV7NdygiP8UQM3/AxXdkZGD0ri/hNBLJ4XOs3a4vNcnfUpMjkI5/dL+EYTj612lAHEf8ACN33hSe4vfBx82ymkM1xokrAREnlmt2x+7cnnafkJP8ACeat3Vjp3jXToL+3a60zV7bIhulQR3di5+8jAg8H+JDlWH4Gusry3xH4sa3+KllYeFLMapdw2skuvJBIP3cC48sHt5wYnCnBxkdwQAWofEGta9beIvCNrqGnWfjKwiQG9hJeExyHHmqvVXAByh6Njkgg13Wh2B0vR7Kwa7ubxraJYjcXL75ZSBjcx7k1y974H0e7R9W8LiLSNZmdruPUbRcGV35Pmj+NGOMqfwwaqQfEm2XRIY5rcXXiszPYnRbVwZXuY+HAz92Mfe3ngKR1OAQDtdX1Sx0bT5b7VbuG0tIhl5ZnCqPz7+1cRNcar46glJN14e8IAEyTyZhvL5B1xn/UQkfxffI6bRzV3SfB9xqF9FrHjiaHUtSRt9vZIM2die3lqfvP6yNz6AVJ8Qi2rnT/AApbls6s+bxkODHZRkGXkdN+VjH++fSgD5o8H+Hk1j9pjRJoLKGy0ryhqlpaRR7BDbIGEIIx1bajn/fr628SRtcaRNaxX6afLclYEnaNZMFiBtCtwSRkfjXz58L9ag8TftVeLL63ZWtrWze1tygwpWMxx5+mQx/GvpVlVwNyhgCCMjvQBHaW0Fnaw21pDHBbwoI44o1CqigYAAHAAHapaKKAPN/jhA8/h6FWutcsbRzJFPe6aBLHbqy43XEJyZIvUgZXrxXkH7Lfh7RtY0rxt4Y1tLDXLCC7jKHG+NxhgJIz1XOM5GDX0f4qj1t9L3eGZrJNQjcOI7xC0Uy85jJHK5z94dCK8B+Ds93pH7R/ijS7nQk0AahZfaGsYpBJGGUqd6EADDZY8DvQB1o+EF94ZlU+C7jR9R09TlNL8SWgnWLnP7udV3r16ENXY+GNW8aPqVrY6z4O0/TtOUFZLu21VZFQAfLtj2A4JwMcYruKKACiiigAooooAKKKKACiiigAooooAy/E+uWXhrQbzWNVaRLG0TzJmjQuQuQM4HJ61oW80dxbxzQsHikUOjDoQRkGo9SsoNS066sbxPMtrmJ4ZUzjcjAgj8iaZpOn2+k6XaafZKy2trEsMSsxYhVGAMnrwKALdFFFABXh3xjtbTwn8WPAfj5wqQvdHSb5umFkRlR/wBfPsBXuNeR/tU6SdU+DGruoBexkhu149HCn/wAdZqAPVNQQyWFyi53NEyjHqQah0JQmiaei5wtvGvPsoFUfA+ojWPBWg6ju8z7XYQTE+paME/zp/h1jaxvpVy4N1a5I9XiLHa39D7igDZooooAK5f4ia7daJoSJpAVta1GdLCwDruUTPn52HdVUMx/3cd66ivO/i0lzp82j+KYzG9toS3Mpt2zmaeVBFAo/4G2D9aAM2LTvtCw/DzwtezwWGnxhte1NGPnEv8xiR/8AntKSzM38Kn1YY9TgiSCGOKJdscahVHoAMCue+H3h0+GfC9tZTzG41CVmub65b709zId0jn8TgewA7V0lABRRRQAUUUUAMmijnheKeNJInBV0cZVgeoIPUVwur6PHoFpPBdJ/afg26Pl3VhdjzfsSnjchPJiHGUOSvVeBiu9rkNWkl8N3stxcA3Phq9dvtYkJY2bueX56xMT8w/h6jjIoA8Z8V/DfUvhp4ptfHPgyO41zSLKOYvp7vvuLdGhKDZIcs8a5BC87QO/JrT+AWr6XqWs6fLDe27Q6R4Z07TU5HFzOzNKv+/ujUEda9d8Hh9Mku9AmZmWyxJaOxzvtnJ2DP+yQU/4CPWvCvjP4GvPAPiCLxn4PSWLw9LeQXetWVtgCNo5QyyKAOF5OcdD7HgA+hvFFybTw9qEqvsk8lkjb/bb5U/8AHiKvWNsllZW9rDny4I1iXPXCjA/lXM6zq9prfh3RLnSp47iz1O9tTFMvIKiQSH9EIxXWUAFcJ8WLqS70+x8KWEjpqPiKb7LuQEmK2GDcS+2EyBnuy13dc14YvptevrnWra9L6Kwa1tYDCvzFJCrzB+pViMAdMKD3oA6KCGO3gjhhQJFGoRFHRQBgCsjxH4r0DwysZ8QaxY6d5isyC4mCM4UZO0dT+FQeNPEqeHbCEQQG81a9fyLCxQ4a4l/ooHLN0AH0rmLL4TaLf3VrrPjSJdc8SiUXEtzKzeUrdo4484ES9lxzjJzk0AQWkniD4lxrcrNeeGvB7ndEIj5d/qKdmLdYIzwQB85HcZruPDXhvRvDFibPQdOt7GAncwiX5pD/AHnY8sfckmtcDAwOlUNe1W10LRL7VdQfy7SzheeVv9lRk49+KAON+JHje98J6zoGmaTp9tqF1rLSW9vbmXy3WbAKu3by+u7v6VieDfCU3gb4ijUdSuV1K98VpIt3dCFUWG7QGXZH3EbIH4JJzGCTzWPZaVF41+FWqeOJZI5/EV9GdRtp062IgcvFbxk9MbSGIxuJbPavRNXvlv8Aw74b8RIP3cE9vet7JIhjY/QLKT+FAHWzzR28Ek07rHFGpd3Y4CqBkk15C+p3moWVxq+ns8Ov+L5Bp+jh15tLJM5mx2AXfMf9pkHpXoHjvSodY8PS21/qDWOlhhLfMvHmwLy8Zb+FSByRzjNY3gGzfV9Qm8W3tu0CzxC10m2dNptrIHIOOzSEBj6AIO1AHgPwwFn4V/ax1PRbFPIsWSSyiX/diVhn1JKZz3Jr64r4h+Md9P4J/afk1ssGVLm2vRjjMZRQwP5MK+2bS4iu7WG5t3DwzIsiMOjKRkH8jQBLRRRQBg+L/sFxYrpuqm6hgvAwW5gYoYXQbwQ6nKt8pIx/dI9j8q+KPGGseEvjv4Y8Ra3d21/p8lpFFHqVsu1L2zckeYR/Cw3ZIHGV7A4r6K8b3839rSW1tcOR5IAjK5EV0mZ4SPZ1WRT9FFfNvinwonifU/HiXEvlaX4X003Ok+iLM/nhDjrgFwB70AfZ0brJGroQyMAQR0Ip1ea/s6eJW8UfCTRLiZy9zaIbGYk5O6PgH8V2n8a9KoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsvxVo0HiLw1qmj3WPJvraS3Y/3dykZ/Dr+FalFAHzd8PvGJ8Oaf4B8L30gt9Q0nW7jRNSgMhwSUk8txnGUJZSD04r6D1Sxa68ua2k8i9hyYpcZHurDupwMj8RggGvn39ofwdp2j+O/Dnj+WHbYNdR22qsg5Q9I5/qOh/wB1a918I6x/bGkq8hX7XCfLmUHuOjD2YYYHuDQBqWT3D2sbXkSQ3BHzpG+9QfY4GR+AqeqxvbddQWyZ9ty0fmqpGNy5wcHvjuO2R61ZoAK4r4lxrdy+FdPkAKXOtQs6nGCsavJ/NFrrNSvEsLCe6kVnWJd21erHsB7k4Fct8S7W4eDQL+ytJru40/V7eby4U3NsYmNz9Arkn6UAdlRRRQAUUUUAFFFFABXPeNWaHTVuQonigLNc2uMm4gKlZFA74B3fhXQ1zfjWMRR6ZqmdpsLtGc/9Mn/dyAjuMN09QKAKXhVZBcw2aXRnOlsYxJ1861lTfEST1Iwq/wDAfeusureG7tpbe5jWWCVCkkbjIZSMEGuV8FWdxbX19HJMht7LNiiclyA7OjMf91wAK6+gD5g8PRXvwu+LejeB9RmU+ErzUW1DTbiUY2u0boIs9PvMAffB719P1w/xh8CW/j/wdcaedsepwZn0+56GKYDjnsD0P59hWR8CPHtz4s0CfS/EKPb+K9FYWuowSja7EZAkx7459wexFAGx8UdXu4rKw8O6JMItb8QTG0gl/wCfeIDdNN/wFMgf7TLV/wANaZbfD/wLHZ32qzXOn6VCxFzcqqskK5IU7QAcDjPU1gaIo1j44+IryY700LT7ewtweiPNmWQj3ICD8KPELHxt4+i8NRkNoWhmO91cdp5z80FufUDHmMPZAetAF/wHpt1qd7L4w8QQNHqN6myxtZOTYWh5VOgw78M/fOF7V3FFFABXLavc6X4n1LVfBuoabeXVr9kV7yRkKQbXPyoHyCWOCfl6Y610Gp3Mlnpt1cwW0l1LDE0iQRfflIBIUe56UaZcveada3MttLayTRLI0E2N8RIyVbHGR0oAgtdHsLPQ10eytYrbTkhMCQRLtVUIxgD8a5r4U3CS/DXTIr3aPskT2VwJeADEzRsGz/u967WvMtM0aPXdI+JXhqY4FxqFwg9F86FHUj8WzQBaumX4jam9jArHwdaS/wClzbcLqcyniJf70SkfMw4YgKOM13d5c2+nWE1zcyJBaW0Zkkc8KiKMk/QAVk+A9STV/BeiX8aonnWkZdEAARwoDKAOmGBH4V5/8WvEEmq3C+HtHC3OJ1geI52Xl4eY7bI/gQfvZT2VQO5FAHzv48ubXxl+0BpL+ImeWxv7iGCW2A2fZoWOEiLDneFZWb0ZyO1fT3wXurvTrDUPBmsuW1Lw7L5Mbscme0bJgk/75+U+6mvnf41abc6ZpmjX+nPHLofh3VPsTXm39/fXzHzLmdiP4Q6bB7ggcAV9Z22jaffa7Y+KUSRNRNj9m3KxAeJyHCsvfB6emTQBu0UUUAeceMXS71RpIWAikt2DsqlmWW1ukxx9JJPzrk/CS39ifG83hqy03Wo5NSjsPIup/JF5FDbhXWI4IZstt5+Xg0vxWt71NJuU02+a2uLzXBpkChsPJ9pkgMiA9l2q+cc16F4h+H+haj4MOgWmmWlvFbxt9gIDL9mlwdsispDA55JBye+aAPA/2S9dl0z4geK/CLWlzZ2cpe7htbniS3eNwpRh/eKsuf8Acr6sr4i8B6lrfhf4/aBdeKtSW71S4nbSr4OQZYz/AKoB/Ucoyv8AxDnsRX27QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHDfHDSH1z4T+JrKJN8v2RpUXHVk+cf8AoNVPh7pwm+H3hbUvDd/5lymnRR+Zc8rcpgZSTHOQc4Ycrz1BIPoUqLLG8cgDIwKsD3BryL4KXB8MeIfEnw6vpcNpk5vNLDnmSylORj12scH0zQB2uoatplxBFB4nhk0i4B3o00mxVYd451O3PtkHHUdqktTqlw0zaP4j0u9gCjy1mtvNZfdnjkUEf8Braj1Kxnsri6S5he0haSOWTd8qlCVcE+xBB+lYPibULqa0Sw8OZFzJbi4V0GAqEhUHbG5j+StQBlX91qr64umJPHrGsxqk4jS3MFlp4OQssnzFnbgkJuyeuF+8OrtoNXiu7FZb21ns0t2W5ZoCsss3GGXB2qv3uME8jnvT9A0i30TTI7O13tgl5JZGLPNIeWdyeSxPP6DgCnxaasetT6l9pu2eWFYfIaXMKBSTlU7Mc8n2FAF6iiigAooooAKKKKACsvxQsbeHdRE5Ij8hiSBnHHH64rUrL8TpDJoV4LudLe1VN88rZwsa8sePYGgCXToLeztpbohInuMT3EjMcFtoBPPQYA9qxJ/H3h949RTSNQg1nUbKJpTp+nSrLcSY7IoPJzxWXpOmXHjhotX8SwPFogYSadpDHCso+7NcAfeYjBEZ+VR1BNdRd+HNIurrTbmbT4PP01/MtHRdhhOCDjbjjB6dPagCXUNYtdM0KTV9U820tIYRNNvjLNEuMncq5PHfGa8W+K0J8P6rpvxg8DSR3sCxpFq0NudyXlocfvMjuOAT2wp/hOfeq8s8SeCL/wANz32r+AYY5rO6DHU/DUpAt70HO5os8RSEE9PlbjI9QDnJ/HNh4V1/XvF1pG91oviPR4dQs2jQ4ku4z5QhJHRm3J9MNXV/CZ/7KuLjw29u1xrccK6l4g1DcAovbj5hH6s236AKq+tfN3gjxFo1j8SLLwzdarNaeAodR/tVbO/jKtbXCoxELk8gK/XsSo9c17N8N729v/E/h1Hu3s5NYS88WX6b8NcJI4itYfdVjIJH+wKAPdqKKKACiiigArjfCI8jx344t3K75Li1u1AGPka3RBn/AIFG1dlXHWLCy+K+qx3GFOpaZbyWxx9/yXkEi59R5kZx6NmgDhdE8RyaV4QvtB0YtZjSb2+j1XVrhT5OnRCeRyyk/wCskZXXaq55POAOcrRrO6t309NJgks/EWtxPFosExMjaTYdZr2bnmaTO4k8lmRegNTeIWhtviJ4lg1W5a/tku7e80zwxbEbr+7eFQHk77AY8kH5QfmPofSPBmgv4ftdQ13xPdwS69fDz9QuydsUCKCVhQn7sSD8zljyaAOJ/aA8LaXp37Pt9pdqy21rpaRSW5kbLO4cdT/EzFmye5Oa9C+GN6+pfDvw3dynLy6fCzH1OwV518RdNl+IHgbxFreowSpottYTtpFnICrSOFP+luODyPuKRwPmPJGOu+A93HefB/wpJExYLYpGxK4+ZflI/MHmgDvaKKKAOP1nwg+r+PtF1m7nh/srSo5JobNUwz3j/L5znodqDA75JrR8XeJIPDkFo8yFmuZ0hQk4UZYA5P0JwO+K368i+IGpvr0mr6ZdJJbR6TNDfRqoBd1glVpWB9DG3T60AeQ/thaWui/EPwx4lsgEubpMOR3kgdSrfXDqP+AivrWyuFu7OC4QYSaNZB9CM18x/tJ6Ba6/4i8Q3jNLdTWXhiDUbDEp8uMC6KysB0OUx+f0r334ZXZvvh14ZuS+9pNOt9zZzkiMA/qDQB0tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV45+0Ppl5pNnpnxC8PIBrPh2QNMP8AnvaMcOjeoBOfYFjXsdVtSsbbU9PubG+iWa0uY2hljbo6MMEH8DQB4/8ACS8bX/g54bNyiE6vqs8k0WcgqbuaVl9+FIr07w8/2m+1m6KjP2o24OMHEYA/LOa8C/Zp1Z7Wd/Bt8/7/AEDWrlIw3BCNFKpH/fauf+BV9EaNYHT47pCVPm3Mk+QSfvHPOe9AGhRRRQAUUUUAFFFFABRVTS7EafbNCtxc3AMjyb7iQyN8zE4yewzgDsKt0AFUtZ0221jTLjT79C9rOu2RQ2MjOcZ/CrtFACABQAoAA4AHaloooAKKKKAPAv2kfgxF4r0+fxH4atkTxDApeeJBj7YgHP8A20AHHr09K8p/Z/8AEuo+Lvjd4RbWWiEmi6TJYQbF2lkjjkC7h3bD8/7tfadfJP7QOnJ8Lfi/4d8b+GrfY140lxcW6r+7Z0KiTp03rJz75PegD62orN8OazZ+IdBsNX02QSWd5Cs0bexHQ+46H3FaVABRRRQAVxHxMWcXXhCSxkEF7/bUcUc2wMVR4ZRIMHrlc/iB6V29eb/E3xTo2h+J/DSai1xeXkDT3VvptknnTyS7NiHyxzjEkmCcD8qANbw94Z0bwve6xrl9JNPqj/NeazqRQMyBQcKQAqRqOMAAcd+tc7rGt2WvRR614ouP7M8EwShrO0nUiXVpAcrI0eN5jzgpGASxAYjGBXmGqx+J/HckmueN/FFr4V8IyXpNvo04EszGFioVou7blyVOeedvSu18L6JfapqEWo6Bpt6LlhtfxN4nTdcqmBxa2/AQY6HCD1zQBlfGfxjqmoeDNSSd7nw9Y3FpIbXTki36leqBy8iYIt4QOufmx1K9K9N+CcRh+EvhNG6jTov4cds1xfjay0LTPhh8RbbRr2a41u1s2j1PUrg77iWRl3BGkx6HG1cBd3AFejfDa3Np8PfDcDDBTToARjp+7FAHSUUUUAR3MbS20scbsjuhUMpwVJHUGvLQUlvLDUri2uJbqaEJdR7N+8Kfs8449irnvgV6H4nhln8P36WxYTiIvGVOCGX5h+oFeeeN/EH/AAjHg/xNr0VsBOka3GkzsnPm3KBcDPGQ2CRQByHxNtbPT9Q8YWOmJ/oOjeA/sBXcW8svK3lqSec7Uzz1zXpHwFYv8HfCZJJP2Fev1Ncj8QfCdl4S/Z08R2lvGWvJbJJb66dy8tzPlNzu55POeOgHAxXZfA2EwfCHwnGSCfsEZyPfn+tAHc0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8xf2M/h39rG7t1kjt4teiF7ayyISBJ95gPUlkkH/Avevp2vEP2p/D91P4Z0vxXpIcah4cuRcM0TFX8kkb8MORghT9M1614U1q08ReG9N1fTn3Wt5AkqZbJGRyCfUHg/SgDVooooAKjuZ47a3lnncJDEhd3PRVAyT+VSVwXxvvZbf4e3ljayNHd6xNDpMLDsZ3CE/8AfJagCXxF4+tovCOl6j4bj/tHUde2x6NbMpQzyOMhmBwVRR8zHsB7itXwJ4dn8OaM8WoajNqeqXUrXN5dyHiSVsZCL/CgwAq9gK43wfp0d98X9XZkP2Lwjp1tpGnoR8qvLGJJZAOzbfLXPpXqtABRRRQAUUUUAFFFFABRRRQAV5X8ZLqws9Y0qbV7NL2wTSNWeeBv40EcOVHpngZ969Urw/4/Sm816w0yJSWOmyW7Ef8AT3cwQKPxCv8AlQBynwTn174afFAeANanR9D1SFrvT2ZiQCRuAjJ+jAj1XP1+m68c/aM8KST+G7bxfoheLXvDGLm2K8q0QILqV78DP0Br03wlrlv4l8M6ZrNmQYL63SdcdsjkfUHI/CgDWoork9Z8UzS6jNovhSCLUdZiIW4d2It7IHvKw6n0RfmPt1oA0vF+qaTpWiTya9qQ060l/c+aspjkLHose35ix7BefSvJW0PUBrmgXHhfSx4U0+4uZLaTVr4CbUrkPGx+6+7aDs6udwODtHIO1pKI3iOabRg3inxbH+4u9ZuiUs9PyOUjXOF/3Y8sc/M1dn4k06xET6n4m1SSPTba2UTQlxHbh1bcZf727sPm6ccmgDl/hF4P0PSZvEEsMQ1DUbfVpo21G7ImnfKo/L+vz84xnvXR+O/Fy+H47ew02OO+8S6gfK0/T93Lsf8Alo+OViXqze2ByRXEaeq6TolwNBFr4B8Dh/Pa+uB/pV2Soy0aSHEQIUcsCx6he9ec3Xxh8KeC0vx8M9Fv9e1acAXWr37SyeZjPLM3zMPYbVoA7L4waQvhH4HXmj/bTcaxrd9EtzcNw95cTSqZWC+mBgAdFAFe4afALWxtrcdIo1j/ACAFfGvh7xXa/ET4k/D17ttTufES3/nag124W2RV+YJBGDhV4PbJ7k19o0AFFFFACMAwIPQ1z3/CNWmqeG7XS/EdrFdxwSiUISduUcmM9ewA4roqKAPNf2j4zL8FPFA8zy8QI2fXEqHH49K6D4UIY/hl4VUxiPGmW/yj/rmOfx61zP7TJQfBLxJ5j7BsiAPqfOTA/Gup+GErz/DjwvJIu1jplvkf9s1GaAOnooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCC/tIb+yuLS6QSW88bRSIejKwwR+Rryb4Zyf8IBr1z4K1HMVjuB06ZhhZA2dvPTLAYP8AtL7ivYK5fx/4XHiTTEa28pNVtNz2kkudhYjBR8c7Tx05BAI6UAdRRXmXwp+Iba1e3nhbxNE+n+LtNJWW2m/5eIx0kQ9G98ex78em0AFed/Ff97rnw+tn/wBTJr8cjHtlIpGUfnXolcT8WdOvbnQLHUtKt2ub7RL+HU0gQZaZUJEiL6kozYHcgUAbejeH49L8Q+INVjnZ21eWGV4yuBGY4lj4PfIUGtuqOiarZ63pVtqOmTrPaXC70df1B9CDkEdiKvUAFFFFABRRXHXvjC6m8ar4e8PaS2otalH1S7aYRxWaN0UHB3yEc7R26mgDsay9e1u20SGKS6gv5hK+xVs7KW5bOM8iNTjp1OKg8S6A+uPZFda1jTFtpPMK6fOsQm5B2yEqSV46AjqasRxavFfMzXNpcWklwW2tGY3hh2YCqQTubeM5OOCaAK+neKdKvr1LMSzW164ylveW8lu7/wC6HUbvwzW3XIeNtXi02aGLxFpUc/hm42xyXwO/7LKTgGVcfInIxIDweuODVtprzw+qyNJPqeinkyEmS4twe5I5kT3+8Bz83YA6SvC30vUtd+MWiz61C8E087am1mXBNpY2gKWwfBI3PPK0hHOOmeK9O1iefTrhdfsJnutLaMG8t0JfKY4mi9wDyB1Ueo5uaVaaFJrV5rOmm2l1K8iiinnjl3syKMoMZ4GGzwBnIJ7UAa1xDHc28sE6LJDKpR0YcMpGCDXiP7OF7JoWreL/AId3ju76FevNZluM2znjH4kN/wBtK9yrwvxDbt4f/av8N6iilbfxDpktpIw7yRqSc/gsNAHba1q1/wCK9ZvfD/hq7ay0+yITVdXjPzIx5+zwHp5mPvN/ACO5GMjRbKLxTZnRPCok0vwJbM0c99AxWXVH5DpG3Xy8/elzlzwpxkmS70u31/ULjwX4cj/s7wxYyF9amtzg3EjnebVW6/NkmRuoBC8ZrpNf1eXS4V0PwlZ2j38MIz5p8u10+EDh5SOgwOEHJA7DmgCxrWqaT4G8OxR21qFWNPKstOtF/eTN0CIv1xk9B1JrxvWfFl7qfiu3sbe2i8UeOFbdDpML50zQ/V5ZBjzJF6FievA28A4UK3fjXxlf+HvAWpz3dxKuzX/GUwzI0Z6wW4HCR9gq4z64GT718O/AGgeANKNl4ftNjyYNxcyHdLOw7s34ngYAz0oA47RfhA+qaqmt/E/V38TakOY7Mrssrf2WP+LHv+VeqwWNpbxhILWCJANoVIwoA9MCrFcx8TPFMPgzwLrGuTOivbQN5Ct/HMeI198sR+GaAPMvD1raeMv2jtW1S3ggjsPCNuLJGiUDzbl924kj+7lx9Vr3SvGv2UdMe3+Fo1a7Um+1m8mvJpWHzSfMVBP/AHyT/wAC969loAKKKKACiiigDw/9rf7bd/DmPTNOTe8srXlxzgC3gQs5/wC+jHXZfAXUn1X4P+FrmXG8WYhOBj/VkoP0UVh/EaAeIH8fIZJEg0vw+9iD1USzKZnIHsqw/nUf7KV0bn4LaUpYt5M08Qz2/eE4/WgD16iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDh/ib8OdO8cWsMwml03XrT5rLVLY7ZYWByASPvLnt+WK4vQvidrHgnU4vDvxgtxasfktPEEKk212B034+62Ov6gdT63relnVYII1v7+waGdJxJZyhGbb/C2QQynuCOaxPiTcJHoP2a68KXniexumMdxa2qxsUXH3trsM+2ORQB09rcwXltHcWk0U9vINySxOGVh6gjgipa+M9U8I+MPDuuG5+GeieN7TR3jctZXEjQmBz/AHCj/MM+oPTBz1rV0qXTb7zNL8VfEX4h+FNdkIeSDV7gpGz+qsABt54GRQB9IeLtVttDs7HT7SSO2v8AVLxLa1iiADFnfMjhfZd7E/4109eL+D/B/hr4feJNJ1SW5l1p9TBtItfvbvz3juG+7GP4VWQFgGHORtJ+YV7RQAUUVX1C6WxsLm7kGUgiaVuccKCT/KgCn4p1iHw94b1TWLnHk2FtJcsPXapOPxxiuK8CyJ4J+F6a34gEjajqT/2pfhF+dri4YHYAT/DlU69FrW8TG31rQfD0Ws30Onw6jdwCW0kiEqXoZWb7Mc9AcZz/ALNcp+0yZB4FsYYflVr5T8vGCsbsoH4gUAdF4V1a58XpdeKdIF1BEqT2Nha3U2Le5Cyf8fDKoyMlcA8/KPeuZ8JeONbtNeL+Kpozp95enTrqHaA2j34OEj3D70Eq7SjnnLDPU47z4YW8Fr8OvDMNoFEK6dBt2jA5QE/qTXjP7SurWei6o8OnT263GsWi2utrJA8scEO7EFy+zlZFYkKepHbgUAfRFzBFdW8tvcxJLBKhjkjdQyupGCCD1BFcX4Skfwxr7eD7qR3sWha50aWRsnyVID25J5JjJXb6ow/uk1534R+N7zyeDvDup20kXiK8u1tb5rmCRAYdnyTAEDBkyhAPTnPFeveKvDw1yTR547g2t5pl9HeQzBdxwMq6H2dGZT9R6UACj+wtSjiUEaVeOQOeLeYngD0Rv0b/AHq5/S/Ddl4dv9Q0vSYIbWa7lfVLCZVwfMGA8bHuAWAA/uNj+HNbekalZ+MdJ1S2nt5ITb3Utjcwsw3I6NwwI9trA+9L42ZLSwstSIbfYXkUisBnCu3lPn22yN+h7UAaWg6mmsaXDeRo0TNlZImIJjdSQynHcEEV4r+0mdZHjT4Yjww8aaw97cx27OoYKzLEpYg9gCSa9G8NXrw+M9Vs5AqC5UTPCp4imX5WI9nUow/Edq53xO9vP+0J4XXUGCwaXod5fwsx+VZGZY2J+iZoA6CK3TwR4bstA8PKt7rVxvMX2huZ5TlpLiYjnGTlj7gDtXhGpeHvHXijXE+Hx12xQSZvfEU2mqzKm9j/AK6RsF3YD5YxgAAZ4GR3154iabXmvPDVlDceO/EtuIrHcSVsNPUnbPNn7oOS+3+IlR2r0vwB4QsfBmgrp9kzzzyOZ7u8lOZbqZvvSOe5P6CgCXwT4S0fwXoUOk6BaLb2yD5m6vK3dnbuT/8AqrfoooAK8j8RWyfEn4oQaKwEnhrwswub4Hlbi+ZT5cfoQiksfc4rq/it4yi8E+ELjUAY21CYi2sYXIAknbhc5/hHUn0BrnfgpqemxadHomhQ3uqJGHuNR18R7ba4u2OZNrtgyEsT90EAAc0Ad54R0OHw14Z03RrVi8VlAsQcjG4jqcdsnJxWvRRQAUUUUAFI7BEZnICqMknsKWq2qWUeo6bdWUzSJFcxNC7RttYKwwcHscHrQB5/awm9+EXiTUZIn83W4LzUChPOyRGEY/CJYx+FYH7IoI+DNnnvd3BH/fVeneI7ZLfwXqlrbJtjj0+WKNB2AjIArzT9koAfBmwwBzdTk4/3qAPZaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkPihBpz+GJJtW8LyeJbaNh5lpBCskyoeropwSRxwDmuvooA+N/F3w6uV0+WXwxo3jnw/o9yN7WksYuo8htykxRuZE555Bxiu1+Cvx9gJh8MfEKZrbUoG8iLUplKrNg4AlyAUb/aPB74Ne5eLND1TWPsx0nxLf6G8Wd32aGGRZc4xuEiN0x2I615l43+Der+KLi2utW1rSNdngIAGoaWLd2X+6ZYGU49sUAe2qwZQykFSMgjkEVW1a2N5pV7agAmeF48Hodykf1r5y8OT/FL4MwfZtX0keJ/CUZ+X7DMZZLRPRCw37R6MMehFe4+BfHPh/wAcaYL3w7fpcAcSQt8ssR9HQ8jr16e9AFLRvEtqmn+C7W4tw0mqqYonGNkTxQsx69/kIFbHi7wzY+KtOhstT8wRxXEdwrRnDBkOevoRkH61xepaJdyLYWuniNL7w3raahAkkgQS2b7g+Cf9iWQf7yV6BrS31zod2uh3EEOoSQt9lnkG+NXI+ViOcjOKAPBdP8eeIdO8L634Q8MWsS6j4Zim83WdQcRW8dqhby3VTy7FVK9NoIzkivN/CranZ3+h+Jr7R9S1fR/EkimPT5r1ZZdQ1KJTtmlXA/dB9xAPAABI6V694r0fUv7R0/VPHOmXHivXY4Ctpomi2bDT9wOd00rj5uRuAfAHZSa4T4S+FvEGqadqbaJol14e1a8luRNqd9GUj0yFnJFvZRnnLfxPxtHqcCgCexiNj8RJPE9yia94qilNhb4YiK61SXAaOP0gto+C3174r6kh8zyk84qZdo37OBnvj2rzT4SfDebwukOoa/LBPq8UH2W2htyTb2MOclY93JZj8zueWPtXpN1MttbSzukjrGhcrEhdjgZwFHJPsKAOH8GukPxO8e2cR+UtZ3JGOjNDg/8AoIrf8dIz+E9RVMbig259dwxUvh3R7Cwe91CyhmW51WQXVxJcA+axKgKpB5UKOAvaqnxHubez8D6vc3j+XbxQ73bOMAEHOaAOakaJfjnDNG0u57FrWRScoWC+YCPcDg/UV5n8fE1LWPjN4e0jwdLBcazdabLaXkDP8kcBcP8AvSPuqQCT3I47gHf8SeL7Lw3qumeI76M/aprS9v4LdVJe4eVkjt4wP9pVH5muz+DfgmTw1o8+q66qTeLNZc3eo3LKN6s/IhB/urwMdM5PpgA2fh/4LsvB+nyhHN5q123mX2oSqBJcP+H3UHRVHAH511VFFABVLWdVsNE0y41HVruGzsbdS8s0rbVUf4+3U1S8YeJtL8IeH7nWdduRb2UA5PVnY9FUd2PYV5Z4W8M6p8UtatfGPj+DydAiPmaN4ff5lCnpNOOjMRyB/IcEASx8IyfF7xHa+LfGFvJF4Vtl/wCJNo8vBnUn/XzDtu4IX0xnjr7VbwxW0EcNvEkUMYCpHGoVVA6AAdBUgGBgdKKACiiigAooooAKKKKAKHiBQ2g6krDINtICP+AmvLP2TYzH8FtMOc77idvp+8P+FemeLpRB4U1qZiFEdlMxJ7YQ1xn7OVkbH4LeGEddrSQNMfffIzA/kRQB6TRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGPN4k0qLxMvh97k/wBrNbfbPJWNmxFkjcWAwOQcAnnFT+H9asfEGlRajpUry2kpYK7xNGSVJB4YA9Qe1aAUbi2BuIwTjn/PJpaAOIufEPjSG7ZU8ExTW3O101ZN34gpXiPxOsU02K/8TeG/BHi7w74y88Ti5tEWS3PTdu8tmUoRyRjr1r6X1zTI9Y0u4sZbi8tkmABls52glXBB+V1II6flXJR/Da3gXFr4o8Yw46f8TmWTH4PuFAHL/Cvx/pPxV0WJpJILLxdaRNFc27AfvEIw3ynlom7jqD6cE6nhrWLn4dWtr4c8ZDZo9uoi0/XFz9n8oHCQzk/6t1GFDH5WAHIOa89+JPwB1p9bfxX4J8S3Ta9ERKqXISOR2UYysqBQCRxyvOeTXQ+DPjNHbMvh34uQQaFrwgVzLIytb3KHIy20kRtwcqePp0oA9thljnhSWCRJInAZHQ5VgehBHUU+uBs/CWkTRm/8Ba7NpBky4GnTrPZuxPUwElP++dp966O60rU7qSMSa7PDAbMwTR2sCIWmJH75GO4qevy8jn2oAteItZsfD2h32r6rMIbGziaaVz6DsPUk4AHckCrOm3S3+nWt2kckS3ESShJV2uoYA4YdiM8is7VfDOj6xNYzaxYQ381kQ0DXC79rDo2OhORnOK2c/pQAVxnxbsJNZ8HPokRQf2rcQ2cjOfuxlw0jD3CKxrq9QvrXTbOW71C5itraJS8ksrhVUDqSTXzNrPxS1v4jePZtH+GtsszxxyW1peTKQlsjACW6bPfHyp6DPBLYoAox6cnxh/aFi1Pw+7N4X8OeQrTOP3Z8tiQsQ9GYfkCfSvq+uT+GXgbTPh/4Wt9I0tFaTAe6uSuHuJccu39B2HFdZQAVX1C8ttOsbi9vpkgtbeNpZZXOFRFGST9AKsV4d8b9VvfG2vWvwt8KTbbm523GtXS522lsCDtPPJOQcd8qP4qAMjwrZ3vx08ZJ4o1xJIPAukTkaXp7j/j8lH/LRx6ev/fI/iz9DgBQAoAA4AHas7w1olj4c0Gx0fSohDZWcQiiT2HUn1JOST6mtKgAoqvqN7b6dYXF7eyrDa28bSyyN0VVGST+FeTah4x8aW1npPil00y30TUb63tbfRJYW+1yRTOEV/NzgSEHfs24AHJJFAHsNFFcj491y9t2s9A8ONGfEWq7lhdhuW0hGBJcsO4XIwP4mIHTNAGlD4u8PzeJ5PDsWr2b65Gu9rNZAZAMZPHrjnHXHNblePax4a03T/EngPwx4cjB1Sxvv7ZvbsjdL5KqyyyTP1LSuwXnrz2FewOyojO7BUUZJJwAKAFoBB6c15nFHefFISXBvbvTfBSytHbpZyGKfVQpIMjSD5khJztUYLDkkAgVS+CGl2ljrvjp9DSSDQE1JbO0h85pE3RRgSuNxPVjjr2oA6P42Xv2D4S+LJw21jp0sSn/AGnXYP1YVs+A9ObSfBOgafIu2S2sIInHowjAP65rjvjqBqtj4a8KqSz67rFvFKg6/Z4m82VvoAq/mK2fEHxH0fTNUOk6bFea9rY5aw0mMTPEPWRshYx/vEUAdrRXL+DPGVv4muL+yfTtR0nVbDYbmxv4wsiq+djgqSrKcHkHsa6igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArnfGeq65ptrax+GdD/ALXv7mTYPMnEMMCgZLyNycegAJJroqKAPL4/DHjHxlMx8eajHpGkxnaNK0Sdh9p/2pZ+Gx/srj3rWvvDnw98F6GZtR0nQ7GwVseZcwLIzse2WBZ2PYck1v8Ai/xTpPhLSJNQ1q6SGMAiKLOZJ37JGvVmPAAHrXlHjWS88PeC7zx34kNj/wAJzJGP7Ls7nEiafuICwwJ/FJg/M2Mls/wgCgDD1zwXZ+K3kuPh54I1PQ5JclNWN22lx5P8YgGWYf8AAVzVK8u/EvgO08jUvjPYz6nHgLp5s/trsey4GZPzFekaD8NBrul2WoePNb17W7y4t0kms57k29tGxGSohi2jjOOc13Hh7wn4f8ORlNB0XT9PBOSbeBUYn3IGTQB89+GfFvx/16MyWejWSW/8M17aLb7h24Zgf0qDXfhF8WfFusHVNW1rSdLunwXNlczJuOAASF4yAAOK+pqKAPnLTP2aZL0Rv408Z6rqZ6yQxM20n/eck+navafAvgrQfA2kDTvDliltETukkPzSTN6u3Un9B2rpKKACiikZgqlmICgZJPAAoA5H4qeMofA3g271ZkM14cQWduASZp24RcD35PsK5b4eaLY/C3wTfeIvGl4i65qLfa9VvJDudpGJKwr3bGcADqSah0GxPxI+I83ie+eOfwzoEzW2jRI2+O4nwPMuc9Dg/KvXke1aPlJ4w+NM32mNJNM8HwKI1YZD3twobdjp8kYGPQvmgDC8Q+LPH1kukeI7hLPS9LvNSt7ODQJIfMupo5W27pZM4R8ZbaOB0JzXtVeZ+Pymp/Ff4faNIcRwSXOrNk/eaKPagHry5P4V2fiXxHY+H1sFvPNkuL+6S0tbeFd0ksjeg9AMsSeAAaAOY8fsPEfibR/BSO4t5lOpaps720bALGf9+TA+itVa9KeKvjBp1nbjfp3hKJrm5I+4byZNsSemUj3t7bxXW6P4btdM8QazrQlnuL/VGj3vMQfKjRcLEmAMICWbHqxrzO9v9a+GfinxQlh4c1PX7XxDOdQ01rKMuEumUK8UzfwLkBg3Py59KAPUvFOv2PhnQrrVNTkCQQr8qj70rnhY0HdmOAB6muN0ct4S8N61478Zhv7au4RPcRDn7PGP9VaR/QsB/tOxJpvgfwXrF3qC+I/iZPaalr6sGs7SEE22mr6RqeDJnq5yeMA9zJ8Z0kkg8JK0F3Pp6a/bS3qW0DS5jQOw3KoJK7whPH8qANP4X6Fe6fpVxq/iAZ8R61J9svs8+SD/AKu3H+zGuFx67j3rN8a383i/VG8F+Hpx5BONevY2/wCPWDvApH/LWQfLj+FST6VYu/EM3jWx1bRPC/8AbWj3nkgDVLrTpYI48uAwQuFJfbkjAwOueK6fwv4d0zwxpMem6NbLBbqdzHO55HPV3Y8sx6knk0Acd4xu73U9dsvAHhWb+zU+yC41G9g4aztAdiRxDoHfBAP8IBODXTR/8I78PvCkUTS2uk6LZJsVpX2j16nlmJye5J9TWFpWh69p3xT8VaoltZyaVrFrbiG7Mv7yCSGMqEMePmUlmbII/wAL934a0ON7XxL4yj0+61bTrYCS/nBWGHHJdEZiqc9+vvQBwl74X1b4m+NbfxMtzqfhvQLeyaygIbZd3kbvud1UjMAYYGfvkAcCuzOreBPhjpQ037dpekRRjd9lEgaeQn+LYMyOx9cEmsWK+1n4njzdJvL3w/4K523sWI7zUucZjyD5UPX5vvNxjAqCSf4V/C8qSdNTVHbAIU3l/M/1+aQkn1wPpQB2Hw9vdW1bSbnVdctDZve3TyWlvJGElitRgRLIP7xALEdt+O1dRXmFnpvir4gRvea/eah4V0GQkW+lWTCO8mj7NcS8mMn+4mCAcE5rh/F/hmyk1VtI+FF54h/4S61kXz72PU52tLQfxC4d2ZSxH8Cgse4AoA+h6KzvDtrfWOhWFrq18dQ1CGFUnuigTzXA5bA4HNaNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFed/E3xPqS31n4P8HOv/CT6ou4zkbl062zhrhx0z1CjuaAM3xv4jnTxq2leF4I/EPiUxR+TaTIn2XR8E7p5ZANwZtw+XOSFGPfW8L/AA2trTVYtf8AFd7J4i8TKAVurpQIrY+kEfRB78n3roPBHhLTfB+kfYtMV3kkbzbm7mO6a6lP3pJG6sx/TtXQUAFFFFABRRRQAUUUUAFeZ/FS/u/EGo2vw+8P3AhvdUiM2p3SH5rKxBAY/wC/JnYv49ODWt41+J3hXwnZ3RvNXs59RhQlNOgnV7iV/wCFAgyQSeORXlnwq17xjJZX+paf4Dv7rxJrVy099qeqyLZ26AZEccYOXaNFwAAPWgD3nT7PTvDuhwWlqsFjpllCEQEhEjRR3J/UmuA+DMya5q3jbxZZup0zWNSWO0AOQ6W8YiMv/AiD+AFM/wCFZXviyaK8+KWr/wBrFADHpFgXt7CE+4zulP8AtMR6YrWutW8SaDOdK8PfDw3Gl22I7Wa31K2ghKY4+RiGX6bT+NAE/wARfB154kuNF1LRNWXSda0idpbe4aATIwZdrIy5GQR71xN18LppfFuk+JPiF49uru5t7hFs4YQtnCsp6InzH72Og5PTNYXxQXxpp+hap4r8aS3n2GNVjtdG0DU5IEtcn/WTyKFMnOOmcZ/Ly+3+IdrfaTLZHwd4m1S31GIIbXUNWnurZXyMTRkoXDA91OaAPtgnAyelZV7r+nWeoaVYyXCvdam7JbRx/MXCqWZuP4QByemSPWvn+7+GV1Y+CZY/EvxI8T3Gp3Fr9oi0+0ndh5YxuVYHbdJgMB1GPSvLLn4f6jp1zDf+DoPGur20cDIwaxm0+a3UjOUkOQw/2QKAPsXW/GugaLrVhpF7qMI1W+kEcNojbpOf4mA+6uO5xWda/EPSZk8QX80iQeHtJZYv7VdwIriQAmRY/wC9t4XIzlsgZr8/IdOmkJ1HWLhxbpPsutsyNdISeT5bMGJJzyfevX/APw41LxrfHS75fFFx4atXjFo32+3iW2ibks8ZZ+cdAnWgD6W0H4teFb3wra61qus6Xpv2hWkFs92jyom47dyjkMVAJGOCcVjeGfitpfi7xUs2n67pmm+G7MPGVvLiOO41CYjgqjHKxryc9WPoBXnWpfs1eG3vobfw3rE97d6dcR/2pZ3Uyhmif5gAyr8j7ORkEH2qdP2dT/bOseH49RuofCzwLd2lybeB5PPJIMbybdxC4B4xkHtQB7bq3xC8N6eiLBqMWqXkhxFZ6Ywup5D7KhOB7nA96yvFPhuTxRriXPi14U8FWdmJ/sEkmwSXByWa47bUUDAzjJJPSvlfWB43+DviOWTRNKv9Cspo40uXjVbqCZl4Zo5GU4U/eCtyM8ivbPhQZ/ihs1PxJD4ovtIUZH9o3MMVk8ikYUW8QUyc5OWBXj1oA7e0+EXgaVIrizsZzaSIGjjj1CfyWQjIwofGMfhWcdb+G3ga/lsvDOlWd5ryjBs9FtBcXWfRmUHbz/eYda9D8TabNqnhnU9MsLprC4ubWS3huIxzCzKQGGPTPavMvBer/wDCsNBtdF8V+F20m1tlETa1pkf2izuMf8tZCv7yMk8neuM556UAankePfGsZS9Mfg3RZR80cMgm1F19N2NkWfbJFdz4Z0HTvDWjwaZo1usFpFk4zlnY9XZjyzE8knk1No2r6drlgl7o99bX1o/3ZreQOp/EVeoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApsjrGheRgqKMlmOABTq5288GaFfXklzqFkbx3YuUuZnljBPojEqPwFAGRrHj6Ke4l0zwXbHX9ZHy/uTi2tz/elm+6APQZY+lXfAPhAeG4ru91G6/tHxFqTiXUL8rt8xh91EH8MajgD8Tya6a0tbezgWC0gighX7qRqFUfgKmoAKKKKACiiigAooooAK8xLXfxRv51gup7LwLaTNEZLaQxy6vIpwwDjBWBTkZBy5B5Ar0HWtPXVtIvNPkmngS6haFpIG2yKGGCVPY89a8+0X4Rx6Nax6dYeMPFUOiRZ8rT47tUVATkrvVA+Mk9+9AD9d0r4d+ADpt9/YNgmq2u5dOt7S3El3M7f3FHzO3+03Tk5FLHJ8SvE2JY103wdYMOFmT7beEepGRGv05rpvDHgfw74Yme40fTIo7yQbZLuQmWdx7yOSx/OrPi/wAS2PhXRnv9QLuxIjgtoVLy3Mp+7HGo5Zif8TxQB5/8O7fxBZfFjxDpupeKdR12wstOgaQ3CIiJPKxIAVRgfKmfx713PjDxjpPhSK3GoPLNe3TbLWxtYzLcXLeiIOfqTgDua4DRtRvPBlvLaPaLq3xG8TXD6hLYQP8AJbA8L5r/AMEMagLu/iIO0HNdX4b8OWnhOC+8R+KdSjvdckiL32q3HyLEg58uIHiOIdgOvU5JoAv+CfE2nePfDDX0VpJHE0klrc2V4g3xOh2tHIvIz7e9HiXxTYeGZtO0u3tZbzVLwiO002zUbyg4LnoEjXuxwOwzXGfDvVk8OfDvxN4t1G2nitdS1S61W1t2UrLLG5VYRtI4Z9qkD/aFdT4A8NyWdhdapr6JN4h1kCa/dhnywR8tuueiIDtx35PegDY8TeGNE8UWa2viDTLa/hU5TzV+ZD6qw5U/QiuU8TeLtE+GukxaLo2m3+pXsEBlh0uwV7iVI8/fdjkque5PPbNV/hbfRaR4V8V3LSyjw/puqXq2KyOXMVtDgMoJ52h1l2jsMCtP4SWDnw/J4h1CPGreIZP7RuC2dyI3+qi55wke0AfWgCXwbeeH/iB4as9Zm0zTbi4kTZdRSQLI1vNgb4m3LkEE4ORz9DWjdx+G/AehajqsVhYaVZQx+ZMbW3SIvjhVwoGSSQAPUgCuAudc0/wn8TvHmuKXGmwWFkl7BCAWuL9ywjVB3cptH/Ahmt/S/Ceq+JNSsdd8fyput3W4s9Ct2zbWcg5V5G6zSj1Pyg9B3oAyf2etWOpaZ4kGqWs9l4nbVJLvVLadSHTzuYcZ/h8tVUf7prpfil41fwZosD2GnTarrV9IbewsYgSZZApYk4/hAGTWN43t/wCyfir4M1bRm26nqkz6bfQKOLi0WNpC7e8ZUYP+1irPxqjNjo2k+KYo3eXw5qEV9JsBLfZz+7nGB/sOT/wGgDnfCmu/GWbR/N1bwrojzlmkxPeeQ7KekYQBgCPUn612PhPxpB4v03UrGxD6P4ns42juNPvE/eWkhBCsV6OmcEMOCPSuyhkSaFJYXV4nUMrKchgeQQa88+JWmajp/iXw/wCNNB02TUbjS/Ntr+1tgPPntJBzsH8TIwDBep5xQBxHw40LU9Zl1LTNc8Z+LdN8b6dIWvYTdo0Lhidk0SFMGJhjgdDwcV2o1Xxr4OyNfs/+Ep0hT/yENNiEd3Ev/TS36P8AVDn2qtqD6B8SGg1TwdrqWHi/TFZbeYqUnh/vQzwsAxjJ6gj3FdN8OfFUninR7g39qtlrOn3D2Wo2qtuWOZOpU9SrAhhnse+M0AcS1h8KfFdzLf2N/b6XqkpJlezvH0653d98YKndnuVJpPh54yhsfFtt4bbxfb+JNNv0kOnTy8XkLx8mKU8bwRkhiATjFeo3mhaTfXcd1eaZZT3MZykskCs6n2JGam/s2x+1JdfYrb7Sn3ZfKXev0OMigC3RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ3iPVU0Pw9qmrTRtLHY2st00anBcIhbA9zjFeOJfXdvLo+pP5WvfEvX7bztOgY5tdJt35LqB92NQcF/vORgHtXuM0Uc0LxTIskUilXRxkMDwQR3Fcx4N8AeHPBt1f3Hh+wFtLeEb2Z2faoyRGm4nagJJ2jj8hgAXwF4OtvCtnPJJO+oa3fMJdQ1KcfvbmT+iDoqjgD8a5/x5AniL4n+EfDd2vn6TDBc6ve2rfcmMZRIN47qHcttPBIGelek1w/jrwJN4j1qx1bStevdC1CKB7Kee0VS01s5DGPJ+6QwBDDkUAZt258e/ECG0t33eGvDNwJbpwMpd34GUiB6ERZ3N/tYHau91rUYdI0a+1K6OLezge4kP+yilj+gqHw1oWn+GtEtdJ0e3FvZW67UXOST1LMTyWJyST1Jqzqlha6rpl3p+oQrPZ3UTQTRt0dGGCPyNAHg/mSf8Kc0zwdav9o8VeK1a6e1iOWtYrmUzSSOB91FVyuTjJr3qFIdO05I9wjt7aILk9FVR1/IVheC/A/h3wXbPD4d02O2ZwFkmYl5ZAOgZ2JYgdhnArop4o54ZIZkV4pFKOrDIYHgg0AfPV5bzz/DrTvEkiMtz4i8X2mrxRP1WJ5lSFD6/u1U+2favoivOPDvwrttJ1DTWudc1XUtJ0iTzdK025ZfLtGwQpyAC+0HC7ulej0Aec+NZ49C+KfhHXNQONMuILjSDM/3LaeQo8bE9Bu8spn3FaXxnvhp/wAKvFEhAZ5rCW1jU/xPKPLUD1JLiuo1jTLHWdNuNP1W1iu7KddksMq7lYe4rgbD4YzW/izT7m91++1Tw1pymSz0m/Yy+RcAjY+/OXCjO0Pkr2NAHdeHtPXSdA0zTkGFs7WK3AznhEC/0rQoooA5rxZ4H8P+KgH1bT4zeoMRX0P7q5hOOqSr8wx9ce1ZHwp8E3vg2PXjquqNqt5qN8bg3bn55Iwqqm8dNwAIOODXeUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34659=[""].join("\n");
var outline_f33_54_34659=null;
var title_f33_54_34660="Carglumic acid: Patient drug information";
var content_f33_54_34660=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carglumic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/43/31411?source=see_link\">",
"     see \"Carglumic acid: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/49/38675?source=see_link\">",
"     see \"Carglumic acid: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10107689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbaglu&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10229146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692120",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat urea cycle problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10229145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2760199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carglumic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10229150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10229425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10229152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10229148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695894",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take right before a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not chew or swallow.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2760231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix each tablet with a",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       teaspoon (2.5 mL) or more of water. Drink it right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse cup with more water and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749825",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not mix with juice, milk, or other drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2760235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the tablet. Mix each tablet with a &frac12; teaspoon (2.5 mL) or more of water. Give right away. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694866",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10229149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10229426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened containers in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2760279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After opening, store at room temperature. Throw away after 30 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10229153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15624 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34660=[""].join("\n");
var outline_f33_54_34660=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10107689\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10229146\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10229145\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10229150\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10229425\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10229152\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10229148\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10229149\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10229426\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10229153\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/43/31411?source=related_link\">",
"      Carglumic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/49/38675?source=related_link\">",
"      Carglumic acid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_54_34661="Rasburicase: Drug information";
var content_f33_54_34661=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rasburicase: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/30/20964?source=see_link\">",
"    see \"Rasburicase: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/5/23636?source=see_link\">",
"    see \"Rasburicase: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elitek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fasturtec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F217438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme;",
"     </li>",
"     <li>",
"      Enzyme, Urate-Oxidase (Recombinant)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F217417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hyperuricemia associated with malignancy:",
"     </b>",
"     I.V.: 0.2 mg/kg once daily for up to 5 days (manufacturer-recommended dose)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Alternate dosing (unlabeled; Coiffier, 2008):",
"     </i>",
"     0.05-0.2 mg/kg once daily for 1-7 days (average of 2-3 days) with the duration of treatment dependent on plasma uric acid levels and clinical judgment (patients with significant tumor burden may require an increase to twice daily); the following dose levels are recommended based on risk of tumor lysis syndrome (TLS):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     High risk: 0.2 mg/kg once daily (duration is based on plasma uric acid levels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermediate risk: 0.15 mg/kg once daily (duration is based on plasma uric acid levels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Low risk: 0.1 mg/kg once daily (duration is based on clinical judgment); a dose of 0.05 mg/kg was used effectively in one trial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Single-dose rasburicase (unlabeled use; based on limited data):",
"     </i>",
"     0.15 mg/kg (Campara, 2009; Liu, 2005)",
"     <b>",
"      or",
"     </b>",
"     3-7.5 mg as a single dose (Hutcherson, 2006; McDonnell, 2006; Reeves, 2008; Trifilio, 2006); repeat doses (1.5-6 mg) may be needed based on serum uric acid levels",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F217427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/5/23636?source=see_link\">",
"      see \"Rasburicase: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hyperuricemia associated with malignancy:",
"     </b>",
"     I.V.: 0.2 mg/kg once daily for up to 5 days (manufacturer-recommended dose)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Alternate dosing (unlabeled; Coiffier, 2008):",
"     </i>",
"     0.05-0.2 mg/kg once daily for 1-7 days (average of 2-3 days) with the duration of treatment dependent on plasma uric acid levels and clinical judgment (patients with significant tumor burden may require an increase to twice daily); the following dose levels are recommended based on risk of tumor lysis syndrome (TLS):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     High risk: 0.2 mg/kg once daily (duration is based on plasma uric acid levels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermediate risk: 0.15 mg/kg once daily (duration is based on plasma uric acid levels); may consider managing initially with a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Low risk: 0.1 mg/kg once daily (duration is based on clinical judgment); a dose of 0.05 mg/kg was used effectively in one trial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Single-dose rasburicase (unlabeled use; based on limited data):",
"     </i>",
"     0.15 mg/kg; additional doses may be needed based on serum uric acid levels (Liu, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F217418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elitek&reg;: 1.5 mg, 7.5 mg [supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F217402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. infusion over 30 minutes; do",
"     <b>",
"      not",
"     </b>",
"     administer as a bolus infusion. Do",
"     <b>",
"      not",
"     </b>",
"     filter during infusion. If not possible to administer through a separate line, I.V. line should be flushed with at least 15 mL saline prior to and following rasburicase infusion. The optimal timing of rasburicase administration (with respect to chemotherapy administration) is not specified in the manufacturer&rsquo;s labeling. In some studies, chemotherapy was administered 4-24 hours after the first rasburicase dose (Cortes, 2010; Kikuchi, 2009; Vadhan-Raj, 2012); however, rasburicase generally may be administered irrespective of chemotherapy timing.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F217401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial management of uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies receiving chemotherapy expected to result in tumor lysis and elevation of plasma uric acid",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F217436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (&le;50%), fluid overload (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (46%; serious: 5%), headache (26%), anxiety (&le;24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (13%; serious: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia (&le;17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (50%), nausea (27%), abdominal pain (20%), constipation (20%), diarrhea (20%), mucositis (15%; serious: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (&le;16%), ALT increased (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngolaryngeal pain (&le;14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Antibody formation (healthy volunteers: 61% to 64%; patients with malignancies: 11%), sepsis (&le;12%; serious: 3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Ischemic coronary disorder, supraventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperphosphatemia (&le;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal/gastrointestinal infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenic fever (serious: 4%), neutropenia (serious: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory distress (serious: 3%), pulmonary hemorrhage, respiratory failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, anaphylaxis, arrhythmia, cardiac arrest, cardiac failure, cellulitis, cerebrovascular disorder, chest pain, cyanosis, dehydration, hemolysis, hemorrhage, hot flashes, ileus, infection, intestinal obstruction, liver enzymes increased, methemoglobinemia, MI, pancytopenia, paresthesia, pneumonia, pulmonary edema, pulmonary hypertension, retinal hemorrhage, rigors, seizure, thrombosis, thrombophlebitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F217405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of anaphylaxis or severe hypersensitivity to rasburicase or any component of the formulation; history of hemolytic reaction or methemoglobinemia associated with rasburicase; glucose-6-phosphatase dehydrogenase (G6PD) deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F217390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylaxis reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Severe hypersensitivity reactions (including anaphylaxis) have been reported; immediately and permanently discontinue in patients developing serious hypersensitivity reaction.",
"     </b>",
"     Reactions may occur at any time during treatment (including the initial dose); signs and symptoms may include bronchospasm, chest pain/tightness, dyspnea, hypotension, hypoxia, shock, or urticaria. The safety and efficacy of more than one course of administration has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolysis:",
"     <b>",
"      [U.S. Boxed Warning]: Due to the risk for hemolysis (&lt;1%), rasburicase is contraindicated in patients with G6PD deficiency. Discontinue immediately and permanently in any patient developing hemolysis. Patients at higher risk for G6PD deficiency (eg, African, Mediterranean, or Southeast Asian descent) should be screened prior to therapy.",
"     </b>",
"     Severe hemolytic reactions occurred within 2-4 days of rasburicase initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobinemia:",
"     <b>",
"      [U.S. Boxed Warning]:  Methemoglobinemia has been reported (&lt;1%). Discontinue immediately and permanently in any patient developing methemoglobinemia.",
"     </b>",
"     Initiate appropriate treatment (eg, transfusion, methylene blue) if methemoglobinemia occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hydration: Patients at risk for tumor lysis syndrome should receive appropriate I.V. hydration as part of uric acid management; however, alkalinization (with sodium bicarbonate) concurrently with rasburicase is not recommended (Coiffier, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple courses: Rasburicase is immunogenic and can elicit an antibody response; efficacy may be reduced with subsequent courses of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Uric acid degradation:",
"     <b>",
"      [U.S. Boxed Warning]: Enzymatic degradation of uric acid in blood samples will occur if left at room temperature, which may interfere with serum uric acid measurements;",
"     </b>",
"     specific guidelines for the collection of plasma uric acid samples must be followed, including collection in prechilled tubes with heparin anticoagulant, immediate ice water bath immersion and assay within 4 hours.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F217407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F217421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8774026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue breast-feeding or to discontinue rasburicase should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Elitek Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (1): $749.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (1): $3748.03",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F217398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma uric acid levels (4 hours after rasburicase administration, then every 6-8 hours until TLS resolution), CBC, G6PD deficiency screening (in patients at high risk for deficiency);  monitor for hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fasturtec (AT, AU, BE, BG, BR, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, IE, IT, KP, MT, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TR, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F217389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rasburicase is a recombinant urate-oxidase enzyme, which converts uric acid to allantoin (an inactive and soluble metabolite of uric acid); it does not inhibit the formation of uric acid.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F217404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset: Uric acid levels decrease within 4 hours of initial administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Children: 110-127 mL/kg; Adults: 76-138 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~16-23 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arnold TM, Reuter JP, Delman BS, et al, &ldquo;Use of Single-Dose Rasburicase in an Obese Female,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38(9):1428-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/15292497/pubmed\" id=\"15292497\" target=\"_blank\">",
"        15292497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Campara M, Shord SS, and Haaf CM, &ldquo;Single-Dose Rasburicase for Tumour Lysis Syndrome in Adults: Weight-Based Approach,&rdquo;",
"      <i>",
"       J Clin Pharm Ther",
"      </i>",
"      , 2009, 34(2):207-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/19250141/pubmed\" id=\"19250141\" target=\"_blank\">",
"        19250141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coiffier B, Altman A, Pui CH, et al, &ldquo;Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(16):2767-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/18509186/pubmed\" id=\"18509186\" target=\"_blank\">",
"        18509186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coiffier B, Mounier N, Bologna S, et al, &ldquo;Efficacy and Safety of Rasburicase (Recombinant Urate Oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin&rsquo;s Lymphoma: Results of GRAALI (Groupe d&rsquo;Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(23):4402-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/14581437/pubmed\" id=\"14581437\" target=\"_blank\">",
"        14581437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cortes J, Moore JO, Maziarz RT, et al, &ldquo;Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone &ndash; Results of a Multicenter Phase III Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(27):4207-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/20713865/pubmed\" id=\"20713865\" target=\"_blank\">",
"        20713865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutcherson DA, Gammon DC, Bhatt MS, et al, &ldquo;Reduced-Dose Rasburicase in the Treatment of Adults With Hyperuricemia Associated With Malignancy,&rdquo;",
"      <i>",
"       Pharmacother",
"      </i>",
"      , 2006, 26(2):242-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeha S, Kantarjian H, Irwin D, et al, &ldquo;Efficacy and Safety of Rasburicase, a Recombinant Urate Oxidase (Elitek), in the Management of Malignancy-Associated Hyperuricemia in Pediatric and Adult Patients: Final Results of a Multicenter Compassionate Use Trial,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2005, 19(1):34-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/15510203/pubmed\" id=\"15510203\" target=\"_blank\">",
"        15510203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kikuchi A, Kigasawa H, Tsurusawa M, et al, &ldquo;A Study of Rasburicase for the Management of Hyperuricemia in Pediatric Patients With Newly Diagnosed Hematologic Malignancies at High Risk for Tumor Lysis Syndrome,&rdquo;",
"      <i>",
"       Int J Hematol",
"      </i>",
"      , 2009, 90(4):492-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/19701676/pubmed\" id=\"19701676\" target=\"_blank\">",
"        19701676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee AC, Li CH, So KT, et al, &ldquo;Treatment of Impending Tumor Lysis With Single-Dose Rasburicase,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(11):1614-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/14565793/pubmed\" id=\"14565793\" target=\"_blank\">",
"        14565793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu CY, Sims-McCallum RP, and Schiffer CA, &ldquo;A Single Dose of Rasburicase is Sufficient for the Treatment of Hyperuricemia in Patients Receiving Chemotherapy,&rdquo;",
"      <i>",
"       Leuk Res",
"      </i>",
"      , 2005, 29(4):463-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/15725482/pubmed\" id=\"15725482\" target=\"_blank\">",
"        15725482",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDonnell AM, Lenz KL, Frei-Lahr DA, et al, &ldquo;Single-Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults,&rdquo;",
"      <i>",
"       Pharmacother",
"      </i>",
"      , 2006, 26(6):806-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/16716134/pubmed\" id=\"16716134\" target=\"_blank\">",
"        16716134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reeves DJ and Bestul DJ, &ldquo;Evaluation of a Single Fixed Dose of Rasburicase 7.5 mg for the Treatment of Hyperuricemia in Adults With Cancer,&rdquo;",
"      <i>",
"       Pharmacother",
"      </i>",
"      ,  2008; 28(6):685&ndash;90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/18503395/pubmed\" id=\"18503395\" target=\"_blank\">",
"        18503395",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trifilio S, Gordon L, Singhall S, et al, &ldquo;Reduced Dose Rasburicase (Recombinant Xanthine Oxidase) in Adult Cancer Patients With Hyperuricemia,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      ,  2006, 37(11):997-1001.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/16708061/pubmed\" id=\"16708061\" target=\"_blank\">",
"        16708061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vadhan-Raj S, Fayad LE, Fanale MA, et al, &ldquo;A Randomized Trial of a Single-Dose Rasburicase Versus Five-Daily Doses in Patients at Risk for Tumor Lysis Syndrome,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(6):1640-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/54/34661/abstract-text/22015451/pubmed\" id=\"22015451\" target=\"_blank\">",
"        22015451",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10189 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34661=[""].join("\n");
var outline_f33_54_34661=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709399\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217416\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854900\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217438\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217417\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217427\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217418\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217400\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217386\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217402\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217401\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217436\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217405\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217390\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299985\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222722\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217396\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217407\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217421\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774026\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323780\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217398\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038797\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217389\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217404\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10189\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10189|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/30/20964?source=related_link\">",
"      Rasburicase: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/5/23636?source=related_link\">",
"      Rasburicase: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_54_34662="Low grade dysplasia";
var content_f33_54_34662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric mucosa with low grade dysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abnormal tubulo-glandular structures lined by crowded epithelial cells with dark, elongated nuclei. Metaplastic glands are seen among the dysplastic elements.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34662=[""].join("\n");
var outline_f33_54_34662=null;
var title_f33_54_34663="Placental abruption: Management";
var content_f33_54_34663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Placental abruption: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34663/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34663/contributors\">",
"     Yinka Oyelese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34663/contributors\">",
"     Cande V Ananth, PhD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34663/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34663/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34663/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34663/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/54/34663/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abruption of the placenta can lead to serious maternal and infant morbidity, as well as maternal or perinatal death. The risks to the mother are primarily related to the severity of the abruption, while the risks to the fetus are related to both the severity of the abruption and the gestational age at which delivery occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=see_link&amp;anchor=H601335#H601335\">",
"     \"Placental abruption: Clinical features and diagnosis\", section on 'Consequences'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the impact of placental abruption on pregnancy outcomes is well-described, no randomized trials and very few studies have examined the management of pregnancies complicated by this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, recommendations for the management of placental abruption are based on case series and reports, personal experience, and good clinical sense.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12397516\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute abruption can be life-threatening for the mother and fetus and can be associated with co-morbid disorders (preeclampsia, cocaine abuse, trauma), thus pregnant women with signs and symptoms of abruption should be evaluated promptly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of these pregnancies is determined on a case-by-case basis, and will depend upon the severity of the abruption, the gestational age, and maternal and fetal status. Any patient who presents with even slight bleeding from placental separation is at risk of developing sudden severe abruption. Therefore, all of these patients should be monitored and undergo continuous fetal heart rate assessment until their status is clear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=see_link&amp;anchor=H6#H6\">",
"     \"Placental abruption: Clinical features and diagnosis\", section on 'Chronic abruption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following actions are reasonable initial interventions for women with potentially severe acute abruption:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediately initiate continuous fetal monitoring, given the high likelihood of a reduction in placental perfusion.",
"     </li>",
"     <li>",
"      Secure intravenous access with at least one, and preferably two, wide-bore intravenous lines. Closely monitor the mother's hemodynamic status (heart rate, blood pressure, urine output). Urine output should be maintained at above 30",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      and monitored with a Foley catheter. Assessment of multiple parameters is important because normal blood pressure may mask hypovolemia if the mother was",
"      <span class=\"nowrap\">",
"       hypertensive/preeclamptic",
"      </span>",
"      prior to the abruption.",
"     </li>",
"     <li>",
"      Keep maternal oxygen saturation &gt;95 percent and keep the patient warm.",
"     </li>",
"     <li>",
"      Estimate the extent of blood loss by collection in a volumetric container",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      by weighing",
"      <span class=\"nowrap\">",
"       pads/towels",
"      </span>",
"      used to absorb vaginal bleeding. In addition to the practical difficulties in determining the volume of blood passed from the vagina, actual blood loss may be far in excess of what is observed due to retained retroplacental hemorrhage.",
"     </li>",
"     <li>",
"      Draw blood for a complete blood count, blood type and Rh, and coagulation studies. A crude clotting test can be performed at the bedside by placing 5 mL of the patient's blood in a tube with no anticoagulant for 10 minutes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. Failure to clot within this time or dissolution of an initial clot implies impairment of coagulation, and is suggestive of a low fibrinogen level. Prolonged oozing from needle puncture sites also suggests coagulopathy.",
"      <br/>",
"      <br/>",
"      Notify the blood bank so blood replacement products (red blood cells, fresh frozen plasma, cryoprecipitate, platelets) will be readily available, if needed. Blood products should be replaced aggressively, as required. If disseminated intravascular coagulation (DIC) is suspected, activate the institution&rsquo;s massive transfusion protocol. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment of disseminated intravascular coagulation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Notify the anesthesia team. Anesthesia-related issues in these patients include management of hemodynamic instability, technical issues related to bleeding diathesis, and the potential need for emergency cesarean delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indications for delivery are discussed below. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment of disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with DIC, we transfuse blood and blood products to achieve the following minimum levels:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &ge;50,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Fibrinogen &ge;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Prothrombin (PT) and partial thromboplastin time (PTT) less than 1.5 times control",
"     </li>",
"     <li>",
"      Hematocrit 25 to 30 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of DIC during pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15961?source=see_link\">",
"     \"Disseminated intravascular coagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial assessment and stabilization, management of pregnancies complicated by an acute, clinically significant abruption depends primarily on whether the fetus is alive or dead, and maternal status. If the fetus is alive, then gestational age and fetal status also play a role in decision-making. The following guidelines provide a general approach that should be modified as appropriate for individual patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982397\">",
"    <span class=\"h2\">",
"     Severe abruption at any gestational age and nonsevere abruption at  &gt;36 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend expeditious delivery for pregnancies at any gestational age complicated by severe abruption, which can be defined as an abruption where the mother is unstable (eg, significant coagulopathy, hypotension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ongoing major blood loss) or the fetal heart rate tracing is nonreassuring. We also recommend delivery for pregnancies with nonsevere abruption at &ge;36 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/1\">",
"     1",
"    </a>",
"    ]. For nonsevere abruptions at &ge;36 weeks, this approach takes into account the relatively low neonatal morbidity of the near-term infant in pregnancies at risk of severe maternal-fetal morbidity or mortality in the event of a future sudden severe abruption.",
"   </p>",
"   <p>",
"    Vaginal delivery is reasonable if the mother is stable and the fetal heart tracing is reassuring. With a clinically significant abruption, the patient is often contracting vigorously, but if she is not in active labor, then amniotomy and administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    frequently result in rapid delivery. Partial abruption can progress to total abruption suddenly and without warning. Thus, the fetus should be continuously monitored and preparations must be made in case urgent operative delivery is required. Because these patients often progress rapidly in labor, they have a high likelihood of successful vaginal birth. However, an attempt at vaginal birth should only be undertaken if there is access to immediate cesarean delivery, if necessary.",
"   </p>",
"   <p>",
"    Prompt cesarean delivery is indicated if the mother is unstable or the fetal heart tracing is nonreassuring and vaginal delivery is not imminent, or when vaginal delivery is contraindicated (eg, malpresentation, prior classical cesarean delivery) or unsuccessful (failure to progress). In one of the only studies that evaluated cesarean delivery for severe abruption, a decision to delivery interval of less than 20 minutes was associated with better outcomes than a 30-minute interval when fetal bradycardia was present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/6\">",
"     6",
"    </a>",
"    ]. Although this was a small case-control study of 31 cases, it underscores the principle that the duration of prolonged bradycardia influences outcome when the abruption is severe.",
"   </p>",
"   <p>",
"    Major maternal morbidity or death is a real risk when a cesarean is performed in the presence of coagulopathy. Some experts recommend that operative intervention should not begin until coagulopathy is corrected. However, such a delay could lead to fetal death, further blood loss, and worsening of the coagulopathy. It is desirable, but not always possible, to correct the clotting abnormality prior to cesarean. If a cesarean has to be performed urgently, blood, fresh frozen plasma, platelets, and cryoprecipitate should be available in the operating room and should be administered if there are signs of impaired hemostasis (eg, persistent bleeding without clotting from incision and needle sites), without waiting for the results of coagulation studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15961?source=see_link\">",
"     \"Disseminated intravascular coagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At cesarean delivery, blood extravasated into the myometrium (called a Couvelaire uterus) may be observed. The Couvelaire uterus is atonic and thus prone to postpartum hemorrhage. Patients with a Couvelaire uterus are less likely to respond to conservative measures, and have a much higher risk for hysterectomy. If a Couvelaire uterus is detected, aggressive management of atony is needed to prevent disseminated intravascular coagulation (DIC) and exsanguination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12398205\">",
"    <span class=\"h3\">",
"     Postpartum care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum, we administer an intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    infusion as the first line uterotonic agent. Maternal vital signs, blood loss, urine output, uterine size and consistency, and laboratory results",
"    <span class=\"nowrap\">",
"     (hemoglobin/hematocrit,",
"    </span>",
"    coagulation studies) should be monitored closely to ensure that bleeding has been controlled and that coagulopathy is resolving, and to guide replacement of fluids and blood products, as needed.",
"   </p>",
"   <p>",
"    If the uterus remains atonic after delivery of the placenta, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32549?source=see_link\">",
"     methylergonovine",
"    </a>",
"    as a first-line treatment (in the absence of preeclampsia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/7\">",
"     7",
"    </a>",
"    ]. In patients who fail methylergonovine or have contraindications to use of this drug, we recommend a prostaglandin F2a analog (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/29/20948?source=see_link\">",
"     carboprost tromethamine",
"    </a>",
"    [Hemabate&reg;]).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is an alternative. When these measures fail, uterine vessel ligation, uterine compression sutures, embolization,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hysterectomy may be necessary to prevent exsanguination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with severe abruption, shock, and DIC are at risk of multiorgan failure. After delivery, organ function usually improves with aggressive supportive care and treatment of complications, as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33479?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982534\">",
"    <span class=\"h2\">",
"     Nonsevere abruption at 34 to 36 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;We tend to deliver most patients with a new diagnosis of abruption at 34 to 36 weeks of gestation, even if the abruption is not severe (ie, fetal status reassuring, maternal vital signs normal, laboratory tests normal or mildly abnormal, mild to moderate bleeding), since these patients remain at risk of developing a sudden severe abruption. Decision-making in these cases is based on patient-specific factors, balancing the estimated risk of",
"    <span class=\"nowrap\">",
"     progression/recurrence",
"    </span>",
"    against the relatively small risks of prematurity in the late preterm infant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22713?source=see_link\">",
"     \"Late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982067\">",
"    <span class=\"h2\">",
"     Minor abruption at 34 to 36 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;For carefully selected patients between 34 and 36 weeks with probable minor abruption (ie, minimal signs and symptoms of abruption), conservative management is a reasonable approach if the mother is stable, fetal status is reassuring, laboratory tests are normal, and active bleeding has stopped. However, as discussed above, these patients are at increased risk for sudden, severe abruption. They should be monitored closely and delivered if they have recurrent bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nonsevere abruption at &lt;34 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectant management of abruption in pregnancies &lt;34 weeks of gestation is reasonable when the mother is stable and when tests of fetal well-being are reassuring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/1,8-10\">",
"     1,8-10",
"    </a>",
"    ]. Coagulopathy of any significant degree, in our opinion, constitutes patient instability and is an indication for delivery. Similarly, non-reassuring fetal heart rate evaluation (persistent fetal bradycardia, late decelerations, loss of variability or a sinusoidal fetal heart rate pattern), or nonreassuring biophysical scores are indications for delivery; these patients should not be managed conservatively, even if &lt;34 weeks.",
"   </p>",
"   <p>",
"    Corticosteroids to promote fetal lung maturation should be administered to pregnancies at 23 to 34 weeks of gestation, given the increased risk of need for preterm delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abruption frequently causes uterine contractions. These contractions are partly caused by thrombin and may lead to further placental separation, which may in turn cause further bleeding, creating a cycle of bleeding and contractions. Tocolytics may prevent further contractions, in theory breaking this cycle. However, tocolytics may cause cardiovascular symptoms (tachycardia, hypotension), which may worsen any hemodynamic instability resulting from abruption, and may also make it difficult to recognize signs of worsening hypovolemia. For these reasons, several authorities have argued against their use in this setting.",
"   </p>",
"   <p>",
"    A few small, retrospective, uncontrolled studies have examined tocolytic use (eg, ritodrine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ) in management of abruption in hemodynamically stable pregnant women with reassuring fetal heart rate tracings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. These studies have not demonstrated harm and have suggested a potential benefit; however, given the limitations of these data, the results of these studies need to be interpreted with caution. In the rare cases in which we use tocolytics, we give a 48-hour course of indomethacin (only at gestational ages &lt;32 weeks),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , or magnesium sulfate. We generally administer these drugs for &le;48 hours to allow administration of corticosteroids for fetal lung maturation. Although the effectiveness of magnesium sulfate as a tocolytic is unclear, it has the potential benefit of fetal neuroprotection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=see_link\">",
"     \"Inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We perform fetal assessment with a non-stress test or biophysical profile at least weekly. We also perform serial sonographic estimation of fetal weight to assess growth since over time these fetuses are at risk of developing growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no compelling data to guide the length of a hospital stay in these pregnancies. A reasonable approach is to monitor the patient in the hospital until the bleeding has subsided for at least 48 hours, fetal heart rate tracings and ultrasound examinations are reassuring, and the patient is asymptomatic. At that point, discharge may be considered. Importantly, the patient should be counseled to return immediately should she experience further bleeding, contractions, reduced fetal movement, or abdominal pain. In patients with sonographic evidence of a large hematoma, we feel it is prudent to keep the patient in the hospital for a longer period of close monitoring.",
"   </p>",
"   <p>",
"    For patients with abruption &lt;34 weeks who have been managed conservatively without any further symptoms, it is reasonable to schedule delivery at 37 to 38 weeks because of the increased risk of stillbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/1\">",
"     1",
"    </a>",
"    ]. We do not typically perform amniocentesis to document fetal lung maturity prior to delivery. For each patient, the potential risk of neonatal respiratory problems, which is low at this gestational age, should be weighed against the potential risk that a serious abruption will occur while awaiting development of fetal pulmonary maturity.",
"   </p>",
"   <p>",
"    Delivery before 37 weeks is indicated if additional complications arise (eg, fetal growth restriction, preeclampsia, premature rupture of membranes, nonreassuring fetal assessment, recurrent abruption with maternal instability). Placental abruption occurring in the second trimester carries an especially poor prognosis when accompanied by oligohydramnios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fetal demise",
"    </span>",
"    &nbsp;&mdash;&nbsp;When fetal death has occurred, the mode of delivery should be chosen to minimize the risk of maternal morbidity or mortality. Vaginal delivery is generally preferable. Since the patient is often contracting vigorously, amniotomy may be all that is required to expedite delivery.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    can be given, if needed to augment labor.",
"   </p>",
"   <p>",
"    The frequency of coagulopathy is much higher in abruptions in which fetal death has occurred and blood replacement is often necessary. Cesarean delivery is often the best option when (1) rapid control of bleeding is required, or (2) there are obstetrical contraindications to vaginal birth, or (3) the mother is unwilling to accept adequate blood replacement therapy, as a prolonged labor complicated by severe abruption may be associated with greater blood loss than cesarean delivery. A previous classical hysterotomy is a relative contraindication to vaginal birth. Although these patients are at increased risk of uterine rupture during labor, this risk is relatively small (4 to 9 percent) and may be acceptable since cesarean delivery has no benefit for the fetus. The approach to these patients should be individualized, taking into account factors such as gestational age and cervical status. (See",
"    <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=see_link\">",
"     \"Uterine rupture after previous cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If possible, coagulopathy should be corrected prior to, or during, the cesarean delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15961?source=see_link\">",
"     \"Disseminated intravascular coagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ultrasound diagnosed placental abruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental abruption is occasionally an incidental finding on ultrasound examination of an asymptomatic patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. These cases are managed on a case-by-case basis. A thorough history and physical examination should be performed, with particular attention to risk factors such as smoking, hypertension, trauma, and use of cocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the pregnancy has reached term, we expedite delivery to avoid potential complications in case the area of placental separation extends. In preterm pregnancies, conservative management is a reasonable approach. For pregnancies less than 34 weeks of gestation, we administer corticosteroids to promote fetal lung maturation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RECURRENCE RISK AND MANAGEMENT OF SUBSEQUENT PREGNANCIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4678807\">",
"    <span class=\"h2\">",
"     Recurrence risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with placental abruption are at several-fold higher risk of abruption in a subsequent pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. The risk of recurrence has been reported to be 5 to 15 percent, compared to a baseline incidence of 0.4 to 1.3 percent in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/15,20,21\">",
"     15,20,21",
"    </a>",
"    ]. After two consecutive abruptions, the risk of a third rises to 20 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]. The risk of recurrence is higher after a severe abruption than after a mild abruption, and the woman's sisters appear to be at increased risk of also having an abruption (OR 1.7-2.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/19\">",
"     19",
"    </a>",
"    ]. When the abruption is severe enough to kill the fetus, there is a 7 percent incidence of the same outcome in a future pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, there are no studies demonstrating that any intervention lowers this risk. Nonetheless, it is reasonable to identify risk factors for abruption and address those risk factors that are modifiable. Women who smoke or use cocaine should be encouraged to stop. Poorly controlled hypertension should be controlled. These changes have proven health benefits even in the absence of pregnancy. On the other hand, placental abruption resulting from trauma is not likely to recur, so these women can be reassured.",
"   </p>",
"   <p>",
"    There are no laboratory screening tests that are predictive of an increased risk for abruption. Testing women with a history of abruption for antiphospholipid antibodies or an inherited thrombophilia is not indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41000?source=see_link\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44041?source=see_link\">",
"     \"Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4678800\">",
"    <span class=\"h2\">",
"     Antenatal monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence on which to base a recommendation regarding antenatal surveillance of subsequent pregnancies. A cohort study using data from the Medical Birth Registry of Norway calculated gestational age-specific risks of complicated placental abruption (eg, abruptions resulting in preterm birth, a small for gestational age infant, or perinatal death) in a second pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/24\">",
"     24",
"    </a>",
"    ]. The authors determined the risk of complicated placental abruption was 7 per 1000 for an initial event and 33 per 1000 for a first recurrence. To reduce the risk of recurrent abruption to the baseline rate, both antenatal surveillance and delivery six weeks prior to the gestational age of the initial abruption would be necessary during the subsequent pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An active area of investigation is the hypothesis that placental abruption, intrauterine growth restriction, and preeclampsia are different manifestations of ischemic placental disease and predispose the patient to preterm labor and birth. There is evidence that these disorders often co-exist in a pregnancy, or one may occur in one pregnancy while another occurs in a subsequent pregnancy (eg, abruption in the first pregnancy, growth restriction in the second pregnancy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34663/abstract/18,25-27\">",
"     18,25-27",
"    </a>",
"    ]. For this reason, in our practice, we perform an ultrasound examination to look for growth restriction in subsequent pregnancies and, if fetal growth restriction is detected, we manage these pregnancies accordingly. Monitoring for preeclampsia is already a standard focus of routine antenatal care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4678793\">",
"    <span class=\"h2\">",
"     Timing of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically await spontaneous labor until the estimated date of delivery, or perform a repeat cesarean delivery at 39 to 40 weeks of gestation. In selected patients, such as those with a prior perinatal death or with more than one prior abruption, delivery before 37 weeks of gestation after documentation of fetal lung maturity is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/29/39377?source=see_link\">",
"       \"Patient information: Placental abruption (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risks of abruption for the fetus depend on the gestational age at which it occurs, as well as its severity, whereas for the mother, the risks depend entirely on its severity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A potentially severe placental abruption is an obstetrical emergency. These women should undergo rapid evaluation, including continuous fetal heart rate monitoring, placement of large bore intravenous lines, and assessment of blood loss, hypovolemia, and coagulopathy. Blood and blood products should be replaced aggressively, when indicated. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Initial approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After initial evaluation and stabilization, the management of pregnancies complicated by clinically significant abruption depends on whether the fetus is alive or dead, the gestational age, and",
"      <span class=\"nowrap\">",
"       maternal/fetal",
"      </span>",
"      status. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnancies where the mother is unstable at any gestational age (eg, significant coagulopathy, hypotension,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ongoing major blood loss), or the fetal heart rate tracing is nonreassuring at any gestational age, or the gestational age is &ge;36 weeks, we suggest expeditious delivery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). When there is partial placental separation, total abruption may occur suddenly and without warning in pregnancies managed conservatively. (See",
"      <a class=\"local\" href=\"#H3982397\">",
"       'Severe abruption at any gestational age and nonsevere abruption at  &gt;36 weeks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prompt cesarean delivery is indicated if the mother is unstable (in these cases, correction of hypovolemia and coagulopathy should be performed concurrently) or the fetal heart tracing is nonreassuring and vaginal delivery is not imminent, or when vaginal delivery is contraindicated (eg, malpresentation, prior classical cesarean delivery) or unsuccessful (failure to progress). Otherwise, vaginal delivery may be attempted. (See",
"      <a class=\"local\" href=\"#H3982397\">",
"       'Severe abruption at any gestational age and nonsevere abruption at  &gt;36 weeks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is desirable, but not always possible, to correct the clotting abnormality prior to cesarean. If a cesarean has to be performed urgently, blood products should be available in the operating room and administered if there are signs of impaired hemostasis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15961?source=see_link\">",
"       \"Disseminated intravascular coagulation during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Expectant management of carefully selected cases of abruption in pregnancies &lt;36 weeks of gestation is reasonable when the mother is stable and when tests of fetal well-being are reassuring. We administer a course of glucocorticoids to women with pregnancies between 23 and 34 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H3982067\">",
"       'Minor abruption at 34 to 36 weeks'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Nonsevere abruption at &lt;34 weeks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When fetal death has occurred, the mode of delivery should minimize the risk of maternal morbidity or mortality. Vaginal delivery is preferable, but cesarean delivery may be the best option when (1) rapid control of bleeding is required, or (2) there are obstetrical contraindications to vaginal birth (eg, previous classical hysterotomy), or (3) the mother is unwilling to accept adequate blood replacement therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Fetal demise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of recurrent abruption is 5 to 15 percent, compared to a baseline incidence of 0.4 to 1.3 percent in the general population. A past history of placental abruption predicts a greater likelihood of a small for gestational age infant, spontaneous preterm birth, or preeclampsia in future pregnancies, even in the absence of recurrent abruption. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Recurrence risk and management of subsequent pregnancies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/1\">",
"      Oyelese Y, Ananth CV. Placental abruption. Obstet Gynecol 2006; 108:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/2\">",
"      Neilson JP. Interventions for treating placental abruption. Cochrane Database Syst Rev 2012; :CD003247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/3\">",
"      POE MF. Clot observation test for clinical diagnosis of clotting defects. Anesthesiology 1959; 20:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/4\">",
"      WEINER AE, REID DE, ROBY CC. Incoagulable blood in severe premature separation of the placenta: a method of management. Am J Obstet Gynecol 1953; 66:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/5\">",
"      Lee RI, White PD. A clinical study of the coagulation time of blood. Am J Med Sci 1913; 145:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/6\">",
"      Kayani SI, Walkinshaw SA, Preston C. Pregnancy outcome in severe placental abruption. BJOG 2003; 110:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/7\">",
"      Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam QM. Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database Syst Rev 2007; :CD005456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/8\">",
"      Bond AL, Edersheim TG, Curry L, et al. Expectant management of abruptio placentae before 35 weeks gestation. Am J Perinatol 1989; 6:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/9\">",
"      Combs CA, Nyberg DA, Mack LA, et al. Expectant management after sonographic diagnosis of placental abruption. Am J Perinatol 1992; 9:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/10\">",
"      Sholl JS. Abruptio placentae: clinical management in nonacute cases. Am J Obstet Gynecol 1987; 156:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/11\">",
"      Saller DN Jr, Nagey DA, Pupkin MJ, Crenshaw MC Jr. Tocolysis in the management of third trimester bleeding. J Perinatol 1990; 10:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/12\">",
"      Towers CV, Pircon RA, Heppard M. Is tocolysis safe in the management of third-trimester bleeding? Am J Obstet Gynecol 1999; 180:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/13\">",
"      Ananth CV, Berkowitz GS, Savitz DA, Lapinski RH. Placental abruption and adverse perinatal outcomes. JAMA 1999; 282:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/14\">",
"      Ananth CV, Cnattingius S. Influence of maternal smoking on placental abruption in successive pregnancies: a population-based prospective cohort study in Sweden. Am J Epidemiol 2007; 166:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/15\">",
"      Ananth CV, Savitz DA, Williams MA. Placental abruption and its association with hypertension and prolonged rupture of membranes: a methodologic review and meta-analysis. Obstet Gynecol 1996; 88:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/16\">",
"      K&aring;reg&aring;rd M, Gennser G. Incidence and recurrence rate of abruptio placentae in Sweden. Obstet Gynecol 1986; 67:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/17\">",
"      Rasmussen S, Irgens LM, Dalaker K. The effect on the likelihood of further pregnancy of placental abruption and the rate of its recurrence. Br J Obstet Gynaecol 1997; 104:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/18\">",
"      Rasmussen S, Irgens LM, Dalaker K. Outcome of pregnancies subsequent to placental abruption: a risk assessment. Acta Obstet Gynecol Scand 2000; 79:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/19\">",
"      Rasmussen S, Irgens LM. Occurrence of placental abruption in relatives. BJOG 2009; 116:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/20\">",
"      Toivonen S, Heinonen S, Anttila M, et al. Obstetric prognosis after placental abruption. Fetal Diagn Ther 2004; 19:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/21\">",
"      Tikkanen M, Nuutila M, Hiilesmaa V, et al. Prepregnancy risk factors for placental abruption. Acta Obstet Gynecol Scand 2006; 85:40.",
"     </a>",
"    </li>",
"    <li>",
"     Clark, SL. Placentae Previa and Abruptio Placentae. In: Maternal Fetal Medicine, 4th ed, Creasy, RK, Resnik, R, (Eds), WB Saunders Company, Philadelphia, Pennsylvania 1999. p. 623.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/23\">",
"      Pritchard JA, Mason R, Corley M, Pritchard S. Genesis of severe placental abruption. Am J Obstet Gynecol 1970; 108:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/24\">",
"      Rasmussen S, Irgens LM, Albrechtsen S, Dalaker K. Women with a history of placental abruption: when in a subsequent pregnancy should special surveillance for a recurrent placental abruption be initiated? Acta Obstet Gynecol Scand 2001; 80:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/25\">",
"      Rasmussen S, Irgens LM, Dalaker K. A history of placental dysfunction and risk of placental abruption. Paediatr Perinat Epidemiol 1999; 13:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/26\">",
"      Ananth CV, Vintzileos AM. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am J Obstet Gynecol 2006; 195:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34663/abstract/27\">",
"      Ananth CV, Peltier MR, Chavez MR, et al. Recurrence of ischemic placental disease. Obstet Gynecol 2007; 110:128.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6803 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34663=[""].join("\n");
var outline_f33_54_34663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12397516\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3982397\">",
"      Severe abruption at any gestational age and nonsevere abruption at  &gt;36 weeks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12398205\">",
"      - Postpartum care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3982534\">",
"      Nonsevere abruption at 34 to 36 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3982067\">",
"      Minor abruption at 34 to 36 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nonsevere abruption at &lt;34 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fetal demise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ultrasound diagnosed placental abruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RECURRENCE RISK AND MANAGEMENT OF SUBSEQUENT PREGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4678807\">",
"      Recurrence risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4678800\">",
"      Antenatal monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4678793\">",
"      Timing of delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33479?source=related_link\">",
"      Acute kidney injury (acute renal failure) in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15961?source=related_link\">",
"      Disseminated intravascular coagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22713?source=related_link\">",
"      Late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44041?source=related_link\">",
"      Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/29/39377?source=related_link\">",
"      Patient information: Placental abruption (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=related_link\">",
"      Uterine rupture after previous cesarean delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_54_34664="Hematopoietic support after hematopoietic cell transplantation";
var content_f33_54_34664=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematopoietic support after hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34664/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34664/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34664/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34664/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34664/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34664/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/54/34664/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous and allogeneic hematopoietic cell transplantation (HCT) are associated with neutropenia, anemia, and thrombocytopenia in the peri-transplant period. The degree of myelosuppression and the time to hematopoietic recovery differ with multiple factors including the preparative regimen and graft source. Blood product transfusions and hematopoietic growth factors are essential components of transplant care.",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, umbilical cord blood). Otherwise, the source of such cells will be specified (eg, autologous PBPC transplantation).",
"   </p>",
"   <p>",
"    Hematopoietic support after HCT will be discussed here. Other supportive care issues surrounding HCT are presented separately, as is quality of life following HCT and acute and chronic graft-versus-host disease (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link\">",
"     \"Supportive care after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/59/25529?source=see_link\">",
"     \"Quality of life following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=see_link\">",
"     \"Treatment of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and treatment of pulmonary, renal, and infectious complications following HCT are also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40106?source=see_link\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=see_link\">",
"     \"Pulmonary complications after autologous hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=see_link\">",
"     \"Kidney disease following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H876301\">",
"    <span class=\"h1\">",
"     BLOOD PRODUCT SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood product support is usually required before, during, and following HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, blood product support, with resulting iron overload, is commonly seen in those patients undergoing HCT for a hematologic disorder. Such iron overload (eg, serum ferritin &gt;1000",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    may adversely affect overall survival post-HCT, increasing the likelihood of acute graft-versus-host disease, as well as the incidence of blood stream infections and sinusoidal obstruction syndrome of the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virtually all patients undergoing transplantation require blood product support in the form of red blood cell and platelet transfusions until the transplanted marrow cells engraft sufficiently to support hematopoiesis. This generally requires 14 to 21 days or more with bone marrow but is accelerated with peripheral blood progenitor cells with engraftment typically requiring 10 to 14 days.",
"   </p>",
"   <p>",
"    All cytomegalovirus (CMV)-negative patients who receive bone marrow cells from a CMV-negative donor should receive seronegative blood products. In addition, it is highly recommended to use irradiated blood products with or without leukodepletion methods to avoid the risk of transfusion-associated graft-versus-host disease and other transfusion-related complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transfusional needs may be significantly reduced in patients undergoing nonmyeloablative preparative regimens. As an example, in a comparative retrospective analysis, platelet transfusions were required in 23 versus 100 percent, and red cell transfusions in 63 versus 96 percent of those undergoing nonmyeloablative or myeloablative transplants, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H876308\">",
"    <span class=\"h2\">",
"     Red blood cell transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for transfusion of blood products vary from center to center. With respect to transfusion of red cells, many centers use a threshold of 7 to 8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    of hemoglobin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link&amp;anchor=H5#H5\">",
"     \"Use of red blood cells for transfusion\", section on 'Choice of component'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This threshold may be influenced by a number of factors including the number of days from the transplant, the clinical condition of the patient, and evidence of engraftment of other cell types including reticulocytes. Patients with GVHD or those being treated with immunosuppressive drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    may have continued blood product requirements from bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microangiopathic hemolysis.",
"   </p>",
"   <p>",
"    Cases of delayed hemolysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pure red cell aplasia have been described in patients with pre-existing alloantibodies against Rh or ABO antigens, despite the presence of 100 percent donor chimerism of the circulating lymphocytes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=see_link&amp;anchor=H12#H12\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'ABO and Rh status'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H876315\">",
"    <span class=\"h2\">",
"     Platelet transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are thrombocytopenic with bleeding require platelet transfusions. In comparison, the role of prophylactic platelet transfusions remains controversial. Many transplant centers have relied upon threshold values of platelet numbers to determine the timing of platelet transfusions. This has been questioned because of the risk of alloimmunization, the relatively short half-life of transfused platelets, and expense. A multicenter study of platelet recovery has addressed this issue. In this report, 789 patients, transplanted in 1995, were studied at 18 centers in the United States and Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Variables associated with accelerated platelet recovery included a higher CD34+ cell count of the infused hematopoietic stem cell product, a higher platelet count at the start of myeloablative therapy, and a graft from an HLA-identical sibling donor. As noted above, platelet recovery is also more rapid with PBPCs than with bone marrow transplants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Variables associated with delayed platelet recovery included prior radiation therapy, post-transplant fever, hepatic veno-occlusive disease, the presence of GVHD, CMV infection, cell dose, and the use of post-transplant growth factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Eleven percent of all patients had a significant hemorrhagic event during the first 60 days following the transplant, contributing to death in 2 percent. However, these deaths were independent of the platelet count.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was concluded that enhancing platelet recovery is not likely to have a significant impact on 60-day mortality but could significantly decrease health care costs and potentially improve patient quality of life. Similar conclusions have been reached in studies of patients who became thrombocytopenic after allogeneic HCT or following chemotherapy for acute leukemia; reducing the platelet transfusion threshold from 20,000 or",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    led to decreased use of platelet transfusions without any significant effect on morbidity and only a small adverse effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] or no effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/11\">",
"     11",
"    </a>",
"    ] on bleeding.",
"   </p>",
"   <p>",
"    We generally transfuse for platelet counts less than",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    or for higher values if clinical bleeding is present (",
"    <a class=\"graphic graphic_table graphicRef52206 \" href=\"mobipreview.htm?11/29/11741\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=see_link\">",
"     \"Use of blood products in the critically ill\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the expense of prophylactic platelet transfusions is the risk of accelerating alloimmunization against future platelet transfusions, which can be a very significant problem without clear treatment options. To that end, a trial comparing the safety and efficacy of prophylactic platelet transfusions for platelet counts",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL",
"    </span>",
"    versus platelet transfusion only if there is evidence of bleeding is ongoing in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H876322\">",
"    <span class=\"h2\">",
"     Granulocyte transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocyte transfusions have generally not been used because of the lack of efficacy in clinical trials and the difficulty of obtaining sufficient numbers of cells due to the short half-life of neutrophils. However, there is renewed interest in this form of therapy with the ability to obtain large numbers of donor neutrophils following the use of G-CSF. Currently, there are very few if any clinical indications for granulocyte transfusions outside of a clinical trial setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/18/4393?source=see_link\">",
"     \"Granulocyte transfusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GROWTH FACTOR SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cloned hematopoietic growth factors that have been explored in the transplant setting include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), erythropoietin (EPO), and thrombopoietin (TPO). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16890?source=see_link\">",
"     \"Introduction to recombinant hematopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     G-CSF and GM-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of cloned recombinant human hematopoietic growth factors such as G-CSF and GM-CSF has resulted in clear clinical benefits in the autologous transplant setting, particularly following autologous transplantation with bone marrow or peripheral blood progenitor cells and for the mobilization of PBPCs.",
"   </p>",
"   <p>",
"    In 1996, the American Society of Clinical Oncology (ASCO) issued guidelines for the administration of hematopoietic colony-stimulating factors after bone marrow and stem cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/14\">",
"     14",
"    </a>",
"    ]. It was concluded that the data supported the use of colony-stimulating factors for mobilization of PBPCs for transplantation, as well as following autologous transplantation using either bone marrow or PBPC.",
"   </p>",
"   <p>",
"    In the post-transplant setting the usual dose is 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day for G-CSF (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    ), which we prefer, or 250",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for GM-CSF (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/43/5814?source=see_link\">",
"     sargramostim",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/14\">",
"     14",
"    </a>",
"    ]. Therapy is usually begun one to five days after transplantation and continued until the absolute neutrophil count reaches",
"    <span class=\"nowrap\">",
"     10,000/microL;",
"    </span>",
"    a shorter duration until clinically adequate neutrophil recovery is achieved is a reasonable alternative.",
"   </p>",
"   <p>",
"    Given the limited general utility of colony-stimulating factors following allogeneic transplantation, and the fact that their use may have been deleterious in some allogeneic settings, there appears to be little reason to routinely treat allogeneic HCT patients with these growth factors as post-treatment prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Exceptions include those patients with delayed neutrophil engraftment or a reduction in WBC due to infection or drug treatment. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Allogeneic HCT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Autologous HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized phase III trials with both GM-CSF and G-CSF have shown a reduced number of days required for neutrophil engraftment following transplantation with bone marrow as a stem cell source, associated in some studies with a reduction in the days of antibiotic therapy and length of hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. These findings led to the FDA approval of both drugs for this indication. However, the positive effects in these trials were limited to neutrophil engraftment and neutropenia-related complications. In no study was red blood cell or platelet engraftment enhanced, nor was a survival advantage demonstrable.",
"   </p>",
"   <p>",
"    A study of once daily versus split (twice daily) lenograstim was not associated with superior clinical efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/23\">",
"     23",
"    </a>",
"    ]. Similarly, three randomized phase III trials of single dose pegfilgrastim (6 mg) versus daily filgrastim (5",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per day) in patients undergoing autologous peripheral blood stem cell transplantation revealed no difference in time to neutrophil engraftment or any clinical sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Autologous PBPC transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that hematopoietic growth factor administration produces a time-limited enhancement in hematopoietic stem cell mobilization has had a major impact on autologous transplantation. Upon re-infusion of these \"mobilized\" peripheral blood progenitor cells, hematopoietic engraftment of all lineages is accelerated significantly. This is especially true for platelet engraftment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/7,27,28\">",
"     7,27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multinational study compared the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    (G-CSF)-mobilized autologous PBPCs versus autologous bone marrow in 58 patients with relapsed Hodgkin lymphoma and non-Hodgkin lymphoma treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/7\">",
"     7",
"    </a>",
"    ]. Early post-transplant morbidity and mortality and overall survival (median follow-up, 311 days) were similar in both groups, but use of filgrastim-mobilized PBPCs was associated with the following significant benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A shorter time to platelet recovery above",
"      <span class=\"nowrap\">",
"       20,000/microL",
"      </span>",
"      (16 versus 23 days)",
"     </li>",
"     <li>",
"      A shorter time to neutrophil recovery (11 versus 14 days)",
"     </li>",
"     <li>",
"      A shorter time in hospital (17 versus 23 days)",
"     </li>",
"     <li>",
"      A cost saving of 23 percent (13,521 US dollars) due to lower autograft collection costs and shorter hospitalizations with less supportive care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was no notable toxicity attributable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    . Similar results were noted in another report in which patients who received G-CSF-primed PBPCs, as compared with placebo, had more rapid recovery to an absolute neutrophil count above",
"    <span class=\"nowrap\">",
"     500/microL",
"    </span>",
"    (10 versus 20 days) and a shorter time to platelet transfusion independence (16 versus 31 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of colony-stimulating factors following autologous PBPC transplant is less well defined. The addition of G-CSF may further accelerate neutrophil engraftment, with an absolute neutrophil count",
"    <span class=\"nowrap\">",
"     &gt;500/microL",
"    </span>",
"    being achieved one to six days more quickly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. We begin G-CSF on day six following infusion of autologous PBPCs which results in rapid hematopoietic engraftment by day 10 to 12.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with autologous transplantation, accelerated engraftment has been noted in the allogeneic setting with the use of G-CSF mobilized PBPCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. The impact of G-CSF-mobilized PBPCs as compared with bone marrow-derived hematopoietic stem cells on the risk of acute and chronic GVHD is an area of controversy and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link&amp;anchor=H16#H16\">",
"     \"Sources of hematopoietic stem cells\", section on 'Relative efficacy of PBPC versus bone marrow'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a separate issue is the value of administration of hematopoietic colony-stimulating factors following transplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized, controlled trial, 109 patients who underwent allogeneic HCT received either GM-CSF or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/37\">",
"       37",
"      </a>",
"      ]. GM-CSF therapy was associated with significant reductions in the time to an absolute neutrophil count (ANC) above",
"      <span class=\"nowrap\">",
"       500/microL",
"      </span>",
"      (13 versus 17 days) and the incidence of infection; no differences in platelet or erythrocyte recovery were noted.",
"     </li>",
"     <li>",
"      In a second randomized, placebo-controlled study of 54 patients undergoing HLA-matched allogeneic PBPC transplantation, G-CSF treatment was associated with a significant reduction in the time to an ANC &gt;500 (11 versus 15 days); there were no significant differences in time to a platelet count",
"      <span class=\"nowrap\">",
"       &gt;20,000/microL",
"      </span>",
"      (13 versus 15.5 days), red cell transfusion independence, incidence of acute GVHD, or 100-day mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/38\">",
"       38",
"      </a>",
"      ]. Similar findings were noted in a third study involving 42 patients, in which there was a trend to earlier hospital discharge in the G-CSF-treated group (day 16 versus day 20) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results have been observed in children undergoing autologous or allogeneic HCT. In one study, 221 children receiving allogeneic or autologous bone marrow (BM) or peripheral blood precursor cell (PBPC) transplants were randomly assigned to receive G-CSF or not following transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/40\">",
"     40",
"    </a>",
"    ]. Myeloid engraftment and neutrophil recovery were significantly faster in transplant recipients receiving G-CSF. A significantly reduced platelet transfusion requirement and earlier patient discharge was noted for patients who received G-CSF in the BM but not the PBPC group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Graft versus host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether use of colony-stimulating factors following allogeneic HCT increases the risk of developing graft-versus-host disease (GVHD) has not been adequately settled. Two meta-analyses, eight retrospective cohort studies, and one case-control study concluded that there was no significant change in the risk of acute or chronic GVHD after allogeneic HCT when growth factors were used to shorten the initial period of neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/15,41\">",
"     15,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue was also investigated in a large, retrospective, multi-institutional study that included 1789 patients with acute leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/16\">",
"     16",
"    </a>",
"    ]. Use of G-CSF in patients receiving transplantation with bone marrow-derived cells was associated with an increased risk of acute GVHD, chronic GVHD, and transplant-related mortality, along with reduced survival. No such effects of G-CSF were noted in patients receiving transplantation with peripheral blood stem cells.",
"   </p>",
"   <p>",
"    Another large retrospective analysis of 2719 patients from the International Blood and Marrow Transplant Research database evaluated the impact of G-CSF on outcomes for patients transplanted between 1995 and 2000. In this study, which included both patients receiving BM and PBPCs, G-CSF shortened the neutropenic period following transplantation but did not affect treatment-related mortality, acute or chronic GVHD, or leukemia-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythropoietin (EPO) has been used in an effort to accelerate the recovery of red blood cells. The rationale for this approach was provided in part by the observation that EPO levels were lower than predicted for the degree of anemia following transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/43\">",
"     43",
"    </a>",
"    ]. However, studies in both allogeneic and autologous transplants have not shown prominent benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Allogeneic transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variable results have been found after allogeneic transplantation. Initial small trials suggested that EPO administration produced more rapid recovery of red blood cells and reduced transfusional requirements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Larger randomized trials have confirmed these benefits.",
"   </p>",
"   <p>",
"    One such trial randomly assigned 215 patients receiving allogeneic HCT recipients to receive placebo or EPO (150",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per day as a continuous infusion) from bone marrow infusion until stable hemoglobin levels were achieved for seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/47\">",
"     47",
"    </a>",
"    ]. The median time to transfusion independence was reduced from 27 to 19 days, but transfusion requirements for the two groups as a whole were similar. There were, however, subsets at high risk for transfusion (eg, GVHD III and IV) in which EPO reduced transfusion requirements.",
"   </p>",
"   <p>",
"    Another trial from Australia evaluated 91 patients who underwent allogeneic transplantation followed by randomization to placebo or EPO (300",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    three times weekly) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/48\">",
"     48",
"    </a>",
"    ]. There was no reduction in transfusion requirements, although EPO therapy was associated with increases in the reticulocyte count, hemoglobin concentration, and bone marrow erythropoiesis on day 14.",
"   </p>",
"   <p>",
"    Because of the mixed results obtained in these studies, most centers do not employ EPO early after allogeneic transplantation. One issue that has not been adequately studied is whether EPO therapy would result in decreased transfusional needs following engraftment in patients who either continue to require red cell transfusions for prolonged periods or require red cells transfusions after the use of certain drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . In addition, patients with graft-versus-host disease are frequently anemic due to the disease process or therapy, and EPO treatment can often decrease the requirements for RBC transfusions. We routinely treat patients who have prolonged or newly developed anemia with EPO products, with positive results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Autologous transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three randomized clinical trials have evaluated the efficacy of EPO after autologous transplantation in patients who were treated with G-CSF; none found a significant reduction in the transfusional requirement for red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34664/abstract/47,49,50\">",
"     47,49,50",
"    </a>",
"    ]. The lack of benefit is especially true now that the majority of these transplants are being performed with PBPCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Thrombopoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombopoietin has the potential to mobilize platelet progenitors, thereby accelerating platelet recovery and treating patients with prolonged platelet recovery and graft failure states. The development of antibodies, resulting in significant thrombocytopenia, has limited the development of these products. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16680?source=see_link\">",
"     \"Biology and physiology of thrombopoietin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the approval of the thrombopoietic growth factors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    , additional studies are needed in the HCT setting to determine if these agents can effectively stimulate platelet production, reduce bleeding risks, and reduce transfusional requirements for platelets. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21466?source=see_link\">",
"     \"Clinical applications of thrombopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875843\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Virtually all patients undergoing transplantation require blood product support in the form of red blood cell and platelet transfusions until the transplanted marrow cells engraft sufficiently to support hematopoiesis. This generally requires 14 to 21 days or more with bone marrow and 10 to 14 with peripheral blood progenitor cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All cytomegalovirus (CMV)-negative patients who receive bone marrow cells from a CMV-negative donor should receive seronegative blood products. In addition, irradiated blood products with or without leukodepletion methods should be employed to avoid the risk of transfusion-associated graft-versus-host disease and other transfusion-related complications. (See",
"      <a class=\"local\" href=\"#H876308\">",
"       'Red blood cell transfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for transfusion of blood products vary from center to center. With respect to transfusion of red cells, most centers use as a threshold hemoglobin of 7 to 8 g. (See",
"      <a class=\"local\" href=\"#H876308\">",
"       'Red blood cell transfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally transfuse for platelet counts less than",
"      <span class=\"nowrap\">",
"       10,000/microL",
"      </span>",
"      or for higher values if clinical bleeding is present (",
"      <a class=\"graphic graphic_table graphicRef52206 \" href=\"mobipreview.htm?11/29/11741\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H876315\">",
"       'Platelet transfusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cloned hematopoietic growth factors used in the transplant setting include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF). Randomized phase III trials with both GM-CSF and G-CSF have shown a reduced number of days required for neutrophil engraftment following transplantation with bone marrow as a stem cell source, associated in some studies with a reduction in the days of antibiotic therapy and length of hospitalization. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Growth factor support'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The usual dose is 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per day for G-CSF (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       filgrastim",
"      </a>",
"      ), which we prefer, or 250",
"      <span class=\"nowrap\">",
"       mcg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for GM-CSF (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/43/5814?source=see_link\">",
"       sargramostim",
"      </a>",
"      ). Therapy is usually begun one to five days after transplantation and continued until the absolute neutrophil count reaches",
"      <span class=\"nowrap\">",
"       10,000/microL;",
"      </span>",
"      a shorter duration until clinically adequate neutrophil recovery is achieved is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'G-CSF and GM-CSF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the limited general utility of colony-stimulating factors following allogeneic transplantation, and the fact that their use may have been deleterious in some allogeneic settings (see above), there appears to be little reason to routinely treat allogeneic HCT patients with these growth factors as post-treatment prophylaxis. Exceptions include those patients with delayed neutrophil engraftment or a reduction in WBC due to infection or drug treatment.",
"     </li>",
"     <li>",
"      Erythropoietin (EPO) does not appear to be or benefit immediately following allogeneic or autologous transplant. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Erythropoietin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional studies are needed in the transplant setting to determine if thrombopoietic growth factors can effectively stimulate platelet production, reduce bleeding risks, and reduce transfusional requirements for platelets. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Thrombopoietin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/1\">",
"      Gajewski JL, Johnson VV, Sandler SG, et al. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008; 112:3036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/2\">",
"      Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/3\">",
"      Maradei SC, Maiolino A, de Azevedo AM, et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009; 114:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/4\">",
"      Mahindra A, Bolwell B, Sobecks R, et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009; 146:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/5\">",
"      Avery RK, Adal KA, Longworth DL, Bolwell BJ. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 2000; 26:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/6\">",
"      Bernstein SH, Nademanee AP, Vose JM, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998; 91:3509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/7\">",
"      Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/8\">",
"      Dominietto A, Raiola AM, van Lint MT, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001; 112:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/9\">",
"      Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusion in adults with acute myeloid leukemia. N Eng J Med 1997; 337:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/10\">",
"      Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997; 15:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/11\">",
"      Diedrich B, Remberger M, Shanwell A, et al. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 2005; 45:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/12\">",
"      Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/13\">",
"      Blajchman MA, Slichter SJ, Heddle NM, Murphy MF. New strategies for the optimal use of platelet transfusions. Hematology Am Soc Hematol Educ Program 2008; :198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/14\">",
"      Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1996; 14:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/15\">",
"      Dekker A, Bulley S, Beyene J, et al. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24:5207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/16\">",
"      Ringd&eacute;n O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/17\">",
"      Appelbaum FR. Use of granulocyte colony-stimulating factor following hematopoietic cell transplantation: does haste make waste? J Clin Oncol 2004; 22:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/18\">",
"      Link H, Boogaerts MA, Carella AM, et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/19\">",
"      Advani R, Chao NJ, Horning SJ, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992; 116:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/20\">",
"      Gorin NC, Coiffier B, Hayat M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. Blood 1992; 80:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/21\">",
"      Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992; 116:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/22\">",
"      Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/23\">",
"      Jang G, Ko OB, Kim S, et al. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma. Transfusion 2008; 48:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/24\">",
"      Gerds A, Fox-Geiman M, Dawravoo K, et al. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2010; 16:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/25\">",
"      Rifkin R, Spitzer G, Orloff G, et al. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/26\">",
"      Castagna L, Bramanti S, Levis A, et al. Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 2010; 21:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/27\">",
"      Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/28\">",
"      Nademanee A, Sniecinski I, Schmidt GM, et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/29\">",
"      Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/30\">",
"      Spitzer G, Adkins DR, Spencer V, et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/31\">",
"      Klumpp TR, Mangan KF, Goldberg SL, et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/32\">",
"      Demirer T, Ayli M, Dagli M, et al. Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol 2002; 118:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/33\">",
"      Thompson JM, Carlton P, Akard LP, et al. Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilization. Transfusion 2009; 49:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/34\">",
"      Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/35\">",
"      K&ouml;rbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/36\">",
"      Schmitz N, Bacigalupo A, Labopin M, et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996; 95:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/37\">",
"      Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/38\">",
"      Bishop MR, Tarantolo SR, Geller RB, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/39\">",
"      Przepiorka D, Smith TL, Folloder J, et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001; 97:3405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/40\">",
"      Dallorso S, Rondelli R, Messina C, et al. Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: results of a prospective randomized trial. Haematologica 2002; 87:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/41\">",
"      Ho VT, Mirza NQ, Junco Dd Dd, et al. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant 2003; 32:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/42\">",
"      Khoury HJ, Loberiza FR Jr, Ringd&eacute;n O, et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006; 107:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/43\">",
"      Beguin Y, Clemons GK, Oris R, Fillet G. Circulating erythropoietin levels after bone marrow transplantation: inappropriate response to anemia in allogeneic transplants. Blood 1991; 77:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/44\">",
"      Link H, Brune T, H&uuml;bner G, et al. Effect of recombinant human erythropoietin after allogenic bone marrow transplantation. Ann Hematol 1993; 67:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/45\">",
"      Steegmann JL, L&oacute;pez J, Otero MJ, et al. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. Bone Marrow Transplant 1992; 10:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/46\">",
"      Klaesson S, Ringd&eacute;n O, Ljungman P, et al. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 1994; 13:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/47\">",
"      Link H, Boogaerts MA, Fauser AA, et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84:3327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/48\">",
"      Biggs JC, Atkinson KA, Booker V, et al. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. Bone Marrow Transplant 1995; 15:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/49\">",
"      Chao NJ, Schriber JR, Long GD, et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 1994; 83:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34664/abstract/50\">",
"      Vannucchi AM, Bosi A, Ieri A, et al. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplant 1996; 17:527.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3538 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34664=[""].join("\n");
var outline_f33_54_34664=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H875843\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H876301\">",
"      BLOOD PRODUCT SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H876308\">",
"      Red blood cell transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H876315\">",
"      Platelet transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H876322\">",
"      Granulocyte transfusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GROWTH FACTOR SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      G-CSF and GM-CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autologous PBPC transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Graft versus host disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Allogeneic transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Autologous transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H875843\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3538\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3538|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/29/11741\" title=\"table 1\">",
"      Platelet transfusion guidelines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16680?source=related_link\">",
"      Biology and physiology of thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/18/4393?source=related_link\">",
"      Granulocyte transfusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14745?source=related_link\">",
"      Pulmonary complications after autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/59/25529?source=related_link\">",
"      Quality of life following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=related_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_54_34665="Screening for cardiovascular risk with C-reactive protein";
var content_f33_54_34665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for cardiovascular risk with C-reactive protein",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34665/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34665/contributors\">",
"     David A Morrow, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34665/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34665/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34665/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34665/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/54/34665/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerotic cardiovascular disease (CVD) is common in the general population and is the most common cause of death in the United States as well as in most developed countries. CVD can be subdivided into four major areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary heart disease (CHD) manifesting as myocardial infarction (MI), angina pectoris, congestive heart failure (CHF), and sudden cardiac death",
"     </li>",
"     <li>",
"      Cerebrovascular disease manifesting as stroke and transient ischemic attack",
"     </li>",
"     <li>",
"      Peripheral artery disease manifesting as intermittent claudication and critical limb ischemia",
"     </li>",
"     <li>",
"      Aortic atherosclerosis and thoracic or abdominal aortic aneurysm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adequate screening tests for CVD would potentially allow for the use of pharmacologic and non-pharmacologic interventions to decrease the development of CVD in at risk populations. Multivariable risk models (eg, the Framingham risk score) that incorporate established cardiovascular risk factors (eg, older age, smoking, diabetes, dyslipidemia, and hypertension) are commonly employed to estimate the cardiovascular risk in individual patients. Whether these models can be improved by the incorporation of additional tests remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inflammation is a known factor in the development of atherosclerosis and subsequent CVD events. Ongoing inflammation increases the vulnerability of an atherosclerotic lesion to erosion or rupture. C-reactive protein (CRP) is the most extensively studied of numerous inflammatory biomarkers potentially linked to underlying atherosclerosis. Standardized high-sensitivity assays testing for CRP (hs-CRP) are widely available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link&amp;anchor=H2#H2\">",
"     \"C-reactive protein in cardiovascular disease\", section on 'Possible pathogenic role of CRP'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of serum CRP in screening for cardiovascular risk will be reviewed here. The incremental value of CRP beyond traditional risk factors for estimating risk in the individual continues to be debated. The data supporting the association between CRP and cardiovascular disease, the possible mechanisms of this association, and the use of CRP in patients with known cardiovascular disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102480307\">",
"    <span class=\"h1\">",
"     CRP ASSAYS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26637747\">",
"    <span class=\"h2\">",
"     Test characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRP can be measured using various assays with different testing characteristics. The assays, however, are broadly separated into traditional assays and high sensitivity CRP (hs-CRP) assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/1\">",
"     1",
"    </a>",
"    ]. It is the hs-CRP assays that are used to determine cardiovascular risk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traditional assays, developed to aid in the diagnosis of infectious or inflammatory illnesses, have a limit of detection in the range of 3 to 5",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"      While generally helpful for the diagnosis acute infective or inflammatory episodes, this range is above the concentration observed in most apparently healthy individuals, thereby limiting its discriminatory ability to screen for cardiovascular disease (CVD).",
"     </li>",
"     <li>",
"      High sensitivity CRP (hs-CRP) assays detect concentrations of CRP down to 0.3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      and below [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/1,2\">",
"       1,2",
"      </a>",
"      ] These hs-CRP assays are the assays used to assess cardiovascular risk because they are able to quantitate CRP within the range normally seen in asymptomatic patients (&lt;3",
"      <span class=\"nowrap\">",
"       mg/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the ideal value that constitutes a high serum hs-CRP (and increased cardiovascular risk) is not clearly defined, a statement from the Centers for Disease Control and Prevention and the American Heart Association",
"    <span class=\"nowrap\">",
"     (CDC/AHA)",
"    </span>",
"    provides some guidance on the use of serum hs-CRP to estimate cardiovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low, average, and high-risk values can be defined as &lt;1, 1 to 3, and &gt;3",
"      <span class=\"nowrap\">",
"       mg/L;",
"      </span>",
"      these values correspond to approximate tertiles in the general population. A value above 10",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      should initiate a search for a source of infection or inflammation. This value should then be repeated in two weeks to determine if the elevation is sustained.",
"     </li>",
"     <li>",
"      Due to the variability of values in an individual over time, the average of two assays, fasting or nonfasting, and optimally obtained two weeks apart, provide a more stable estimate of cardiovascular risk than a single measurement.",
"     </li>",
"     <li>",
"      The population distribution of hs-CRP may vary by race and ethnicity; however, these differences are likely explained mostly by the prevalence of other risk factors that are associated with hs-CRP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. As such, the same cutoff values are used across most populations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Is CRP an independent risk indicator?'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We incorporate these guidelines into our approach to the use of CRP assays in determining cardiovascular risk. (See",
"    <a class=\"local\" href=\"#H7917694\">",
"     'Our approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26637754\">",
"    <span class=\"h2\">",
"     Clinical context",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any diagnostic test, hs-CRP must be evaluated within the specific clinical context of an individual patient. Of particular interest are comorbid illnesses and medications that may influence CRP levels, such as the use of hormone replacement therapy in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26639124\">",
"    <span class=\"h3\">",
"     Definition of normal",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standardized CRP value which can be considered normal. However, individuals with values &lt;1",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    have been considered to be at lowest risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Variability of measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;High sensitivity-CRP (hs-CRP) values fluctuate in an individual over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These fluctuations are thought to reflect changes in an individual&rsquo;s systemic inflammatory status. As such, the",
"    <span class=\"nowrap\">",
"     CDC/AHA",
"    </span>",
"    recommends that the hs-CRP be checked twice to confirm a stable value prior to taking any therapeutic actions. The following observations illustrate the magnitude of variability of CRP in adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 113 healthy adults, the variability in quarterly serum CRP measurements over one year was similar to that for serum total cholesterol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/7\">",
"       7",
"      </a>",
"      ]. Between the first and second measurements, 63 percent of hs-CRP values remained in the same quartile, with 90 percent remaining within one quartile of the baseline value.",
"     </li>",
"     <li>",
"      In a study of 259 women aged 18 to 44 years in whom CRP levels were measured up to eight times throughout their menstrual cycles, significant variation of CRP levels was noted throughout the cycle, with CRP levels being highest during menses and lowest during ovulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A greater degree of variability was noted in a study in which serial measurements of serum CRP were obtained in 159 patients with stable ischemic heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/8\">",
"       8",
"      </a>",
"      ]. When patients were stratified into three risk categories (CRP &lt;1, 1 to 3, and &gt;3",
"      <span class=\"nowrap\">",
"       mg/L),",
"      </span>",
"      40 percent of patients changed risk category between the first and second measurements. Similar fluctuations were noted in interleukin (IL)-6, another inflammatory marker. Significant within-subject variation in hs-CRP levels measured an average of 19 days apart has also been reported among a cohort of 541 apparently healthy persons, with approximately one-third of those with an elevated hs-CRP level (&gt;10",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      reclassified within the normal range on repeat testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations are consistent with the hypothesis that dynamic systemic inflammatory status may affect coronary risk. They also point to a potential limitation of using serial measurements of CRP to monitor risk status or the response to medical therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26639359\">",
"    <span class=\"h3\">",
"     Specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRP is an acute phase reactant that rises with most inflammatory disorders, thereby reducing its specificity for prediction of CVD risk. Thus, elevated values must be considered in the context of other medical conditions. Levels greater than 10",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    are likely to be due to systemic inflammatory states such as major infection, trauma, or chronic inflammatory disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26637822\">",
"    <span class=\"h3\">",
"     Comorbid illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of comorbid illnesses on the reliability of hs-CRP as a risk marker for CVD is largely unknown. As examples, inflammatory diseases such as rheumatoid arthritis or systemic lupus erythematosus would be expected to result in higher circulating CRP levels, while cirrhotic liver disease may blunt the production of CRP, leading to lower circulating levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/11\">",
"     11",
"    </a>",
"    ]. There are no published studies evaluating the effect of comorbid inflammatory illnesses or liver disease on the discriminatory power of CRP in CVD risk stratification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26639139\">",
"    <span class=\"h3\">",
"     Effect of medications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374046757\">",
"    <span class=\"h4\">",
"     Cardiovascular medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs used in the treatment of cardiovascular disease reduce serum CRP. Beginning as early as two weeks after the initiation of statin therapy, median hs-CRP levels decline 15 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/1,12-16\">",
"     1,12-16",
"    </a>",
"    ]. The magnitude of serum LDL-cholesterol reduction correlates only modestly with the magnitude of serum hs-CRP reduction, suggesting an antiinflammatory effect of statins beyond lowering of LDL-cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. It is therefore possible that reduced inflammation contributes to the beneficial effects of these medications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374046790\">",
"    <span class=\"h4\">",
"     Hormone replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who use hormone replacement therapy (HRT) following menopause have been shown in observational studies to have higher CRP levels than women who do not use HRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. However, no randomized trials have reported how HRT or placebo affects CRP levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSOCIATION OF CRP WITH CARDIOVASCULAR RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from numerous epidemiologic studies have shown a significant association between elevated serum or plasma concentrations of CRP and the prevalence of underlying atherosclerotic vascular disease, the risk of recurrent cardiovascular events among patients with established disease, and the incidence of first cardiovascular events among individuals not known to have atherosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26637843\">",
"    <span class=\"h2\">",
"     Prediction of incident CVD events",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considered alone or in combination with traditional cardiovascular risk factors, elevated CRP levels have been associated with a higher risk of future cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. The following observations have emerged from prospective epidemiologic studies:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26637923\">",
"    <span class=\"h3\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large population-based studies evaluating CRP in unselected asymptomatic populations have been performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among apparently healthy individuals, the baseline level of CRP predicts the long-term risk of a first myocardial infarction (MI), ischemic stroke, peripheral vascular disease, and all-cause mortality (",
"      <a class=\"graphic graphic_figure graphicRef69135 \" href=\"mobipreview.htm?33/43/34493\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/22,25-30\">",
"       22,25-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The correlation between CRP and cardiovascular risk persists after adjustment for age, smoking, lipid levels, blood pressure, and diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/1,6,25,28,30-33\">",
"       1,6,25,28,30-33",
"      </a>",
"      ]. As an example, the predictive value of CRP for first MI is additive to the total-to-HDL cholesterol ratio (",
"      <a class=\"graphic graphic_figure graphicRef56104 \" href=\"mobipreview.htm?14/23/14718\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Is CRP an independent risk indicator?'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26638689\">",
"    <span class=\"h3\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline serum CRP measurements also appear to predict cardiovascular risk in older adults (ie, those over 65 years):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of almost 4000 men and women &ge;65 years of age without prior vascular disease, 26 percent had an elevated serum CRP defined as a value &gt;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/34\">",
"       34",
"      </a>",
"      ]. When compared with age, ethnicity, and sex matched controls with a serum CRP value &lt;1",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      patients with a CRP &gt;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      had the following significant outcomes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A higher risk of myocardial infarction (MI) or cardiac death (relative risk = 1.82, 95% CI, 1.46 to 2.28).",
"     </li>",
"     <li>",
"      The impact of CRP on cardiovascular risk was weaker, yet still present after adjustment for conventional cardiac risk factors (relative risk = 1.45, 95% CI, 1.14 to 1.86).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When an elevated serum CRP alone was used to determine cardiovascular risk, the population-attributable risk for coronary heart disease (CHD) was 11 percent. Serum CRP improved prediction by the Framingham risk score (FRS), particularly in intermediate-risk men and high-risk women. Among men with a 10-year predicted risk of 10 to 20 percent by the FRS, the observed incidence of CHD in patients with elevated serum CRP was 32 percent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link&amp;anchor=H9#H9\">",
"       \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'Framingham risk scores'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another study investigated the use of CRP as a predictor of cardiovascular risk in 5804 elderly patients age 70-82 years with known cardiovascular disease (CVD) or at high risk of developing CVD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. Patients were divided equally into three groups according to CRP value with bottom and top tertiles corresponding to CRP values of &le; 2.0",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      and &gt;4.8",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      respectively. After adjusting for traditional risk factors, patients with CRP measured in the top tertile had a higher risk of CHD death, MI, or stroke when compared to those patients with CRP in the bottom tertile (HR 1.36, 95% CI 1.15 to 1.61). A follow up study on the same patient population showed a higher risk of fatal CHD in patients with CRP in the top tertile versus the bottom tertile (HR 1.32, 95% CI 1.16 to 1.51) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26637931\">",
"    <span class=\"h3\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although women have higher levels of CRP than men both in the general population and in patients with stable angina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/4,37\">",
"     4,37",
"    </a>",
"    ], elevated serum CRP predicts cardiovascular disease in women as well as men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/19,30-34,38\">",
"     19,30-34,38",
"    </a>",
"    ]. The following data, extracted from the Women's Health Study (WHS), have demonstrated the magnitude of this effect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An epidemiologic study of 28,345 women enrolled in the WHS found that baseline CRP levels were a strong marker of risk for future cardiovascular disease. Increasing quartiles of baseline CRP were associated with a significant increase in cardiovascular risk (adjusted relative risks, 1.0, 2.9, 3.4, and 5.6; for patients with CRP values in first through fourth quartiles, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/38\">",
"       38",
"      </a>",
"      ]. This correlation was consistent for very low and very high serum CRP (&lt;0.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      and &gt;10",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another analysis, elevated serum CRP was a strong independent risk factor for cardiovascular disease in these women that added to the predictive value of other factors, such as serum total cholesterol (",
"      <a class=\"graphic graphic_figure graphicRef62229 \" href=\"mobipreview.htm?17/41/18064\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/32\">",
"       32",
"      </a>",
"      ]. The relationship persisted after adjustment for Framingham risk score, and was seen in both users and nonusers of hormone replacement therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H374046790\">",
"       'Hormone replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated serum CRP was a stronger predictor of cardiovascular events than LDL cholesterol (LDL-C) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/33\">",
"       33",
"      </a>",
"      ]. At eight years, women in the lowest quintile of serum CRP (&le;0.5",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      had an event rate of 0.7 percent, while those in the lowest quintile of LDL-cholesterol level (&le;97.6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.54",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      had an event rate of 1.4 percent. When compared to women with CRP values in the lowest quintile, women with CRP values in the second through fifth quintiles had increased cardiovascular events (adjusted relative risks of 1.4, 1.6, 2.0, and 2.3, respectively). The event rate in the highest quintile was 3.4 percent. In comparison, the adjusted relative risks for increasing quintiles of LDL-C were 0.9, 1.1, 1.3, and 1.5 (event rate in the highest quintile 3.3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations support the predictive value of serum CRP in determining cardiovascular risk in women. In addition, serum CRP is one of multiple risk factors in the Reynolds risk score (see",
"    <a class=\"external\" href=\"file://www.reynoldsriskscore.org/\">",
"     Reynolds risk score calculator",
"    </a>",
"    ), which has been successfully used to predict outcomes in women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=see_link&amp;anchor=H29#H29\">",
"     \"Determinants and management of cardiovascular risk in women\", section on 'Reynolds risk score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26637939\">",
"    <span class=\"h3\">",
"     Renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictive value of serum CRP applies to patients with end-stage renal disease (ESRD) on maintenance hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=see_link\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study of 280 stable hemodialysis patients, an elevated serum CRP (&gt;8",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      was seen in nearly one-half (46 percent) of patients in the absence of clinically apparent infection and was significantly related to cardiovascular mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among a cohort of 173 stable ESRD patients on maintenance dialysis, only 58 patients had no history of coronary heart disease (CHD) or CHD equivalent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/41\">",
"       41",
"      </a>",
"      ]. Over a 27-month follow-up of the patients without CHD or CHD equivalent, mortality was significantly higher among those with CRP &ge; 3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      compared to CPR &lt;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (50 percent versus 18 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26639071\">",
"    <span class=\"h3\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a limited amount of data on the ability of CRP to predict cardiovascular risk in minority populations. The major studies that have evaluated CRP in risk assessment included mostly Caucasians from North America and Europe. The following are examples of the use of CRP in other populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Honolulu Heart Program evaluated the relationship between CRP and future myocardial infarction (MI) in 8006 Japanese-American men free of cardiovascular disease (CVD) at the time of enrollment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/42\">",
"       42",
"      </a>",
"      ]. After adjustment for other CVD risk factors, the risk for MI increased with rising CRP levels.",
"     </li>",
"     <li>",
"      The Strong Heart Study evaluated 3277 Native Americans without CVD at the time of enrollment. In this high-risk population with a 50 percent prevalence of diabetes, the median serum CRP was 3.2",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      higher than noted in many other populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/43\">",
"       43",
"      </a>",
"      ]. In addition, 16 percent had CRP values above that usually used to determine cardiovascular risk (&gt;10",
"      <span class=\"nowrap\">",
"       mg/L).",
"      </span>",
"      After adjusting for traditional risk factors, CRP remained an independent predictor for future CVD in most subgroups. However, CRP was not incremental predictor of risk in the diabetic patient subgroup [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a systematic review and meta-analysis of 221,287 individuals from 89 studies, the geometric mean hs-CRP was 2.6",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      in African-Americans (N=18,585); 2.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      in Hispanics (N=5,049); 2.3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      in South Asians (N=1,053); 2.0",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      in Caucasians (N=104,949); and 1.0",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      in East Asians (N=39,521). The differences among groups persisted after adjustment for age and body mass index. The authors concluded that the interpretation of CRP concentration should be in the context of the ethnicity of the patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Association with established risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased serum CRP correlates with the presence of traditional cardiovascular risk factors (eg, older age, smoking, diabetes, dyslipidemia, and hypertension) and may reflect contributions of these risk factors to vascular inflammation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum CRP is significantly associated with age, smoking, hypertension, body mass index, the metabolic syndrome, incident type 2 diabetes, reduced exercise frequency, and the serum concentrations of homocysteine and lipoprotein(a) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/1,45-47\">",
"       1,45-47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"       \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients without known cardiovascular disease, higher values of serum CRP have been observed in patients with more cardiovascular risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Is CRP an independent risk indicator?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large studies have demonstrated that serum CRP adds incremental information to global risk assessment using traditional cardiovascular risk factors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest case-control study, 2459 patients with a history of myocardial infarction (MI) or death from coronary heart disease (CHD) were compared to 3969 controls without a history of CHD within a cohort study of almost 19,000 patients in Iceland [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/49\">",
"       49",
"      </a>",
"      ]. At a mean follow-up of 18 years, when compared to patients with CRP values in the bottom third (&lt;0.78",
"      <span class=\"nowrap\">",
"       mg/L),",
"      </span>",
"      patients with serum CRP in the top third (&gt;2.0",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      had a significantly higher risk of developing CHD (odds ratio [OR] 1.92). However, the magnitude of this effect decreased after adjustment for age, sex, established coronary risk factors, and year of recruitment (OR 1.45). The predictive value of serum CRP in this report remained independent of established risk factors but, in contrast to previous studies, was weaker than that of total cholesterol, smoking history, or systolic blood pressure.",
"     </li>",
"     <li>",
"      The Framingham Offspring Study evaluated CRP levels in 3006 patients without cardiovascular disease (CVD) and followed these patients for an average of 12 years. When compared to patients with CRP &lt;1",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      and after adjusting for traditional risk factors, patients with CRP &gt;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      had a significantly higher risk of hard CHD events including myocardial infarction (MI) or CHD-related death (HR 1.88, 95% CI 1.18-3.00) as well as a higher risk of total CVD (hard CHD plus angina, stroke, TIA, claudication; HR 1.58, 95% CI 1.16-2.15) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among apparently healthy women 45 years or older, the incorporation of CRP values added incremental information to a clinical model including several known CVD risk factors (ie, age, systolic blood pressure, hemoglobin A1c, smoking, total cholesterol, high density cholesterol, and parental history of premature MI) for the prediction of the 10-year risk of a first cardiovascular event [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=see_link&amp;anchor=H29#H29\">",
"       \"Determinants and management of cardiovascular risk in women\", section on 'Reynolds risk score'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is incremental predictive power of CRP in elderly patients independent of traditional CVD risk factors. (See",
"      <a class=\"local\" href=\"#H26638689\">",
"       'Elderly'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, several meta-analyses have found a significant relationship between baseline CRP and subsequent coronary heart disease (CHD) or cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/49,51,52\">",
"     49,51,52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2009 meta-analysis evaluated over 65,000 patients from 22 prospective studies which excluded patients with prior CHD and adjusted for risk factors in the Framingham risk score [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/52\">",
"       52",
"      </a>",
"      ]. When compared to patients with a CRP &lt;1",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      patients with a baseline CRP &gt;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      demonstrated a higher rate of incident CHD (relative risk 1.60, 95% CI 1.43-1.78).",
"     </li>",
"     <li>",
"      A 2010 meta-analysis evaluated outcomes based on baseline CRP levels in 160,309 individuals enrolled in 54 prospective studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/51\">",
"       51",
"      </a>",
"      ]. For each one standard deviation increase in CRP, the relative risk for CHD was 1.37 (95% CI 1.27-1.48).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these findings, other observational studies have suggested only a small or no incremental contribution of serum CRP to traditional risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of over 15,000 individuals from the third National Health and Nutrition Examination Survey (NHANES) in the United States, high serum CRP (&gt;3",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      was rare in the absence of any borderline or abnormal coronary risk factor (4.4 percent in men and 10.3 percent in women) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/53\">",
"       53",
"      </a>",
"      ]. The likelihood of a high serum CRP was largely attributable to the presence of other risk factors (78 percent in men and 67 percent in women). It was concluded that serum CRP may have limited clinical utility as a screening tool beyond other known cardiovascular risk factors.",
"      <br/>",
"      <br/>",
"      Similar findings were noted in the ARIC study, which assessed the association of 19 novel risk markers, including serum CRP, with incident CHD in nearly 16,000 adults followed for up to 15 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/54\">",
"       54",
"      </a>",
"      ]. The CRP level did not add significantly to the basic risk-factor model (age, sex, total and high-density lipoprotein cholesterol levels, systolic blood pressure, antihypertensive medication use, smoking status, and diabetes) as assessed by the change in area under receiver operating characteristic curves.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In total, these studies suggest that, while serum CRP does appear to act as an independent predictor of cardiovascular disease, the predictive value added to that determined by screening for other coronary risk factors in the general population is small. Instead, serum CRP appears to add the greatest predictive value in a subset of patients with intermediate CHD risk as determined by other measures such as the Framingham Risk Score (",
"    <a class=\"calc calc_patient\" href=\"mobipreview.htm?15/14/15599?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_patient\" href=\"mobipreview.htm?15/19/15679?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H579113\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several groups have issued guidelines addressing the role of CRP in screening for coronary heart disease (CHD).",
"   </p>",
"   <p>",
"    The 2003 Centers for Disease Control and Prevention and the American Heart Association",
"    <span class=\"nowrap\">",
"     (CDC/AHA)",
"    </span>",
"    statement on markers of inflammation and cardiovascular disease included the following conclusions concerning the use of serum high specificity CRP (hs-CRP) measurements in determining cardiovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum or plasma hs-CRP was considered the inflammatory marker most useful for clinical practice based primarily upon analytic properties that influence the reliability of testing. If used, hs-CRP should be measured twice, optimally two weeks apart, with the values averaged. Values should be reported in",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"     </li>",
"     <li>",
"      Low, intermediate, and high risk CRP values were defined as &lt;1, 1 to 3, and &gt;3",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"      A value above 10",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      should be repeated after an interval of at least two weeks and the patient evaluated for infection or inflammation.",
"     </li>",
"     <li>",
"      In patients at intermediate risk for CVD (10 to 20 percent at 10 years by the Framingham risk score), serum or plasma hs-CRP may help direct further evaluation and therapy for primary prevention, at the discretion of the clinician (",
"      <a class=\"calc calc_patient\" href=\"mobipreview.htm?15/14/15599?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_patient\" href=\"mobipreview.htm?15/19/15679?source=see_link\">",
"       calculator 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with established atherosclerotic cardiovascular disease, hs-CRP may be useful as an independent marker of prognosis, but should not determine the application of secondary prevention measures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2009, the United States Preventive Services Task Force (USPSTF) issued recommendations about the use of 10 nontraditional risk factors in the risk assessment for CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/56\">",
"     56",
"    </a>",
"    ]. They concluded the following with regards to hs-CRP testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is insufficient data to assess the balance of benefits and harms of using CRP to screen asymptomatic men and women to prevent CHD events.",
"      <br/>",
"      <br/>",
"      \"Fair-to-good evidence\" shows that elevated hs-CRP levels are predictive of CHD risk independent of the Framingham risk score (FRS), and the use of hs-CRP may reclassify as many as 11 percent of intermediate risk individuals (10 to 20 percent at 10 years by the Framingham risk score), into a high risk category [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/52\">",
"       52",
"      </a>",
"      ]. However, the number needed to treat with more aggressive risk factor modification to prevent one CHD event was 209. The USPSTF concluded there was insufficient evidence to determine the effect of CRP on the occurrence of CHD events and CHD-related deaths.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2009, the Canadian Cardiovascular Society issued guidelines covering the treatment of dyslipidemia and the prevention of cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/57\">",
"     57",
"    </a>",
"    ]. Screening hs-CRP was recommended in men older than 50 years and women older than 60 years who were at intermediate risk by Framingham risk score (10 to 20 percent at 10 years) and who would otherwise not qualify for lipid lowering therapy because of an LDL &lt;3.5",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (135",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    These individuals were felt to benefit from screening with hs-CRP due to a potential benefit from statin therapy in those with elevated hs-CRP levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7917694\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of high-sensitivity CRP (hs-CRP) to screen the general population for cardiovascular risk is controversial. While some experts recommend the routine measurement of hs-CRP at the time of cholesterol screening to be used as adjunctive data in the overall assessment of cardiovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/1\">",
"     1",
"    </a>",
"    ], we continue to prioritize the assessment of traditional risk factors and consider hs-CRP primarily for those with intermediate cardiovascular risk as determined by the Framingham risk score. Before routine hs-CRP measurement becomes an accepted practice, there are a number of issues that impact upon the utility and cost-effectiveness of this test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is the appropriate range of \"normal\" concentrations for serum hs-CRP if one were to target therapy? As noted above, the",
"      <span class=\"nowrap\">",
"       CDC/AHA",
"      </span>",
"      statement defined high risk as a value above 3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/3\">",
"       3",
"      </a>",
"      ] and many studies evaluating the predictive value of serum CRP compared patients with serum hs-CRP &gt;2 or 3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      to those with values &lt;1",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/30,34,49,61\">",
"       30,34,49,61",
"      </a>",
"      ]. However, emerging evidence indicates that patients with serum CRP levels above 1",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      may be at increased risk compared to those with lower values [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      How often should hs-CRP be measured for screening? Most studies that have evaluated the prognostic value of serum CRP in patients with cardiovascular disease (CVD) have relied upon a single measurement. However, systemic inflammatory status can fluctuate over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Variability of measurements'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=see_link\">",
"       \"The role of the vulnerable plaque in acute coronary syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      How does the lack of specificity of hs-CRP for cardiovascular disease influence the interpretation of hs-CRP? (See",
"      <a class=\"local\" href=\"#H26639359\">",
"       'Specificity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Should patient management be altered based upon the results of CRP testing? Until the publication of the JUPITER trial, there was no direct evidence that lowering CRP alone would result in a reduction of cardiovascular risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/62\">",
"       62",
"      </a>",
"      ]. The JUPITER trial randomly assigned 17,802 healthy men (aged 50 and older) and women (aged 60 and older) with an LDL-cholesterol level below 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and a CRP level of at least 2.0",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      20 mg daily or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34665/abstract/58,63\">",
"       58,63",
"      </a>",
"      ]. The trial was stopped early for benefit after a median follow-up of 1.9 years. Because the trial did not include a group with low hs-CRP, it is not possible to know whether the demonstrated benefit of rosuvastatin in the trial was specifically related to underlying vascular inflammation manifest by hs-CRP. However, the primary results of the JUPITER trial suggest a benefit to statin therapy among individuals with an LDL-cholesterol level below 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and a CRP level of at least 2.0",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'Clinical trials'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CRP is an important marker of inflammation, and its measurement using commercially available hs-CRP assays can aid in CVD risk stratification. A large body of available evidence guides the treatment of patients with traditional CVD risk factors (ie, hypertension, diabetes mellitus, hyperlipidemia, smoking, obesity) using a combination of lifestyle changes and pharmacotherapies. There is a relative paucity of evidence demonstrating improved CVD outcomes following the treatment of an elevated CRP level on top of treating traditional CVD risk factors. As such, we feel further investigation is warranted prior to implementing the use of hs-CRP to routinely screen for CVD risk in the general population. However, screening with hs-CRP would appear reasonable in certain selected populations considered at intermediate-risk for CVD by Framingham risk score (ie, 10 to 20 percent at 10 years) in whom treatment with a statin would be expected to reduce the risk of future CVD events by 25 percent or more.",
"   </p>",
"   <p>",
"    For patients with intermediate-risk for CVD by Framingham risk score (ie, 10 to 20 percent risk at 10 years) who do not otherwise qualify for lipid lowering therapy, we suggest a screening measurement of hs-CRP. We take the following approach to the interpretation of these values:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A value above 10",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      should prompt consideration of a source of infection or inflammation, with repeat measurement of hs-CRP in two weeks.",
"     </li>",
"     <li>",
"      A value of 3 to 10",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      should prompt a discussion regarding overall CVD risk, life-style modifications, management of risk factors for atherosclerosis, and the possibility of risk reduction therapy using a statin (",
"      <a class=\"calc calc_patient\" href=\"mobipreview.htm?15/14/15599?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_patient\" href=\"mobipreview.htm?15/19/15679?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). A",
"      <a class=\"external\" href=\"file://www.reynoldsriskscore.org/\">",
"       calculator",
"      </a>",
"      is available that incorporates hs-CRP measurements.",
"     </li>",
"     <li>",
"      A value of 1 to 3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      should be repeated in two weeks to determine an average value and prompt a discussion regarding lifestyle modifications and the potential for treatment with a statin if the hs-CRP value is 2.0",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      or greater.",
"     </li>",
"     <li>",
"      A value &lt;1",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      suggests a lower risk of future CVD events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory processes are important contributors to atherogenesis as well as to the vulnerability of an atherosclerotic lesion to rupture or erosion. CRP is the most extensively studied biomarker of inflammation in cardiovascular disease (CVD). High sensitivity CRP (hs-CRP) assays are used to assess cardiovascular risk because they are able to quantitate CRP within the range normally seen in asymptomatic patients (&lt;3",
"      <span class=\"nowrap\">",
"       mg/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H26637747\">",
"       'Test characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased serum CRP correlates with the presence of traditional cardiovascular risk factors and may reflect contributions of these risk factors to vascular inflammation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Association with established risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When considered alone, elevated serum CRP has been associated with a higher risk of future cardiovascular events. In multivariate analysis, after adjusting for traditional risk factors, an elevated CRP level adds incremental information on risk of CVD above and beyond that of the traditional risk factors. However, the value of this incremental information for individual risk stratification and direction of therapy continues to be debated. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Is CRP an independent risk indicator?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening patients at low-risk for CVD using hs-CRP has",
"      <strong>",
"       not",
"      </strong>",
"      been shown to change the current recommendations of lifestyle modifications in such individuals. Similarly, screening individuals at high-risk for CVD with hs-CRP would",
"      <strong>",
"       not",
"      </strong>",
"      change current guideline-based management of established risk factors. Therefore, we do",
"      <strong>",
"       not",
"      </strong>",
"      recommend a strategy of routinely measuring hs-CRP in unselected populations to screen for CVD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7917694\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with intermediate-risk for CVD by Framingham risk",
"      <strong>",
"      </strong>",
"      score (ie, 10 to 20 percent risk at 10 years) for whom a more definite estimate of CV risk might change their individual decision about whether or not to initiate statin therapy, we suggest a screening measurement of hs-CRP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7917694\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the determination of cardiovascular risk, low-, average-, and high-risk values of CRP are defined as &lt;1, 1 to 3, and &gt;3",
"      <span class=\"nowrap\">",
"       mg/L;",
"      </span>",
"      these values correspond to approximate tertiles in the general population. For patients with intermediate-risk for CVD, we take the following approach to the interpretation of these values:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A value above 10",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      should prompt consideration of a source of infection or inflammation, with repeat measurement of hs-CRP in two weeks.",
"     </li>",
"     <li>",
"      A value of 3 to 10",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      should prompt a discussion regarding overall CVD risk, life-style modifications, management of risk factors for atherosclerosis, and the possibility of risk reduction therapy using a statin (",
"      <a class=\"calc calc_patient\" href=\"mobipreview.htm?15/14/15599?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_patient\" href=\"mobipreview.htm?15/19/15679?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). A",
"      <a class=\"external\" href=\"file://www.reynoldsriskscore.org/\">",
"       calculator",
"      </a>",
"      is available that incorporates hs-CRP measurements.",
"     </li>",
"     <li>",
"      A value of 1 to 3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      should be repeated in two weeks to determine an average value and prompt a discussion regarding lifestyle modifications and the potential for treatment with a statin if the hs-CRP value is 2.0",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      or greater.",
"     </li>",
"     <li>",
"      A value &lt;1",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      suggests a lower risk of future CVD events.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/1\">",
"      Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/2\">",
"      Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001; 47:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/3\">",
"      Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/4\">",
"      Khera A, McGuire DK, Murphy SA, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005; 46:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/5\">",
"      Anand SS, Razak F, Yi Q, et al. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol 2004; 24:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/6\">",
"      Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008; 1:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/7\">",
"      Ockene IS, Matthews CE, Rifai N, et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001; 47:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/8\">",
"      Bogaty P, Brophy JM, Boyer L, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 2005; 165:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/9\">",
"      Gaskins AJ, Wilchesky M, Mumford SL, et al. Endogenous reproductive hormones and C-reactive protein across the menstrual cycle: the BioCycle Study. Am J Epidemiol 2012; 175:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/10\">",
"      Bower JK, Lazo M, Juraschek SP, Selvin E. Within-person variability in high-sensitivity C-reactive protein. Arch Intern Med 2012; 172:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/11\">",
"      Mackenzie I, Woodhouse J. C-reactive protein concentrations during bacteraemia: A comparison between patients with and without liver dysfunction. Intensive Care Med 2006; 32:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/12\">",
"      Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/13\">",
"      Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/14\">",
"      Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/15\">",
"      Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/16\">",
"      Sever PS, Poulter NR, Chang CL, et al. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2012; 33:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/17\">",
"      Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/18\">",
"      Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/19\">",
"      Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/20\">",
"      Langer RD, Pradhan AD, Lewis CE, et al. Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study. Thromb Haemost 2005; 93:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/21\">",
"      Kervinen H, Palosuo T, Manninen V, et al. Joint effects of C-reactive protein and other risk factors on acute coronary events. Am Heart J 2001; 141:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/22\">",
"      Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/23\">",
"      Koenig W, L&ouml;wel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/24\">",
"      Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109:2818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/25\">",
"      Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/26\">",
"      Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/27\">",
"      Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/28\">",
"      Koenig W, Sund M, Fr&ouml;hlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/29\">",
"      Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/30\">",
"      Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/31\">",
"      Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/32\">",
"      Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/33\">",
"      Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/34\">",
"      Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005; 112:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/35\">",
"      Sattar N, Murray HM, Welsh P, et al. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med 2009; 6:e1000099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/36\">",
"      Sattar N, Murray HM, McConnachie A, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007; 115:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/37\">",
"      Garcia-Moll X, Zouridakis E, Cole D, Kaski JC. C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. Eur Heart J 2000; 21:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/38\">",
"      Rifai N, Buring JE, Lee IM, et al. Is C-reactive protein specific for vascular disease in women? Ann Intern Med 2002; 136:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/39\">",
"      Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/40\">",
"      Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/41\">",
"      Kanwar M, Hashem M, Rosman H, et al. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients. Am J Cardiol 2006; 98:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/42\">",
"      Sakkinen P, Abbott RD, Curb JD, et al. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002; 55:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/43\">",
"      Best LG, Zhang Y, Lee ET, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 2005; 112:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/44\">",
"      Shah T, Newcombe P, Smeeth L, et al. Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction. Circ Cardiovasc Genet 2010; 3:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/45\">",
"      Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/46\">",
"      Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/47\">",
"      Rutter MK, Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/48\">",
"      Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999; 84:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/49\">",
"      Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/50\">",
"      Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/51\">",
"      Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/52\">",
"      Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/53\">",
"      Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 2005; 165:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/54\">",
"      Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006; 166:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/55\">",
"      Wilson PW, Nam BH, Pencina M, et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005; 165:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/56\">",
"      U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/57\">",
"      Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009; 25:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/58\">",
"      Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/59\">",
"      Mosca L. C-reactive protein--to screen or not to screen? N Engl J Med 2002; 347:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/60\">",
"      Kushner I, Sehgal AR. Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk? Arch Intern Med 2002; 162:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/61\">",
"      Laaksonen DE, Niskanen L, Nyyss&ouml;nen K, et al. C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. Eur Heart J 2005; 26:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/62\">",
"      Smith SC Jr, Milani RV, Arnett DK, et al. Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation 2004; 109:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34665/abstract/63\">",
"      Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1547 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34665=[""].join("\n");
var outline_f33_54_34665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102480307\">",
"      CRP ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26637747\">",
"      Test characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26637754\">",
"      Clinical context",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26639124\">",
"      - Definition of normal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Variability of measurements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26639359\">",
"      - Specificity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26637822\">",
"      - Comorbid illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26639139\">",
"      - Effect of medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H374046757\">",
"      Cardiovascular medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H374046790\">",
"      Hormone replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSOCIATION OF CRP WITH CARDIOVASCULAR RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26637843\">",
"      Prediction of incident CVD events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26637923\">",
"      - General population",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26638689\">",
"      - Elderly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26637931\">",
"      - Women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26637939\">",
"      - Renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26639071\">",
"      - Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Association with established risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Is CRP an independent risk indicator?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H579113\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7917694\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1547\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1547|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/43/34493\" title=\"figure 1\">",
"      CRP risk future MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/23/14718\" title=\"figure 2\">",
"      CRP, cholesterol, and future MI risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/41/18064\" title=\"figure 3\">",
"      CRP, cholesterol, and future CV event risk in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?15/14/15599?source=related_link\" title=\"calculator 1\">",
"      Calculator: 10 year risk of developing cardiovascular disease in men (Patient information)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?15/19/15679?source=related_link\" title=\"calculator 2\">",
"      Calculator: 10 year risk of developing cardiovascular disease in women (Patient information)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=related_link\">",
"      Determinants and management of cardiovascular risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=related_link\">",
"      Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_54_34666="Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene";
var content_f33_54_34666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34666/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34666/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34666/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34666/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/54/34666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/54/34666/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/54/34666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with lung cancer depends upon the cell type (non-small cell lung cancer [NSCLC] versus small cell lung cancer), molecular characteristics, tumor stage, and an assessment of the patient's overall medical condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with stage I, II, or III NSCLC are generally treated with curative intent using surgery, chemotherapy, radiation therapy (RT), or a combined modality approach (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). In contrast, palliative systemic therapy is appropriate for patients with stage IV disease. Palliative systemic therapy is also used for patients who have relapsed with advanced disease following prior definitive treatment.",
"   </p>",
"   <p>",
"    The use of initial systemic chemotherapy (alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ) will be reviewed here for good performance status patients with advanced NSCLC who are not known to have a driver mutation.",
"   </p>",
"   <p>",
"    Other related topics presented separately include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although initial chemotherapy is generally only given for a limited duration, this may be followed by maintenance treatment if an objective response or stable disease is present upon completion of the planned chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/34/9768?source=see_link\">",
"       \"Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elderly and poor performance status patients can have significant comorbidity and may tolerate systemic therapy less well, thus influencing the choice of initial treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36455?source=see_link\">",
"       \"Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although systemic treatment with either chemotherapy or targeted therapy may produce significant benefits, most patients eventually progress and require additional therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/36/40520?source=see_link\">",
"       \"Second-line therapy for patients with previously treated advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272523091\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY VERSUS TARGETED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, therapy should be individualized based upon molecular and histologic features of the tumor. If feasible, patients should have tumor tissue assessed for the presence of a somatic mutation in the epidermal growth factor receptor (EGFR), which confers sensitivity to EGFR tyrosine kinase inhibitors, and for the anaplastic lymphoma kinase (ALK) fusion oncogene, which confers sensitivity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=see_link\">",
"     \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient management is then be determined by the results of these molecular studies. When a driver mutation is present, treatment with an appropriate targeted agent is generally preferred for initial therapy. If no driver mutation is identified, chemotherapy is preferred.",
"   </p>",
"   <p>",
"    In some instances, systemic treatment may be required before the results of genotype testing are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/1\">",
"     1",
"    </a>",
"    ]. In this situation, systemic chemotherapy is indicated. When the results of genotype testing become available, the treatment plan should be reassessed. There are no clinical trials that directly address the optimal approach in this situation (",
"    <a class=\"graphic graphic_algorithm graphicRef86712 \" href=\"mobipreview.htm?39/0/39950\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Even if a driver mutation is identified, we suggest continuing chemotherapy for four cycles as long as therapy is tolerated and there is no evidence of disease progression. Patients can then be switched to targeted therapy based upon the results of molecular studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link&amp;anchor=H798956916#H798956916\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\", section on 'Chemotherapy versus targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of chemotherapy as the initial treatment for patients not selected based upon EGFR status and for those whose tumors do not contain an EGFR mutation is supported by the results of the TORCH trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/2\">",
"     2",
"    </a>",
"    ]. In that trial, 760 patients with advanced NSCLC were randomly assigned to either first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    followed by chemotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ) upon progression or the same first-line chemotherapy followed by erlotinib upon progression. EGFR mutation status was analyzed in 64 percent of cases; among these, 86 percent were EGFR wild type.",
"   </p>",
"   <p>",
"    At a median follow-up of two years, 71 percent of patients had died. Overall survival was significantly longer in unselected patients assigned to initial chemotherapy followed by second-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    (median 11.6 versus 8.7 months, hazard ratio [HR] 1.24, 95% CI 1.04-1.47). For patients known to be EGFR mutation negative, overall survival was significantly longer with chemotherapy (median 9.6 versus 6.5 months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACTIVE SINGLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple cytotoxic agents have antitumor activity in patients with advanced NSCLC when used alone. The most important of these currently in widespread use for patients with advanced NSCLC include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platinum compounds (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Taxanes (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/5\">",
"       5",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/6\">",
"       6",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/29/8664?source=see_link\">",
"       nanoparticle albumin bound paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/7\">",
"       7",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       Pemetrexed",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Camptothecins (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/12\">",
"       12",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/13\">",
"       13",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Single agent chemotherapy as the initial treatment is generally limited to elderly patients and those with a borderline performance status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36455?source=see_link\">",
"     \"Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26199?source=see_link\">",
"     \"Systemic therapy for poor performance status patients with advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combination regimens based upon these agents, potentially in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , are preferred as first-line treatment for younger patients with advanced NSCLC and a good performance status (PS) because of the survival benefit associated with combination regimens (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Two drugs versus single agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SURVIVAL BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In multiple clinical trials that compared regimens incorporating a platinum compound with best supportive care (BSC), systemic chemotherapy increased survival without compromising quality of life (QOL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. These trials primarily enrolled younger patients with a good performance status (PS 0 or 1, (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    )). Subsequent trials indicate that chemotherapy can also prolong survival in the elderly and those with a poor performance status (PS 2). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36455?source=see_link\">",
"     \"Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More recently, the potential benefits of palliative chemotherapy were illustrated by the European Big Lung Trial, in which 725 patients with advanced NSCLC were randomly assigned to BSC plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy or BSC alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/14\">",
"     14",
"    </a>",
"    ]. Radiation therapy (RT) was administered to 47 percent of those receiving chemotherapy and 74 percent of the BSC group. Patients allocated to chemotherapy had a significantly better median survival than those managed with BSC (8 versus 5.7 months), despite the occurrence of 19 treatment-related deaths.",
"   </p>",
"   <p>",
"    QOL was evaluated in a subset of 273 patients. There were no significant differences between the two groups in any QOL endpoint, including nine parameters that focused specifically on lung cancer symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/17\">",
"     17",
"    </a>",
"    ]. However, the absence of data from more than one-half the patients limits the interpretation of these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of the literature and meta-analysis incorporated individual patient data from 2714 cases enrolled on 16 randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/19\">",
"     19",
"    </a>",
"    ]. Chemotherapy was associated with an improved survival at 12 months (29 versus 20 percent, HR 0.77, 95% CI 0.71-0.83). This survival benefit was independent of histology, performance status, and age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMBINATION CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contemporary (\"third generation\") regimens have combined either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    with one of the newer active single agents or used nonplatinum containing regimens based upon these newer agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Modern regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of multiple active agents has led to the development of numerous two-drug chemotherapy regimens. Representative regimens are presented separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6370?source=see_link\">",
"     \"Treatment protocols for non-small cell lung cancer\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Most of these regimens include a platinum compound (either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef62287 \" href=\"mobipreview.htm?15/36/15949\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platinum plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/20-24\">",
"       20-24",
"      </a>",
"      ]&nbsp;",
"     </li>",
"     <li>",
"      Platinum plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/25-29\">",
"       25-29",
"      </a>",
"      ]&nbsp;",
"     </li>",
"     <li>",
"      Platinum plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Platinum plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/29-33\">",
"       29-33",
"      </a>",
"      ]&nbsp;",
"     </li>",
"     <li>",
"      Platinum plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Platinum plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Platinum plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/33,36\">",
"       33,36",
"      </a>",
"      ]&nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, several regimens that do not include either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    have been evaluated to avoid the toxicity associated with platinum compounds:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/29,32,39\">",
"       29,32,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/40-43\">",
"       40-43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       Pemetrexed",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The data from trials with these two-drug regimens have generated several questions, which are addressed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;No single regimen has demonstrated superiority in patients with advanced NSCLC. At least three cooperative group trials compared multiple platinum-based doublets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/26,48,49\">",
"     26,48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest of these trials, 1155 patients were randomly assigned to one of four doublets:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    plus cisplatin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , or cisplatin plus paclitaxel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/26\">",
"     26",
"    </a>",
"    ]. Overall response rates (approximately 19 percent), median survival (average 7.9 months), and one- and two-year survival rates were similar in all four groups. Although there were differences in toxicity, the authors concluded that none of the four chemotherapy regimens studied offered any specific advantage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Two drugs versus single agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple randomized trials compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -containing combinations with single-agent therapy in patients with advanced NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/50\">",
"     50",
"    </a>",
"    ]. Combination regimens were associated with higher response rates and a modest survival benefit, although there have been concerns about more severe toxicity with combination regimens.",
"   </p>",
"   <p>",
"    In a meta-analysis that included 13,601 patients from 65 randomized trials, two-drug regimens significantly increased both response rate and survival compared to single agent chemotherapy (26 versus 13 percent objective response rate with single agent therapy, and 35 versus 30 percent one-year survival) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Three drugs versus two drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although treatment intensification by adding a third drug to a two drug combination improves response rates, the impact on survival is inconsistent and toxicity is clearly increased. We recommend the use of doublet regimens. The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to the chemotherapy doublet is discussed separately. (See",
"    <a class=\"local\" href=\"#H525779160\">",
"     'Chemotherapy plus bevacizumab'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H525779245\">",
"     'Chemotherapy plus cetuximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A 2004 meta-analysis that identified 28 such trials concluded that hematologic toxicity was significantly worse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/50\">",
"     50",
"    </a>",
"    ]. There was no increase in overall survival, even though adding a third drug did significantly increase the response rate. However, only four of the trials in the meta-analysis included a platinum compound plus two additional third generation agents, and these trials used attenuated doses in the three drug regimen to minimize hematologic toxicity.",
"   </p>",
"   <p>",
"    Two multicenter trials that compared full doses of chemotherapy with two and three-drug contemporary regimens have been published since that meta-analysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 324 patients were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      or no gemcitabine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/28\">",
"       28",
"      </a>",
"      ]. The use of a three-drug regimen resulted in significant improvements in objective response rate, time to progression, and median survival (46 versus 20 percent, 7.6 versus 5.1 months, and 10.8 versus 8.3 months, respectively). Grade 3 or 4 neutropenia, thrombocytopenia and anemia were all significantly more frequent with the three-drug regimen (54 versus 30, 30 versus 4, and 15 versus 11 percent, respectively).",
"     </li>",
"     <li>",
"      Another multicenter phase III trial randomly assigned 433 patients to one of four treatment arms:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or gemcitabine plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      with or without cisplatin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/51\">",
"       51",
"      </a>",
"      ]. Although use of a three-drug regimen containing cisplatin gave a significantly higher response rate (48 versus 35 percent with a two-drug combination), median progression-free survival (PFS) and overall survival were similar (6.1 versus 5.5 months and 10.7 versus 10.5 months). Triplet chemotherapy was significantly more toxic. However, the interpretation of this trial is difficult because of the incorporation of nonplatinum regimens into the comparisons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cisplatin versus carboplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    is often substituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in combination regimens for patients with advanced NSCLC due to its more favorable toxicity profile. Overall, the evidence suggests that cisplatin gives a higher objective response rate than carboplatin, although the survival benefit is small and may not be clinically meaningful.",
"   </p>",
"   <p>",
"    In a meta-analysis that included individual patient data from 2968 patients in nine trials, substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    was associated with a significantly lower response rate (24 versus 30 percent, odds ratio [OR] 1.37 95% CI 1.16-1.61) and a statistically nonsignificant shortening of survival (median 8.4 versus 9.1 months, HR for death 1.07, 95% CI 0.99-1.15) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/52\">",
"     52",
"    </a>",
"    ]. In subset analyses, the difference in survival was statistically significant when the analysis was restricted to patients with nonsquamous cancers and when the platinum compound was combined with a third generation chemotherapy agent (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -containing regimens were associated with more nephrotoxicity, nausea, and vomiting, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    combinations caused more severe thrombocytopenia. Improvements in the management of chemotherapy-induced vomiting and the use of lower doses of cisplatin in newer regimens have mitigated some of the concerns about cisplatin toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Careful adherence to full doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    may obviate the difference between carboplatin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . In a phase III trial, 1363 patients with advanced NSCLC were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus one of three platinum regimens: cisplatin (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    cisplatin (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and carboplatin (AUC 6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/54\">",
"     54",
"    </a>",
"    ]. Median survivals for the three treatment arms were 8.3, 9.5, and 10.0 months, respectively; the trial met the predetermined criteria for noninferiority of the carboplatin regimen.",
"   </p>",
"   <p>",
"    Based upon these results, we believe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is appropriate for the majority of patients with advanced disease, for whom quality of life is an important consideration. Carboplatin is particularly valuable in patients with metastatic NSCLC in whom",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is likely to be poorly tolerated (elderly patients, those with poor performance status, and those with significant comorbidities).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    remains the preferred platinum compound when systemic therapy is used with curative intent in conjunction with other treatments (ie, adjuvant therapy, combined modality treatment of stage III disease). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=see_link\">",
"     \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Nonplatinum versus platinum regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the improvement with platinum-based chemotherapy is small compared to a nonplatinum-based doublet (",
"    <a class=\"graphic graphic_table graphicRef51411 \" href=\"mobipreview.htm?34/19/35131\">",
"     table 4",
"    </a>",
"    ), we agree with the recommendation from the American Society of Clinical Oncology (ASCO) guidelines that first-line therapy should consist of a platinum-based doublet regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis that included 4792 patients treated in 17 randomized trials found that the use of a platinum-based doublet regimen was associated with a slightly higher survival at one year (relative risk [RR] of survival 1.08, 95% CI 1.01-1.16) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/56\">",
"     56",
"    </a>",
"    ]. When the trials were analyzed according to the platinum compound used,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    was associated with a significantly high survival at one year compared to nonplatinum regimens (RR of survival 1.16, 95% CI 1.06-1.27). In contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    -based regimens were not better than nonplatinum regimens (RR of survival 0.95, 95% CI 0.85-1.07).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Weekly, lower dose regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most regimens use a three- or four-week interval between courses, weekly administration at lower doses can alter the toxicity profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a phase III trial in which 883 chemotherapy-naive patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , administered either every three weeks or on a weekly schedule with reduced doses (",
"    <a class=\"graphic graphic_table graphicRef62287 \" href=\"mobipreview.htm?15/36/15949\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/57\">",
"     57",
"    </a>",
"    ]. Severe neurotoxicity was significantly less frequent with the weekly schedule (4.4 versus 9.1 percent when given every three weeks) but grade 3 or 4 diarrhea was more common (4.2 versus 1.1 percent). The efficacy of the weekly schedule was not significantly different (response rate 38 versus 33 percent, median time to progression 6.1 versus 7.2 months, and median survival 8.9 versus 9.5 months).",
"   </p>",
"   <p>",
"    Although further data are needed, a weekly schedule of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    may be considered if neurotoxicity is a particular concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Effect of histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histology is an important factor affecting sensitivity with some contemporary agents, even though early studies with different regimens failed to demonstrate a difference in outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest phase III trial to compare two chemotherapy regimens, 1725 previously untreated patients with stage IIIB or IV NSCLC were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    or cisplatin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/36,60\">",
"     36,60",
"    </a>",
"    ]. Overall, there was no difference in median survival (10.3 months with both regimens). However, in a preplanned subset analysis, survival in the 847 patients with adenocarcinoma was significantly prolonged with cisplatin plus pemetrexed compared to cisplatin plus gemcitabine (median 12.6 versus 10.9 months). Conversely, cisplatin plus gemcitabine was superior to cisplatin plus pemetrexed in the 473 patients with squamous cell carcinoma (median 10.8 versus 9.4 months).",
"   </p>",
"   <p>",
"    The extent to which these results represent increased activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    in patients with adenocarcinoma or decreased activity of pemetrexed in those with squamous cell carcinoma is unknown. There are insufficient data to compare pemetrexed-based regimens with other combinations in patients with adenocarcinoma.",
"   </p>",
"   <p>",
"    Additional evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    is less active in patients with squamous cell carcinoma comes from a large trial in which pemetrexed was used as sequential, non-cross-resistant maintenance following induction chemotherapy. In that trial, patients with squamous cell carcinoma receiving pemetrexed did significantly worse than those with nonsquamous histology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/34/9768?source=see_link&amp;anchor=H2#H2\">",
"     \"Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy\", section on 'Cytotoxic chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these results, the United States Food and Drug Administration has restricted the approval of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    in advanced NSCLC to patients with nonsquamous histology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although extending the duration of treatment with the initial chemotherapy regimen for metastatic NSCLC beyond four to six cycles increases progression-free survival, it has at most only a moderate effect on overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/61\">",
"     61",
"    </a>",
"    ], and hence is not recommended. This is consistent with the recommendations from the American Society of Clinical Oncology (ASCO) guidelines for the treatment of stage IV NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, chemotherapy with contemporary single agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    or with EGFR tyrosine kinase inhibitors (TKIs) increases progression free survival and may improve overall survival in patients with stable disease or an objective response following induction chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/34/9768?source=see_link\">",
"     \"Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525779160\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY PLUS BEVACIZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular endothelial growth factor (VEGF) is a potent endothelial-specific angiogenic factor that is expressed in a wide array of tumors. In NSCLC, high levels of VEGF expression are associated with a poor prognosis, suggesting that treatment targeted toward this pathway might be useful therapeutically. One approach to blocking the VEGF pathway is the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a recombinant humanized monoclonal antibody (MoAb) that binds VEGF, thereby preventing its interaction with the VEGF receptor.",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to platinum-based doublets, followed by bevacizumab maintenance therapy, has been evaluated in multiple randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1826601576\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of four randomized trials were combined in a meta-analysis that incorporated data from 2194 patients, including 1313 treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/62\">",
"     62",
"    </a>",
"    ]. The addition of bevacizumab significantly increased both overall survival and progression-free survival compared with chemotherapy alone (hazard ratios for death or progression 0.90, 95%CI 0.81-0.99 and 0.72, 95%CI 0.66-0.79, respectively). The effect on overall survival was significantly greater in patients with adenocarcinoma compared with other histology. Bevacizumab did increase the risk of grade &ge;3 toxicity.",
"   </p>",
"   <p>",
"    The impact of the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is illustrated by results from the two large phase III trials that were included in the meta-analysis, in which bevacizumab was combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525779210\">",
"    <span class=\"h3\">",
"     Carboplatin paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Eastern Cooperative Oncology Group trial E4599, 878 previously untreated patients with advanced, nonsquamous NSCLC were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , or the same chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    on day 1 of each cycle (",
"    <a class=\"graphic graphic_table graphicRef56125 \" href=\"mobipreview.htm?9/49/10014\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76013 \" href=\"mobipreview.htm?24/25/24990\">",
"     table 6",
"    </a>",
"    ). Bevacizumab was continued as monotherapy on the same schedule after completion of six cycles of chemotherapy until there was evidence of progressive disease.",
"   </p>",
"   <p>",
"    Patients receiving chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    had significant increases in the objective response rate (35 versus 15 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    alone), median overall survival (12.3 versus 10.3 months), one-year and two-year survival rates (51 versus 44 and 23 versus 15 percent, respectively), and progression-free survival (6.2 versus 4.5 months). In an exploratory analysis, patients who were progression-free after four cycles of their initial regimen and received maintenance bevacizumab had longer post-induction progression-free and overall survival durations compared with those who did not receive bevacizumab (4.4 versus 2.8 months and 12.8 versus 11.4 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -containing regimen was generally well tolerated, but treatment-related deaths were more common with this regimen (15 versus 2 in those not receiving bevacizumab). These treatment-related deaths included five due to hemoptysis, five due to febrile neutropenia, and two due to hematemesis. Treatment-related deaths and severe toxicity were a particular problem in patients &ge;70 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Grade 3 or 4 hypertension was significantly more common in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    compared to placebo (7.0 versus 0.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/65\">",
"     65",
"    </a>",
"    ]. A subsequent analysis of patients in this trial suggested that the onset of hypertension after treatment with chemotherapy plus bevacizumab was associated with a better response to therapy (overall survival and progression-free survival) compared to the response in patients treated with bevacizumab but not developing hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525779217\">",
"    <span class=\"h3\">",
"     Cisplatin gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the AVAiL trial (Avastin in Lung Cancer), 1043 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    every three weeks with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (7.5",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    bevacizumab (15",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    or placebo on day 1 every three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. The cisplatin plus gemcitabine was continued for a maximum of six cycles, while the bevacizumab or placebo was continued as maintenance until there was evidence of progressive disease.",
"   </p>",
"   <p>",
"    Progression-free survival, the primary end point of the trial, was significantly improved with both low-dose and high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (median 6.7, 6.5, and 6.1 months, for the 7.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and placebo groups, respectively). In addition, the objective response rate was increased with both doses of bevacizumab (34, 30, and 20 percent, for the 7.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and placebo, respectively). There was no increase observed in deaths attributable to complications of therapy (4, 4, and 5 percent, respectively).",
"   </p>",
"   <p>",
"    In a subsequent report with a median follow-up of 13 months, the benefit in terms of progression-free survival was maintained, as was the improvement in response rate (38, 35, and 22 percent, for the 7.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and placebo groups, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/68\">",
"     68",
"    </a>",
"    ]. However, there were no significant differences in overall survival on the three treatment arms (median survival 13.6, 13.4, and 13.1 months respectively, for the 7.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and placebo groups, respectively, hazard ratios for death 0.93 and 1.03 versus placebo).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525779224\">",
"    <span class=\"h2\">",
"     Bevacizumab pemetrexed",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    is being widely used in platinum-based combinations because of its activity in patients with nonsquamous NSCLC. A phase II study demonstrated the feasibility and potential benefit of combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    with the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus pemetrexed followed by maintenance pemetrexed and bevacizumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Effect of histology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Three phase III trials are evaluating the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    along with or in place of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    either during initial therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    as maintenance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00948675?term=NCT00948675&amp;rank=1\">",
"       NCT00948675",
"      </a>",
"      ), the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      followed by pemetrexed maintenance is being compared with the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus carboplatin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      regimen followed by bevacizumab maintenance. No results are available from this trial.",
"     </li>",
"     <li>",
"      In the Point Break trial (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00762034?term=NCT00762034&amp;rank=1\">",
"       NCT00762034",
"      </a>",
"      ), the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      followed by maintenance with pemetrexed plus bevacizumab was compared with a regimen of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , carboplatin and bevacizumab followed by bevacizumab maintenance. A preliminary report of this trial presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology did not demonstrate an improvement in overall survival with the pemetrexed based regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/70\">",
"       70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/34/9768?source=see_link&amp;anchor=H2#H2\">",
"       \"Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy\", section on 'Cytotoxic chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the AVAPERL trial (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00961415?term=NCT00961415&amp;rank=1\">",
"       NCT00961415",
"      </a>",
"      ), all patients are treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      . Those with an objective response or stable disease are then randomized to either bevacizumab plus pemetrexed or bevacizumab alone as maintenance. Preliminary results from this trial indicate that the addition of pemetrexed significantly prolonged progression free survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/71\">",
"       71",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/34/9768?source=see_link&amp;anchor=H1848341651#H1848341651\">",
"       \"Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy\", section on 'Role of bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525779231\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    outside the setting of a phase III clinical trial was studied in the phase IV, open-label, single arm SAiL study that included 2122 patients with advanced NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/72\">",
"     72",
"    </a>",
"    ]. Significant grade 3 or higher adverse events included thromboembolism, hypertension, bleeding, proteinuria, and pulmonary hemorrhage (8, 6, 4, 3, and 1 percent, respectively). Treatment-related mortality occurred in 57 cases (3 percent). Although patients with known brain metastases were excluded, 281 individuals were diagnosed with brain metastases during the course of the study. In this subset, five (2 percent) had central nervous system bleeding.",
"   </p>",
"   <p>",
"    The toxicities associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525779238\">",
"    <span class=\"h2\">",
"     Role of bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;For good performance status patients with nonsquamous NSCLC, the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    doublet offers a higher response rate, a longer progression-free survival, and an improved overall survival compared with chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/65\">",
"     65",
"    </a>",
"    ]. Although response rate and progression-free survival were improved in the AVAiL trial, the data did not confirm a statistically significant effect on overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertension is a frequent side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . Guidelines for pretreatment assessment, monitoring, and management of elevated blood pressure in patients receiving bevacizumab are available (",
"    <a class=\"graphic graphic_table graphicRef73373 graphicRef63338 \" href=\"mobipreview.htm?37/10/38061\">",
"     table 7A-B",
"    </a>",
"    ). This subject is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1994?source=see_link\">",
"     \"Overview of angiogenesis inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both trials were limited to patients with nonsquamous NSCLC, with ECOG performance status 0 or 1, and excluded patients with brain metastases or a history of hemoptysis (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    ). More recent data have demonstrated the safety of utilizing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in patients with previously treated brain metastases and in patients receiving full anticoagulation. However, the risk of severe toxicity may be increased in elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/13/217?source=see_link&amp;anchor=H19#H19\">",
"     \"Systemic therapy for brain metastases\", section on 'Risk of CNS hemorrhage with antiangiogenic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525779245\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY PLUS CETUXIMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibition of the epidermal growth factor receptor (EGFR) pathway with small molecule tyrosine kinase (TK) inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ) can prolong survival of patients with NSCLC who have progressive disease after initial treatment with cytotoxic chemotherapy. However, combinations of erlotinib or gefitinib with platinum-based chemotherapy regimens as initial treatment for advanced disease have not been more effective than chemotherapy alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\", section on 'EGFR TKIs plus chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    is a monoclonal antibody that binds to the EGFR, thus providing an alternative way to interfere with the epidermal growth factor pathway. The FLEX and BMS-099 phase III trials have combined cetuximab with standard chemotherapy doublets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525779295\">",
"    <span class=\"h2\">",
"     FLEX trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the FLEX trial, 1125 previously untreated patients with NSCLC who had locally advanced (stage IIIB with a malignant effusion) or metastatic (stage IV) disease were randomly assigned to chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    or chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/73\">",
"     73",
"    </a>",
"    ]. Immunohistochemical expression of the EGFR was required for inclusion in the trial.",
"   </p>",
"   <p>",
"    Chemotherapy for all patients consisted of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 8), repeated every three weeks for up to six cycles. Patients assigned to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    regimen were given a dose of 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for the initial dose, followed by 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly thereafter. In the absence of excessive toxicity, cetuximab was continued as maintenance after completion of chemotherapy until the development of progressive disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6370?source=see_link\">",
"     \"Treatment protocols for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, 241 of the 548 patients assigned to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    arm (44 percent) did not have progressive disease or significant toxicity at the completion of four cycles of chemotherapy. These patients were eligible to receive cetuximab maintenance, and 80 percent of these actually received such maintenance therapy.",
"   </p>",
"   <p>",
"    Key results of the trial included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      to chemotherapy significantly increased overall survival, the primary endpoint of the study (median 11.3 versus 10.1 months, hazard ratio [HR] 0.87, 95% CI 0.762-0.996). There were no substantial differences in the survival results across the major subgroups.",
"     </li>",
"     <li>",
"      The objective response rate was significantly increased with chemotherapy plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      (36 versus 29 percent with chemotherapy alone).",
"     </li>",
"     <li>",
"      There was no statistically significant difference in progression-free survival (median 4.8 months in both groups, HR 0.94, 95% CI 0.83-1.08).",
"     </li>",
"     <li>",
"      Statistically significant increases in serious toxicity with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      were seen for rash, febrile neutropenia, diarrhea, and infusion-related reactions (10 versus &lt;1, 22 versus 15, 5 versus 2, and 4 versus &lt;1 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prespecified subset analysis of patients assigned to chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    suggested that the development of an acne-like rash during the first three weeks of treatment was associated with a better response to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/75\">",
"     75",
"    </a>",
"    ]. In a landmark analysis of the 518 patients assigned to the cetuximab regimen who completed the first three weeks of treatment without progression, 290 (56 percent) developed a rash. Median survival was significantly increased compared to those who did not develop a rash (15.0 versus 8.8 months, hazard ratio [HR] 0.63, 95% CI 0.52-0.77). Similar changes were seen in all histologic subsets.",
"   </p>",
"   <p>",
"    Based upon these results, the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to a platinum-based combination chemotherapy regimen represents an option for patients with advanced or metastatic NSCLC whose tumors express the EGFR, based upon the patient's assessment of the risks and benefits associated with this regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525779302\">",
"    <span class=\"h2\">",
"     BMS-099 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the BMS-099 trial, 676 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus a taxane (either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) every three weeks for six cycles or the carboplatin taxane regimen plus weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/74\">",
"     74",
"    </a>",
"    ]. Patients assigned to cetuximab continued to receive cetuximab until toxicity or disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary endpoint of the trial was PFS, as assessed by an independent radiologic review committee. The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to chemotherapy did not significantly increase PFS compared to chemotherapy alone (median 4.4 versus 4.2 months with chemotherapy alone, HR 0.90, 95% CI 0.76-1.07). The increase in overall survival with the cetuximab-based regimen was not statistically significant (9.7 versus 8.4 months, HR 0.89, 95% CI 0.75-1.05), although this difference was similar to that observed in the FLEX trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525779309\">",
"    <span class=\"h2\">",
"     Ongoing phase III trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    is being studied in a phase III trial conducted by the Southwest Oncology Group (SWOG 0819,",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00946712?term=NCT00946712&amp;rank=1\">",
"     NCT00946712",
"    </a>",
"    ). In this trial, all patients are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    &nbsp;if there are no contraindications to bevacizumab; if a contraindication to bevacizumab is present, patients are treated with carboplatin-paclitaxel alone. Patients are randomly assigned to treatment with cetuximab on the experimental arm or no cetuximab on the standard therapy arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525779316\">",
"    <span class=\"h2\">",
"     Molecular markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular markers have been studied in an effort to determine which patients are most likely to benefit from the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to chemotherapy.",
"   </p>",
"   <p>",
"    Suggestive results from phase II studies suggested that EGFR gene copy number might be useful in predicting benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    in patients with metastatic NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/76\">",
"     76",
"    </a>",
"    ]. However, a subset analysis of the BMS-099 trial found no correlation between abnormalities in EGFR or k-ras in terms of either progression-free survival or overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/77\">",
"     77",
"    </a>",
"    ]. Similarly, a preliminary analysis of the FLEX trial, which was presented at American Society of Clinical Oncology (ASCO) meeting in 2009, did not find any predictive value for either k-ras mutations or expression of k-ras by FISH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis of the FLEX trial found that&nbsp;patients with the highest expression of EGFR on the tumor, as measured by the EGFR score, which is a product of the percentage of cells stained (0-100) and the intensity of the staining (0-3),&nbsp;had a significantly improved overall survival when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    was added to chemotherapy compared with chemotherapy alone (median survival 12.0 versus 9.6 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/54/34666/abstract/79\">",
"     79",
"    </a>",
"    ]. No benefit was observed in those with limited expression of EGFR, defined as those with a score less than 200&nbsp;(median 9.8 versus 10.3 months). Whether this method is&nbsp;superior than other biomarkers, and more importantly, whether the&nbsp;EGFR score&nbsp;is ready to be&nbsp;used in clinical practice&nbsp;to select patients who benefit from the addition of cetuximab, remains unclear. Further studies are needed to confirm these observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/44/3779?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic chemotherapy prolongs survival in patients with stage IV non-small cell lung cancer (NSCLC) without significantly impairing quality of life (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). However, the availability of targeted therapies makes it important that treatment should be individualized based upon molecular and histologic features of the tumor. Thus, tumor tissue should be assessed for the presence of a mutation in the epidermal growth factor receptor (EGFR) and the ALK fusion oncogene whenever possible. (See",
"    <a class=\"local\" href=\"#H272523091\">",
"     'Chemotherapy versus targeted therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     No EGFR mutation and no ALK fusion oncogene",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients without a mutation in the EGFR or another driver mutation or when the molecular status of the tumor is unknown, chemotherapy is the foundation for initial treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=see_link\">",
"     \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with nonsquamous NSCLC and no hemoptysis, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      plus a chemotherapy doublet (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients in whom the increased toxicity or cost of bevacizumab is a significant issue, chemotherapy alone is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Modern regimens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H525779160\">",
"       'Chemotherapy plus bevacizumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are treated with regimens not incorporating either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      , we recommend treatment with a contemporary chemotherapy doublet (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6370?source=see_link\">",
"       \"Treatment protocols for non-small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H6\">",
"       'Choice of regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combinations using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      have a slightly higher response rate but inconsistent survival benefits compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      -based regimens. For the majority of patients who will receive a chemotherapy doublet, we suggest using a carboplatin-based regimen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, a cisplatin-based regimen is a reasonable alternative in appropriate patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cisplatin versus carboplatin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Nonplatinum versus platinum regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that the duration of the initial chemotherapy regimen be approximately four cycles (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Maintenance therapy prolongs progression free survival and may improve overall survival in patients who have an objective response or stable disease after their initial treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/34/9768?source=see_link\">",
"       \"Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     EGFR mutation positive",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients whose tumors contain a characteristic mutation of EGFR, we recommend initial therapy with an EGFR inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ) rather than cytotoxic chemotherapy (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=see_link\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272523209\">",
"    <span class=\"h2\">",
"     ALK fusion oncogene positive",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients whose tumors contain the ALK fusion oncogene, we recommend initial therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=see_link&amp;anchor=H11#H11\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\", section on 'Crizotinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Elderly and poor performance status patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment of stage IV disease in elderly patients and those with a borderline or poor performance status needs to consider the ability of the patient to tolerate treatment and its associated toxicities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36455?source=see_link\">",
"     \"Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/1\">",
"      Moran T, Sequist LV. Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. J Clin Oncol 2012; 30:3330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/2\">",
"      Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 2012; 30:3002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/3\">",
"      Bunn PA Jr. The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 1989; 16:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/4\">",
"      Bunn PA Jr. Clinical experiences with carboplatin (paraplatin) in lung cancer. Semin Oncol 1992; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/5\">",
"      Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/6\">",
"      Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/7\">",
"      Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/8\">",
"      Depierre A, Lemarie E, Dabouis G, et al. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/9\">",
"      Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/10\">",
"      Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996; 32A:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/11\">",
"      Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/12\">",
"      Fukuoka M, Masuda N. Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol 1994; 34 Suppl:S105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/13\">",
"      Ramlau R, Gervais R, Krzakowski M, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:2800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/14\">",
"      Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004; 59:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/15\">",
"      Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/16\">",
"      Shanafelt TD, Loprinzi C, Marks R, et al. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004; 22:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/17\">",
"      Brown J, Thorpe H, Napp V, et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 2005; 23:7417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/18\">",
"      Donaldson GW, Moinpour CM. Learning to live with missing quality-of-life data in advanced-stage disease trials. J Clin Oncol 2005; 23:7380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/19\">",
"      NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26:4617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/20\">",
"      Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/21\">",
"      Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16:2459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/22\">",
"      Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/23\">",
"      Belani CP, Pereira JR, von Pawel J, et al. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer 2006; 53:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/24\">",
"      Helbekkmo N, Sundstr&oslash;m SH, Aaseb&oslash; U, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007; 97:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/25\">",
"      Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/26\">",
"      Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/27\">",
"      Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/28\">",
"      Paccagnella A, Oniga F, Bearz A, et al. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study. J Clin Oncol 2006; 24:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/29\">",
"      Treat JA, Gonin R, Socinski MA, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 2010; 21:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/30\">",
"      Crin&ograve; L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17:3522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/31\">",
"      Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005; 23:8380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/32\">",
"      Kosmidis PA, Kalofonos HP, Christodoulou C, et al. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 2008; 19:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/33\">",
"      Gr&oslash;nberg BH, Bremnes RM, Fl&oslash;tten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:3217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/34\">",
"      Manegold C, Bergman B, Chemaissani A, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 1997; 8:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/35\">",
"      Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/36\">",
"      Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/37\">",
"      Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/38\">",
"      Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/39\">",
"      Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002; 20:3578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/40\">",
"      Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21:3207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/41\">",
"      Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/42\">",
"      Laack E, Dickgreber N, M&uuml;ller T, et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 2004; 22:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/43\">",
"      Tan EH, Szczesna A, Krzakowski M, et al. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005; 49:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/44\">",
"      Stathopoulos GP, Veslemes M, Georgatou N, et al. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 2004; 15:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/45\">",
"      Gridelli C, Kaukel E, Gregorc V, et al. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2007; 2:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/46\">",
"      Blakely LJ, Schwartzberg L, Keaton M, et al. A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2009; 66:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/47\">",
"      West HL, Wakelee HA, Perry MC, et al. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol 2009; 20:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/48\">",
"      Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/49\">",
"      Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/50\">",
"      Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/51\">",
"      Comella P, Filippelli G, De Cataldis G, et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 2007; 18:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/52\">",
"      Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/53\">",
"      Azzoli CG, Kris MG, Pfister DG. Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed. J Natl Cancer Inst 2007; 99:828.",
"     </a>",
"    </li>",
"    <li>",
"     Ferry D, Billingham L, Harrett H, et al. British Thoracic Oncology Group trial, BTOG2: Randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 versus cisplatin 80 mg/m2 versus carboplatin AUC6 in advanced NSCLC (abstract). J Thorac Oncol 2011; 6:S274.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/55\">",
"      Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27:6251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/56\">",
"      Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/57\">",
"      Schuette W, Blankenburg T, Guschall W, et al. Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer 2006; 7:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/58\">",
"      Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/59\">",
"      Einhorn LH. First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J Clin Oncol 2008; 26:3485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/60\">",
"      Syrigos KN, Vansteenkiste J, Parikh P, et al. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol 2010; 21:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/61\">",
"      Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009; 27:3277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/62\">",
"      Soria JC, Mauguen A, Reck M, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013; 24:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/63\">",
"      Lopez-Chavez A, Young T, Fages S, et al. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. J Thorac Oncol 2012; 7:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/64\">",
"      Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/65\">",
"      Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/66\">",
"      Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010; 28:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/67\">",
"      Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/68\">",
"      Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/69\">",
"      Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009; 27:3284.",
"     </a>",
"    </li>",
"    <li>",
"     Patel J, Socinski MA, Garon EB, et al. A Randomized, Open-label, Phase 3, Superiority Study Of Pemetrexed (Pem)+Carboplatin (Cb)+Bevacizumab (B) Followed By Maintenance Pem+B Versus Paclitaxel (Pac)+Cb+B Followed By Maintenance B In Patients (pts) With Stage IIIB Or IV Non-squamous Non-small Cell Lung Cancer (NS-NSCLC) (abstract LBPL1). J Thorac Oncol 2012; 9:S336.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/71\">",
"      Barlesi F, de CASTRO J, Dvornichenko V, et al. Final efficacy outcomes for patients with advanced nonsquamous non-small cell lung cancer randomized to continuation maintenance with bevacizumab or bevacizumab + pemetrexed after first-line bevacizumab-cisplatin + pemetrexed (abstract #LBA8002). European Multidisciplinary Cancer Congress 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/72\">",
"      Crin&ograve; L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/73\">",
"      Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/74\">",
"      Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/75\">",
"      Gatzemeier U, von Pawel J, Vynnychenko I, et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011; 12:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/76\">",
"      Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008; 26:3351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/77\">",
"      Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:918.",
"     </a>",
"    </li>",
"    <li>",
"     O'Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study (abstract #8007). J Clin Oncol 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/54/34666/abstract/79\">",
"      Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13:33.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4629 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34666=[""].join("\n");
var outline_f33_54_34666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272523091\">",
"      CHEMOTHERAPY VERSUS TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACTIVE SINGLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SURVIVAL BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMBINATION CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Modern regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Two drugs versus single agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Three drugs versus two drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cisplatin versus carboplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Nonplatinum versus platinum regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Weekly, lower dose regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Effect of histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H525779160\">",
"      CHEMOTHERAPY PLUS BEVACIZUMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1826601576\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H525779210\">",
"      - Carboplatin paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H525779217\">",
"      - Cisplatin gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525779224\">",
"      Bevacizumab pemetrexed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525779231\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525779238\">",
"      Role of bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H525779245\">",
"      CHEMOTHERAPY PLUS CETUXIMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525779295\">",
"      FLEX trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525779302\">",
"      BMS-099 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525779309\">",
"      Ongoing phase III trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525779316\">",
"      Molecular markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      No EGFR mutation and no ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EGFR mutation positive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H272523209\">",
"      ALK fusion oncogene positive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Elderly and poor performance status patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4629\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4629|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?39/0/39950\" title=\"algorithm 1\">",
"      Initial approach to patients with newly diagnosed NSCLC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4629|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 2\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/36/15949\" title=\"table 3\">",
"      Plat combinations NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/19/35131\" title=\"table 4\">",
"      Nonplat combinations NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/49/10014\" title=\"table 5\">",
"      Paclitaxel and carboplatin for NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/25/24990\" title=\"table 6\">",
"      Paclitaxel-carboplatin- bevacizumab chemotherapy for NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/7/22652\" title=\"table 7A\">",
"      HTN with VEGF inhib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/36/33356\" title=\"table 7B\">",
"      Risk factors BP VSP rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=related_link\">",
"      Adjuvant systemic therapy in resectable non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/34/9768?source=related_link\">",
"      Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/44/3779?source=related_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=related_link\">",
"      Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/36/40520?source=related_link\">",
"      Second-line therapy for patients with previously treated advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36455?source=related_link\">",
"      Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/13/217?source=related_link\">",
"      Systemic therapy for brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26199?source=related_link\">",
"      Systemic therapy for poor performance status patients with advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6370?source=related_link\">",
"      Treatment protocols for non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_54_34667="Medical probs breastfeed PI";
var content_f33_54_34667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical problems and breastfeeding safety",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Breastfeeding is not recommended for women or infants with the following conditions:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Women who have human immunodeficiency virus (HIV)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Women with human T-cell lymphotropic virus type I or II (HTLV)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Women being treated with chemotherapy or radiation therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Women who abuse drugs or alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Women with herpes simplex lesions on the breasts (ok to breastfeed if one breast has no lesions)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infants with classic galactosemia (galactose 1-phosphate uridyltransferase deficiency)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Breastfeeding is encouraged for women or infants with the following conditions:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Women with hepatitis (A, B, or C)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Women with past or current cytomegalovirus (CMV) infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infants who develop jaundice",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: American Academy of Pediatrics. Pediatric Nutrition Handbook. 6th edition, 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34667=[""].join("\n");
var outline_f33_54_34667=null;
var title_f33_54_34668="Pediatric oropharyngeal trauma assessment and imaging";
var content_f33_54_34668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oropharyngeal trauma physical assessment and suggested imaging",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Minor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechanism",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Low force:",
"         </strong>",
"         eg,",
"        </p>",
"        <p>",
"         Fall from sitting with toy in the mouth",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Intermediate force:",
"         </strong>",
"         eg,",
"        </p>",
"        <p>",
"         Fall while running with pencil in mouth",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Bicycle accident while eating a popsicle",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          High force:",
"         </strong>",
"         eg,",
"        </p>",
"        <p>",
"         High speed motor vehicle accident with impaling oropharyngeal object",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Penetrating injury with knife or gunshot wound",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wound appearance",
"       </td>",
"       <td>",
"        <p>",
"         Mucosal laceration &lt;2 cm in length",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Superficial midline puncture wound",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Submucosal laceration &gt;2 cm in length",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Tonsillar or lateral soft palate deep or indeterminate depth puncture wound",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Protruding or retained foreign body*",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Large, gaping wound with copious bleeding",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         As for moderate injury with associated neurovascular findings",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated findings",
"       </td>",
"       <td>",
"        Superficial gum laceration or abrasion",
"       </td>",
"       <td>",
"        <p>",
"         Tooth fracture, luxation, or avulsion",
"        </p>",
"        <p>",
"         Tongue laceration",
"        </p>",
"        <p>",
"         Jaw fracture",
"        </p>",
"       </td>",
"       <td>",
"        Neurologic abnormality carotid artery bruit on side of injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiographic imaging",
"       </td>",
"       <td>",
"        Not indicated",
"       </td>",
"       <td>",
"        CTA or contrast enhanced MRA&bull;",
"       </td>",
"       <td>",
"        Digital subtraction CAA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CTA: computed tomography angiography; MRA: magnetic resonance angiography; CAA: carotid artery angiogram.",
"     <br>",
"      * A protruding oropharyngeal foreign body should only be removed in the operating room.",
"      <br>",
"       &bull; Contrast enhanced MRA is preferred if available and if the patient can cooperate with not moving for 30 to 60 minutes.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34668=[""].join("\n");
var outline_f33_54_34668=null;
var title_f33_54_34669="Alternative complement pathway";
var content_f33_54_34669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Feedback loop of the alternative complement pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 163px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After C3b is generated, it binds to factor B. Factor D can then cleave factor B to form the C3 convertase (C3bBb). The attachment of properdin (P) stabilizes the complex. The end result is the deposition of large amounts of C3b on the pathogen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Liszewski, MK, Atkinson, JP. The complement system. In: Immunology Scope Monograph, Schwartz, BD (Ed), Upjohn, Kalamazoo, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34669=[""].join("\n");
var outline_f33_54_34669=null;
var title_f33_54_34670="Allerg contact derm PI";
var content_f33_54_34670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows a person with allergic contact dermatitis. The skin is red and raised in the places that were touched by the allergen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34670=[""].join("\n");
var outline_f33_54_34670=null;
var title_f33_54_34671="IVF outcome by age";
var content_f33_54_34671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Percentages of ART cycles using fresh nondonor eggs or embryos that resulted in pregnancies, live births, and singleton live births, by age of woman,* 2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 373px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A woman's age is the most important factor affecting the chances of a live birth when her own eggs are used. The above figure shows the percentages of pregnancies, live births, and singleton live births for women of different ages who had ART procedures using fresh nondonor eggs or embryos in 2006. The percentages of ART cycles resulting in live births and singleton live births are different because of the high percentage of multiple-infant deliveries counted among the total live births. The percentage of multiple-infant births is particularly high among women younger than 35. Among women in their 20s, the percentages of ART cycles resulting in pregnancies, live births, and singleton live births were relatively stable; however, success rates declined steadily from the mid-30s onward.",
"    <div class=\"footnotes\">",
"     * For consistency, all percentages are based on cycles started.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2006 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_54_34671=[""].join("\n");
var outline_f33_54_34671=null;
